Insulin-like growth factor binding protein-2 and its role in angiogenesis by Shah, Pooja Trusha Mehool
The University of Leeds 
School of Medicine 
Faculty of Medicine and Health 
Leeds Institute of Cardiovascular and Metabolic Medicine 
 
 
 
 
 
 
 
Insulin-like growth factor binding 
protein-2 and its role in angiogenesis 
 
Pooja Trusha Mehool Shah 
September 2018 
 
 
 
 
 
 
 
 
Thesis submitted to The University of Leeds in accordance with the 
requirements for the Degree of Doctor of Philosophy 
  
 
Intellectual Property and Publication Statements 
 
I confirm that the work submitted is my own and that appropriate credit has been given 
where reference has been made to the work of others. 
This copy has been supplied on the understanding that it is copyright material and that 
no quotation from the thesis may be published without proper acknowledgement.
  
 
Acknowledgements 
 
Firstly, I would like to sincerely thank my main supervisor Dr Stephen Wheatcroft for his 
continuous guidance, knowledge and support that has inspired me to completion of my 
PhD. I am also extremely grateful to my co-supervisor Dr Kirti Kain for her dedication 
and guidance to motivate me through my PhD. I would especially like to thank my 
second co-supervisor, Dr Hema Viswambharan for all the support and advice you have 
given me since I came to you as a placement student.  
This project would be nothing without the lessons I was taught by Dr Paul Cordell. 
Thank you for being extremely patient with me during all of the mutagenesis work and 
helping me achieve the bulk of my PhD. I would like to thank Dr Nadira Yuldasheva for 
all her help with the animal work carried out in this project. Thank you very much to 
Miss Jess Smith; I have been so lucky to have the pleasure to work with someone as 
kind and helpful as you.  
I would like to thank Dr Natalie Haywood, Dr Alex Bruns and Dr Thomas Slater for their 
continuous laboratory advice and helping me optimise all my experimental work. I would 
like to acknowledge Melanie Reay and Andrew Horner for their help in the animal house 
and Sally Boxall for her help using the bio-imaging facilities. I would also like to thank 
Dr Kerrie Smith for all her support through my PhD. 
The support provided by all the members in Professor Mark Kearney’s group since my 
placement at LICAMM has made my PhD experience unforgettable and helped through 
every step with their laboratory and research knowledge. 
I would like to specially thank Professor David Bates and Dr Andrew Benest for inviting 
me to The University of Nottingham to carry out my permeability studies. It was a 
pleasure to work with you both. 
I am so grateful for all the support provided by my greatest friends, Saba Ullah, Marium 
Anwar, Anneesa Sarwar, Courtney Williams, Eleanor Cawthorne, Elizabeth Taylor, 
Julie Mawson, Carla Asquith, Nathan Asquith, Katarina Miteva and Katie Musalowski. I 
would not have been able to complete this PhD without your motivation and inspiration 
during my lowest points.  
I would sincerely like to thank my amazing grandparents, parents, Masi and Masa, my 
sister, Shriya and my fiancée, Dr Arpan Patel from the bottom of my heart for their 
unbelievable and irreplaceable encouragement. Unfortunately, both my grandads, 
  
 
Nana and Bapuji passed away during my PhD but I hope my Ba (grandma), late Nani 
(grandma), late Nana and late Bapuji are proud of my achievements. 
Finally, none of this work would have been possible without funding provided by the 
University of Leeds 110 Anniversary Research Scholarship, British Heart Foundation, 
European Research Council, The Biochemical Society and Leeds Institute of 
Cardiovascular and Metabolic Medicine. This funding has covered all my maintenance, 
laboratory supplies and attendance and presentations at conferences throughout my 
PhD. 
 
  
  
 
Abstract 
 
Therapeutic angiogenesis is currently under investigation to restore tissue perfusion in 
peripheral arterial disease (PAD). However, clinical trials have proved to be 
disappointing in stimulating the development of functional blood vessels and reducing 
adverse events. 
Insulin-like growth factor binding protein-2 (IGFBP-2) has demonstrated potential in pro-
angiogenic activity but the molecular mechanisms remain unestablished. Structurally, 
IGFBP-2 possesses domains which can interact with insulin-like growth factor (IGF), 
receptor protein tyrosine phosphatase-β, glycosaminoglycans, integrins and can 
potentially translocate into the nucleus to activate cellular and pathological processes. 
In this project, we used two IGFBP-2 over-expressing mouse models, namely a global 
and an endothelial specific model, to determine whether increasing IGFBP-2 can 
increase perfusion in an experimental model of ischemia in vivo. The angiogenic 
potential of IGFBP-2 was investigated in an array of in vitro angiogenic signalling and 
functionality studies in vascular endothelial cells. Recombinant IGFBP-2 was generated, 
in which site-directed mutagenesis was employed to disrupt the integrin binding site 
(RGD), IGF binding site, or the heparin binding domain-1/nuclear localisation signal. 
These mutants were used to determine the primary mechanism IGFBP-2 may use to 
exert in vitro angiogenic effects. 
Upregulation of IGFBP-2 in ischemic muscles was confirmed in wild-type mice following 
hind limb ischemia surgery. IGFBP-2 over-expression significantly enhanced perfusion 
at early stages of recovery. In vitro angiogenic signalling and functional assays 
demonstrated IGFBP-2 increased phosphorylation of Akt and ERK/MAPK, as well as 
enhancing endothelial cell adhesion, wound closure and tube formation. Site-directed 
mutagenesis identified the RGD domain to be critical in IGFBP-2-stimulated in vitro 
angiogenic activity. In contrast to VEGF, exposure of IGFBP-2 to endothelial cells did 
not affect endothelial monolayer permeability. In conclusion, IGFBP-2, via its RGD 
domain displays promising potential as a new therapeutic angiogenic treatment.
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ELISA Enzyme-linked Immunosorbent Assay 
eNOS Endothelial Nitric Oxide Synthase 
EPC Endothelial Progenitor Cells 
ERK Extracellular signal-related kinase 
FA Focal Adhesions 
FAK Focal Adhesion Kinase 
FBS Fetal Bovine Serum 
FGF Fibroblast Growth Factor 
FitC Fluorescein-5-isotheiocyanate 
GLUT4 Glucose Transporter Type 4 
GSK-3β Glycogen Synthase Kinase 3β 
HBD Heparin Binding Domain 
HBSS 
Het 
Hanks’ Balanced Salt Solution 
Heterozygous 
HGF Hepatocyte Growth Factor 
HIF-1 Hypoxia inducible factor-1 
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hIGFBP-2 Human Insulin-like Growth Factor Binding Protein-2 
HF High-Fidelity  
HLI 
Hom 
Hindlimb Ischemia 
Homozygous 
HSaVECs Human Saphenous Vein Endothelial Cells 
HUVECs Human Umbilical Vein Endothelial Cells 
IGF Insulin-like Growth Factor 
IGF-R Insulin-like Growth Factor Receptor 
IGFBP Insulin-like Growth Factor Binding Protein 
IGFBP-2 Insulin-like Growth Factor Binding Protein-2 
IHD Ischemic Heart Disease 
ILK Integrin-linked kinase 
JNK c-Jun N-terminal Kinase 
kDa Kilodaltons 
KO Knock-out 
LB Lysogeny Broth 
LDL Low-Density Lipoproteins 
MAPK Mitogen-activated Protein Kinase 
MCS Multiple Cloning Site 
mIGFBP-2 Mouse Insulin-like Growth Factor Binding Protein-2 
MW Molecular Weight 
NFkβ Nuclear factor kappa β 
NO Nitric Oxide 
PAD Peripheral Arterial Disease 
PAPP-A Pregnancy-Associated Plasma Protein-A 
PBS Dulbecco’s Phosphate Buffered Saline 
PBLEC PBS (pH 6.8) with the addition of 1M MgCl2, 1M CaCl2, 1M MnCl2, 
10% Triton X-100 
PCR Polymerase Chain Reaction 
PECs Pulmonary Endothelial Cells 
PI3K Phosphatidylinositol 3-Kinase 
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SUMOstar 
vector 
Mammalian Small Ubiquitin-like Modifier Secretory Vector 
PTEN Phosphatase and Tensin Homolog 
RGD Arginine, Glycine-Aspartic Acid 
RPTPβ Receptor Protein Tyrosine Phosphatase-β 
RT Room Temperature 
SEM Standard Error of the Mean 
SF Serum-free 
SUMO Small Ubiquitin-like Modifier 
TBST Tris Buffered Saline Tween 20 
TG Transgenic 
TNF-α Tumour Necrosis Factor-α 
VSMCs Vascular Smooth Muscle Cells 
VEGF Vascular Endothelial Growth Factor 
VEGF-R Vascular Endothelial Growth Factor Receptor 
VehiHom Homozygous over-expression of endothelial-specific hIGFBP-2 in 
mice 
VE-PTP Vascular Endothelial Protein Tyrosine Phosphatase 
WT Wild-type 
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Chapter 1 – Introduction 
 
1.1 Introduction 
Cardiovascular disease (CVD) is currently and predicted to continue to be the 
principal cause of worldwide morbidity and mortality, accounting for approximately a 
third of all recorded deaths (Roth et al., 2017). Peripheral arterial disease (PAD), 
along with coronary heart disease (CHD), stroke and aortic diseases are the four 
main types of CVD for which there are currently no definite cures. There are 
pharmacological endovascular and surgical treatments available to improve 
symptoms and to help prevent further damage from the restriction of blood supply to 
the limbs in PAD. However, the increasing prevalence of diabetes and an ageing 
population has led to an increased number of patients with diffuse disease refractory 
to revascularisation, causing critical limb ischemia, often with amputation as the only 
solution. Therefore, the need for new treatments to improve tissue perfusion in CVD 
and in patients with PAD in particular, is more pressing than ever. 
Therapeutic angiogenesis has recently evolved as a potential treatment for limb 
ischemia (Makarevich & Parfyonova, 2017). This involves exploiting angiogenesis by 
an injection of growth factors or other pro-angiogenic factors to stimulate the 
formation of new blood vessels from pre-existing vessels, if successful, this leads to 
restoration of oxygenated blood supply to the lower limb via the newly formed 
network, preventing the need for amputation (Figure 1.1). Current clinical trials of this 
treatment have included the use of a potent angiogenesis inducer, vascular 
endothelial growth factor (VEGF). However, in these trials VEGF-therapy produced 
weak and unstable blood vessels which caused leakage of blood (Deveza et al., 
2012). 
Insulin-like growth factor binding protein-2 (IGFBP-2) has recently been identified by 
our laboratory as a possible acute angiogenesis treatment option. The association of 
IGFBP-2 with angiogenesis was first reported in some cancers, as tumour growth 
positively correlated with the upregulation of IGFBP-2 expression (Adamo et al., 
1992; Kanety et al., 1993). In recent years, further exploration of IGFBP-2 has 
distinguished its role as a significant enhancer of cell migration, proliferation, 
differentiation, survival and invasion across many cell types, via interactions through 
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certain of its structural domains with cell surface receptors (Han et al., 2014; Wang 
et al., 2017a, 2017c). 
 
 
 
 
Integrins, glycosaminoglycans, receptor protein tyrosine phosphatase-β (RPTPβ) 
and nuclear transport importins, in addition to insulin-growth factors (IGF) are 
examples of the multiple molecules to which IGFBP-2 can bind via its structural 
domains.  
IGFBP-2 displays other properties that make it stand out as a potential option for 
therapeutic angiogenesis. IGFBP-2 can exert a protective nature against the onset 
of metabolic diseases. It has been shown to protect against obesity and insulin 
resistance by preventing the proliferation and differentiation of pre-adipocytes 
following high fat feeding in murine models (Carter et al., 2014; Wheatcroft et al., 
2007). This suggests IGFBP-2 has the ability to promote or suppress angiogenic 
effects by preventing or enhancing activity via its interactions. This ensures it can 
modulate healthy angiogenesis, ensuring the vessels formed can withstand the 
forces of shear stress (Fletcher et al., 2013). 
Although associations between IGFBP-2 and angiogenesis have been 
demonstrated, no evidence of IGFBP-2 directly inducing vessel formation has been 
shown in vascular endothelial cells. The aim of this thesis is to investigate the 
Figure 1.1 Schematic displaying delivery of growth factors can stimulate angiogenic 
growth from a pre-existing vessel in an ischemic setting 
This figure displays the development of an atheroma, narrowing the blood vessel and restricting 
the blood supply. The obstructed blood supply finds an alternate route to reduce blood pressure 
and the delivery of pro-angiogenic growth factors promotes formation of new smaller blood 
vessels to help handle the increase in blood flow and direct it to the ischemic site. 
P a g e  | 3 
 
 
angiogenic potential of IGFBP-2 as a clinical therapeutic strategy in critical limb 
ischemia. 
Firstly, to address this aim, global and endothelial specific over-expressing human 
IGFBP-2 (hIGFBP-2) mice were studied to investigate a potential favourable action 
of IGFBP-2 in enhancing recovery from hind limb ischemia in vivo. Next, the effect of 
IGFBP-2 on endothelial cell in vitro angiogenic signalling pathways were interrogated 
leading on to its role in influencing angiogenic mechanisms via in vitro angiogenic 
assays. To determine the predominant interaction and mechanism that stimulates 
IGFBP-2 activity, binding-sites of the protein were mutated to inhibit interaction with 
their receptors. The effects of these mutations were interrogated by replicating in vitro 
angiogenic signalling and assay studies in vascular endothelial cells. We then 
examined the influence of IGFBP-2 on permeability of the endothelial monolayer, 
recognising the importance of excluding an adverse effect on vascular permeability 
for any new angiogenic agent. Findings from the final studies determined which 
IGFBP-2 domain we could exploit as an angiogenic therapeutic target, to promote 
formation of healthy and viable vessels that could rescue a critically ischemic limb. 
 
1.2 Cardiovascular disease 
CVD is mostly characterised by luminal narrowing of blood vessels which restricts 
blood flow to a tissue or organ. This results in ischemia which contributes to tissue 
damage and if prolonged, can lead to necrosis due to restriction of an oxygenated 
blood supply. The narrowing is due to atherosclerosis; the pathological process which 
is characterised by an accumulation of inflammatory material and lipids, primarily 
cholesterol-rich particles and other lipids such as low-density lipoproteins (LDL). The 
development of atherosclerotic plaques often follows damage to the endothelial layer, 
compromising its ability to act as a protective barrier between circulating plasma and 
the vessel wall (George & Johnson, 2010). Expansion of the atherosclerotic plaque 
is driven by endothelial cells attracting monocytes to the accumulating lesion. As 
monocytes differentiate into macrophages, they engulf more LDL which stimulates 
further differentiation of macrophages into foam cells. Foam cells secrete 
chemokines which attract more monocytes to the lesion and activation of this 
feedback loop eventually causes plaque expansion and vessel remodelling leading 
to luminal compromise (Figure 1.2) (Bentzon et al., 2014). 
Following reduction of oxygenated blood flow to the tissues, hypoxic and 
inflammatory signalling pathways become activated due to the inhibition of oxygen-
sensing prolylhydroxylase enzymes which require oxygen to function (Eltzschig & 
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Carmeliet, 2011). Hypoxia-inducible factor-1 (HIF-1) and nuclear factor-κB (NFκB) 
are activated via signalling cascades, which in turn interact with hypoxia response 
elements, inducing the transcription of angiogenic growth factors such as vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF), fibroblast growth 
factor (FGF) and platelet derived growth factor (PDGF) (Ramakrishnan et al., 2014). 
A subunit of HIF-1, HIF-1α has also been reported to stimulate the transcription of 
IGFBP-2 (Das et al., 2013). Growth factors including VEGF, FGF and PDGF begin 
to stimulate angiogenesis in an attempt to restore blood flow to the ischemic limb or 
tissue in CVD. However, whether IGFBP-2 promotes angiogenesis in the context of 
tissue ischemia remains unclear and has only been established in the context of 
tumour expansion (Lin et al., 2015). 
Cardiovascular risk factors promote the development of atherosclerosis and 
significantly increase the risk of a CVD event. The major risk factors include diabetes 
mellitus, hypertension, high cholesterol levels and smoking: which can all be 
modulated via lifestyle changes to prevent a CVD event (Canto & Iskandrian, 2003). 
However, genetic factors have also been shown to contribute to offspring having a 
higher risk of developing CVD if their parents are sufferers of CVD (Lloyd-Jones et 
al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic diagram of atheroma formation 
The mechanism of atheroma formation, attracting more monocytes and their differentiation 
into macrophages and then foam cells, continuously contributing to the expansion of the 
lesion. This leads to a restriction of the blood supply through the vessel and contributes to 
contributing factors of CVD, such as hypertension. 
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1.2.1 Peripheral arterial disease 
PAD is increasingly affecting morbidity and mortality across the worldwide population, 
affecting approximately 200 million people by 2010 (Sampson et al., 2014). This 
value continues to rise as CVD continues to grow as the majority cause of worldwide 
deaths.  
Atherosclerosis is the main contributor to PAD, by narrowing the lumen of lower limb 
arteries via atheroma formation and thereby reducing perfusion of the lower limbs. 
There are many burdens associated with PAD such as atypical leg pain, leg 
weakness, claudication and ulcers which compromise quality of life and if left 
untreated can progress to critical limb ischemia (CLI) (Morley et al., 2018). Necrosis, 
ganagrene, non-healing wounds and pain in a resting state are the symptoms which 
characterise CLI (American Academy of Family Physicians. & Santilli, 1999). Up to 
40% of CLI patients are unable to undergo revascularisation treatments or 
revascularisation attempts have failed, leaving major amputation as the only solution 
(Novo et al., 2004). Although CLI itself may not be the cause of death, the risk of 
CHD events significantly increases, with 25% of PAD patients also suffering from 
CHD, giving patients approximately a 2-year life expectancy (Sigvant et al., 2007; 
Soga et al., 2014).  
Increasing prevalence of diabetes and increasing population age in the last few 
decades have resulted in an increase in the number of individuals with PAD who 
reach the stage of CLI. Patients are treated with two different aims: firstly, to decrease 
the risk of a cardiovascular event; and secondly to rescue perfusion of the limb. 
Treatments for CVD will be discussed in more depth in Section 1.2.2 of this chapter. 
Non-pharmalogical approaches such as exercise, significantly reduce pain levels at 
rest and when walking, however there is no definite evidence to confirm the reduction 
in pain is due to reperfusion to the limb (Olin & Sealove, 2010). Pharmacological oral 
treatment provided as secondary prevention is used to help improve blood flow to the 
lower limbs, as well as prevent CVD events. Studies with ACE inhibitors and 
antiplatelet therapies have demonstrated a 22-23% reduction in PAD-associated 
CVD events (Antithrombotic Trialists’ Collaboration, 2002; Heart Outcomes 
Prevention Evaluation Study Investigators et al., 2000). Although combined therapy 
including antiplatelet drugs, thienopyridines, aspirin and warfarin have proved 
successful in other CVD, the combination of anti-platelet drugs and warfarin offered 
no positive effect compared to anti-platelet drugs alone and increased the risk of 
death by bleeding on patients with PAD (Warfarin Antiplatelet Vascular Evaluation 
Trial Investigators et al., 2007).  
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Unfortunately, these treatments sometimes fail to sufficiently optimise perfusion of 
the ischemic limb via the existing vessel network, resulting in CLI and leaving 
amputation as the only option. New treatments are urgently needed to restore 
perfusion. Recently, a new approach by promoting the formation of a new blood 
vessel network to restore limb perfusion has been pre-clinically investigated (Iyer & 
Annex, 2017). New blood vessel development arises through three complex and 
highly regulated distinct processes, depending on the pathophysiological context and 
life-stage. These processes are categorised as angiogenesis, vasculogensis and 
arteriogenesis and will be discussed in more detail in Section 1.3. 
 
1.2.2 Cardiovascular disease treatments 
By assessing risk factors, we can identify individuals who may be at a high risk of 
CVD events. Primary prevention involves preventing the onset of CVD in those who 
are at risk by influencing lifestyle change or initiating risk-lowering medication. Drugs 
currently in clinical use are usually offered in combination to reduce risk of 
thrombosis, lower cholesterol levels and lower blood pressure (Wirtz et al., 2016). 
Secondary prevention is the prevention of recurrent CVD in patients who have 
previously suffered from a CVD event and also involves lifestyle and pharmacological 
approaches. 
The final mode of treatment available is interventional or surgical procedures, which 
involve revascularisation to deprived organs. Revascularisation can be broadly 
classified as percutaneous interventions (involving angioplasty and stent 
implantation) and surgical procedures in which narrowed or occluded arteries are 
‘bypassed’ by native or artificial consults. Angioplasty and stents are commonly used 
to recanalise or dilate the lumen of obstructed vessels in the peripheral, coronary or 
cerebral circulations (Al-Lamee et al., 2016). These procedures are effective and 
widely used, but in minority of individuals are associated with restenosis, thrombosis 
or neo-atherosclerosis. Angioplasty offers treatment using a balloon to widen the 
vessel. Early elastic recoil can limit long-term success but can be prevented by 
deployment of a metallic stent (Livingston & Lynm, 2012). The occurrence of stent 
restenosis, due to excessive smooth muscle cell proliferation and intimal hyperplasia, 
has become less of a clinical problem since the evolution of drug-eluting stents, which 
elute drugs to prevent excessive proliferation of vascular smooth muscle cells 
(VSMC) (Htay & Liu, 2005). However, drug-eluting stent restenosis remains a 
clinically challenging problem in some individuals.  
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Surgical revascularisation can be applied to the peripheral, coronary or cerebral 
circulations. Typically, this involves suturing a native artery or vein, or an artificial 
conduit, to ‘bypass’ the diseased segment of artery. The choice of percutaneous or 
surgical revascularisation is decided based on the extent and severity of the arterial 
disease, and the patient’s co-morbidities and overall fitness for surgery. 
In the majority of patients with CVD, symptom control and satisfactory tissue 
perfusion can be achieved through a combination of risk-factor modification, 
pharmacological therapy and revascularisation. However, there remains a group of 
patients who have ongoing symptoms and tissue ischemia despite conventional 
management. These patients may have severe diffuse arterial disease which is 
anatomically unsuitable for percutaneous or surgical revascularisation or may have 
developed restenosis or progressive native arterial disease despite previous 
successful revascularisation (Lozano et al., 2015). Such patients (sometimes termed 
‘no-option’ patients) comprise up to 40% of the total number of individuals with CVD 
(Teraa et al., 2016; Ylä-Herttuala & Baker, 2017). In these individuals, current 
approaches usually focus on symptom control, but quality of life and prognosis are 
often poor. In the setting of PAD, critical limb ischaemia in patients unsuitable for 
(further) revascularisation may require amputation of the affected limb. It is these 
clinical scenarios in which novel therapies, such as those investigated in this thesis, 
are likely to be most appropriate. As mentioned previously in relation to PAD, an 
approach to improve tissue perfusion is to facilitate the development of new blood 
vessels via angiogenesis processes. 
 
1.3 Angiogenesis, vasculogenesis and arteriogenesis  
Angiogenesis is the process characterised by the formation of a new vascular 
network from pre-existing blood vessels, carefully regulated by the balance of pro-
angiogenic and anti-angiogenic growth factors. Growth factor expression is elevated 
in response to activation of hypoxic and inflammatory signalling cascades during 
ischemia to induce revascularisation via activation of cellular angiogenic mechanisms 
such as migration and proliferation. The definition of angiogenesis differs from 
vasculogenesis; which specifically refers to the process of de novo blood vessel 
formation, stimulated by migration and differentiation of endothelial precursor or stem 
cells (angioblasts), rather than by hypoxia in embryonic growth (Vailhé et al., 2001). 
Although vasculogenesis is typically restricted to embryonic development, it has 
recently been reported that endothelial progenitor cells may stimulate post-natal 
neovascularisation (Balaji et al., 2013; Ribatti et al., 2001). 
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Arteriogenesis does not involve the growth of new vessels, but instead involves the 
expansion and growth of pre-existing collateral vessels, resulting in lumen area 
expansion via endothelial remodelling mechanisms (Rizzi et al., 2017). This process 
is triggered by enhanced mechanical forces influenced by fluid shear stress as a 
result of an occlusion preventing normal perfusion (Heil et al., 2006). (Figure 1.3). 
 
 
Angiogenesis may be sub-dived into several types, including ‘developmental’ and 
‘pathological’. Developmental angiogenesis is a highly regulated process required for 
vascularisation during early development of an organism and in physiological growth 
and repair (wound healing). Dysregulation of pro-angiogenic growth factors can 
cause the onset of pathological angiogenesis, which has been implicated in several 
disease states including cancer, diabetic retinopathy and psoriasis. Pathological 
angiogenesis is driven by rapid uncontrolled formation of new vascular networks and 
progression of this can be difficult to halt (Chung & Ferrara, 2011).  
Figure 1.3 Diagram highlighting different angiogenic mechanisms; vasculogenesis, 
angiogenesis and arteriogenesis 
Visual demonstrating the difference between these three types of vessel formation. 
Vasculogenesis is driven by endothelial progenitor cells. Angiogenesis is the formation of new 
vessels from pre-existing vessels. Arteriogenesis is the enlargement of the collateral vessels 
to restore perfusion. 
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Modulation of the expression of pro-angiogenic growth factors on a transcriptional 
level determines angiogenic activity. This modulation has been exploited as a 
possible therapeutic to promote vessel growth and development via angiogenesis 
and arteriogenesis across CVDs but has shown particular promise as a treatment for 
PAD. 
 
1.3.1 Pro-angiogenic growth factors and signalling pathways 
Upregulation of HIF-1α during ischemia enhances the transcription of cytokines, 
including tumour necrosis factor (TNF-α) and pro-angiogenic growth factors, which in 
turn activate angiogenic signalling cascades to induce an angiogenic response. In 
this section, the molecular actions of the pro-angiogenic factors which are activated 
to induce vessel growth are summarised.  
TNF-α is a well-established cytokine secreted in response to an inflammatory 
response with its main role in angiogenesis being to influence cells ability to secrete 
pro-angiogenic growth factors such as VEGF and PDGF. A small insult with TNF-α 
promotes endothelial tip cell formation via upregulation of pro-angiogenic factors 
during the initial sprouting stage of angiogenesis, however continuous expression of 
TNF-α delays the angiogenic effect by blocking VEGF Receptor-2 (VEGFR-2) 
(Giraudo et al., 1998; Sainson & Harris, 2008).   
VEGF is the most potent and well-established pro-angiogenic factors across 
metabolic diseases and cancer, as well as in the maintenance of regular 
homeostasis. There are 5 members to the human VEGF family, however VEGF-A 
has been implicated to induce the most pronounced angiogenic response in 
comparison to its other isoforms. It exerts its activity via binding to its tyrosine kinase 
receptor, VEGFR-2 with high affinity. (Ferrara et al., 2003). 
VEGF-A as well as FGF-1 and FGF-2, which belong to a family of 18 members are 
well known to enhance cell survival, migration and proliferation via activation of key 
cell growth and development signalling cascades such as focal adhesion kinase 
(FAK), protein kinase B (Akt) and mitogen-activated protein kinase (MAPK) (Goetz 
et al., 2014; Johnson & Wilgus, 2014). These pathways will be discussed in more 
detail towards the end of this section. 
Each of these growth factors cross talk with one another or their receptors, directly 
affecting expression levels. VEGF, as well FGF-1 and FGF-2 independently as well 
as coordinating with each other are important for vessel formation in vivo, as co-
stimulation with VEGF-A and FGF-2 significantly increased the formation of a neo 
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vessel network (Kano et al., 2005). FGF may modulate the effects of VEGF as 
disruption of FGF signalling reduced VEGFR-2 expression.  
VEGF-A has been demonstrated to exert its angiogenic properties through its heparin 
binding domain. Expression of a truncated VEGF variant in murine models led to poor 
survival past early childhood (Carmeliet et al., 1996; Ferrara et al., 1996). However, 
VEGF-A over-expression has also been associated with increasing permeability of 
the endothelial layer in vessels walls, resulting in vascular leakage and mortality in 
mice (Lee et al., 2000).   
PDGF, EGF and angiopoietins are also crucial growth factors in angiogenesis by 
regulating cell recruitment, differentiation and survival. Recently it has emerged that 
FGF-2 stimulates PDGF signalling to induce pericyte proliferation and recruitment, 
supporting previous literature highlighting that FGF and PDGF both induce migration 
of osteoblasts via ERK signalling (Hosaka et al., 2018; Kim et al., 2007). The IGF 
axis is also well known for is potent activation of the Akt pathway, promoting cell 
migration and proliferation, and mediating vessel remodelling activity (Franklin et al., 
2003; Lopez-Lopez et al., 2004). 
The majority of pro-angiogenic growth factors activate Akt and ERK/MAPK signalling 
cascades. Akt signalling is mediated by the growth factor’s ability to interact with cell 
surface tyrosine kinase receptors such as RPTPβ which regulates the inhibition of 
phosphatase and tensin homolog (PTEN) phosphorylation, resulting in downstream 
activation of Akt via phosphatidylinositol 3-kinase (PI3K). During angiogenesis, Akt 
activation can lead to further enhanced expression of VEGF and angiopoietins, 
creating a feedback loop for continuous activation of angiogenic mechanisms. 
Mutations of PTEN, as well as Akt itself have been identified in cancers, contributing 
to continuous and enhanced activation of the Akt pathway (Dillon & Miller, 2014; Yi 
& Lauring, 2016).   
MAPK is activated in response to inflammation and induces the expression of genes 
involved in cell proliferation, migration and differentiation (Srinivasan et al., 2009). 
There are three characterised MAPK families which lead the signal from the cell 
membrane to the nucleus; extracellular signal-regulated kinase (ERK) which is the 
classical MAPK pathway, c-Jun N-terminal kinase (JNK) and p38 kinase. In 
angiogenesis, most growth factors stimulate this pathway by the phosphorylation and 
translocation of ERK1 and ERK2 which is activated by small GTP binding proteins, 
MEK1 and MEK2 (Santarpia et al., 2012).   
The cross talk between pro-angiogenic factors and their action of Akt and MAPK 
signalling pathways has been extensively researched. Therefore, using the activation 
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mechanisms, we can modulate activity to achieve sufficient vessel growth via 
angiogenesis to restore perfusion to ischemic limbs. 
 
1.3.2 Collateral vessels 
Collateral circulation is an alternate vessel network consisting of small capillary like 
vessels which supply blood flow to an ischemic tissue, bypassing an occluded area 
in a artery or arteriole (Meier et al., 2013). Collateral vessels pre-exist in the 
vasculature in a non-perfused state. Their expansion is induced by an arteriogenic 
response initiated by elevated mechanical forces of fluid shear stress caused by the 
occlusion of blood flow in the main vessel and increased perfusion pressure of the 
collateral vessels. The opening and widening of collaterals take place following the 
remodelling of the endothelial layer driven by migration and proliferation in response 
to endothelial nitric oxide synthase (eNOS) expression. Monocyte recruitment and 
their differentiation into macrophages stimulate secretion of the inflammatory 
cytokine, TNF-α and VEGF expression, which upregulates growth factor expression 
of PDGF, and FGF (Clauss et al., 1990). Shear stress also induces endothelial cells 
to directly stimulate expression of PDGF and FGF (Patrick, Jr. & McIntire, 1995). 
Arteriogenesis stimulating the opening of collateral vessels drives blood flow to the 
ischemic tissues by maturing collateral arterioles into larger and stable arteries which 
can hold larger volumes of blood to compensate for the restriction in perfusion (van 
Royen et al., 2001). 
 
1.3.3 Therapeutic angiogenesis 
As discussed previously in Section 1.2.2, angiogenesis can be exploited to promote 
the formation of new blood vessels in order to restore perfusion to ischemic tissues 
when revascularisation treatments are unsuitable for CVD patients. Therapeutic 
angiogenesis has been investigated in pre-clinical and clinical studies over the last 
two decades as an alternative therapy to amputation; however, progress of this 
treatment option has been fairly limited. 
Angiogenesis to improve tissue perfusion can be promoted by local or systemic 
delivery of pro-angiogenic factors, via gene, cell or protein therapy. Gene therapy 
involves the transport of genes which encode angiogenic growth factors to the host 
genome via viral or non-viral vectors. Cell therapy relies on the delivery of selected 
cells (e.g. endothelial progenitor cells) involved in vessel formation to ischemic 
tissues. (Shimamura et al., 2013).  However, both methods are not specific or 
controlled enough to be successful as therapeutic options. They rely on the 
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uncontrolled release of angiogenic growth factors from cells and therefore the 
circulating concentrations and duration of release of growth factors can vary from 
person to person.  
Protein delivery could eliminate the problems associated with gene and cell therapy 
as it involves a systemic or local injection of pro-angiogenic growth factors to the 
ischemic tissues. As protein therapy does not rely on hosts, the concentration of pro-
angiogenic growth factors and administration times can be controlled to achieve the 
desired result. However, systemic protein injections have resulted in poor delivery 
due to mechanisms which modulate clearance of growth factors as they are 
transported to the ischemic site (Chu & Wang, 2012). 
There are several pro-angiogenic factors which have shown promise as angiogenic 
therapeutic agents in early phase-clinical studies. Plasmid human (ph) VEGF165 was 
administered to a CLI patient with occluding vessels and gangrene by using an 
angioplasty balloon, directly transferring the VEGF plasmid DNA onto the popliteal 
artery in the lower limb. There was a significant increase in collateral vessels after 4 
weeks, which remained at 12 weeks, restoring perfusion by up to 80%. It was 
reported that the patient developed peripheral edema in the legs, caused by the 
hyperpermeability activity of VEGF, resulting in swelling of the lower limbs and 
claimed to be restored via separate treatment. The treated leg had to be amputated 
5 months after treatment as gene therapy was inefficient to rescue the limb from 
gangrene, however the leakage of fluid could have possibly contributed to further 
problems in the limb. (Isner et al., 1996).  Nevertheless, this study provided hope that 
direct delivery of growth factors could be exploited and optimised to successfully 
restore perfusion.  
Clinical trials on improving recovery from PAD in the last 20 years have been 
attempted using a variety of growth factor and growth factor combinations. Table 1.1 
summarises the growth factors and cells used in the last 10 years which resulted in 
improvement to PAD, as well as delivery mode and study findings from patients 
suffering from CLI (Iyer & Annex, 2017). Therapeutic angiogenesis via bone marrow 
mononuclear cells has shown promising effects in clinical trials, reaching to phase III 
trials, as well as in enhancing endothelial tube formation in vitro and restoration of 
perfusion in ischemic skeletal muscle in vivo studies (Zhao et al., 2008).  
 
P a g e  | 13 
 
 
 
 
Although VEGF previously had shown poor side effects following treatment, recent 
interrogation by a Russian group has confirmed the therapeutic effect stimulated by 
VEGF gene therapy can last for 5 years (Deev et al., 2018). However, the problems 
associated with failure of therapeutic angiogenic treatment lies with the method of 
delivery. Cell therapy has thus far proved the most effective as a therapeutic 
angiogenic treatment via bone marrow-derived mononuclear cells. Treatment with 
this stem cell therapy has also displayed beneficial effects to nitric oxide levels by 
reducing expression levels of its inhibitor, asymmetric dimethylarginine (Madaric et 
al., 2017). Bone marrow-derived allogenic mesenchymal stromal cell therapy is also 
due to be trailed for no-option critical limb ischemia patients as an early hypothesis 
Author/Trial Treatment  Delivery Findings 
Madaric et al., 
2017; Phase II 
Bone marrow 
mononuclear cells  
Intramuscular, 
cell therapy 
Improvement in oxidative 
stress and limb salvage 
Liotta et al., 
2018; 
Phase II and III 
Bone marrow 
mononuclear cells 
and Endothelial 
Progenitor Cells 
Intramuscular, 
cell therapy 
 
Improved muscle 
perfusion, rest pain, pain-
free walking distance, 
wound healing and ankle-
brachial index 
Deev et al., 
2018; Phase II 
and III  
p-CMV-VEGF165 Intramuscular, 
gene therapy 
Improved target limb 
recovery. Improved pain-
free walking distance. 
Increased ankle brachial 
index but this decreased 
after 5 years. 
Gorenoi et al., 
2017; Review of 
20 growth factor 
trials 
FGF, HGF and 
VEGF 
Gene therapy No difference in 
amputation rates or 
improvement in walking 
ability but may reduce the 
rate of amputation 
Table 1.1 Recent advances in clinically trialled therapeutic angiogenic treatments for 
CLI 
This table summarises the recent developments made in phase II and III clinical trial treatments 
to improve recovery from critical limb ischemia. Many of the trials recently investigated are cell 
therapy techniques, predominantly with the use of bone marrow-derived mononuclear cells. 
This data was extracted from a variety of published data referenced in the table.  
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suggests the vasculoregenerative characteristics of these cells can regulate 
revascularisation to the limbs (Wijnand et al., 2018). 
Gene therapy has failed to improve recovery from CLI significantly over a pro-longed 
period (Deev et al., 2018). Although protein therapy has theoretical benefits over 
gene therapy, attempts to improve myocardial perfusion in patients with coronary 
artery disease via protein delivery failed, possibly due to protein half-life being 
shortened in the ischemic environment (Simons et al., 2002; Simons & Ware, 2003). 
Failure of FGF and hepatocyte growth factor (HGF) to improve CLI may be due to 
the administration method used and protein half-life. Another explanation may be the 
growth factors do not independently activate angiogenesis to a sufficient level to 
restore blood supply. It is clear VEGF can induce vessel formation; however, the 
negative side effects can cause further damage (Ylä-Herttuala & Baker, 2017) and 
this has to be modulated via the method of delivery. Therefore, there is potential for 
a protein that is able to modulate activity in ischemia to prevent negative effects, as 
well as enhance recovery effects from CLI to be used as a therapeutic angiogenic 
agent. 
 
1.4 Vascular permeability 
An endothelial cell monolayer lines the inner most layer of the vessel wall, 
maintaining a physical barrier ensuring large molecules do not enter the blood stream 
from the tissue (Stevens et al., 2000). A strong endothelial monolayer and stable 
communication between neighbouring endothelial cells is required for a healthy blood 
vessel.  
Cell-cell and cell-extracellular matrix junctions determine cell permeability and 
communication. There are three main types of junctions, adherens (anchoring), gap 
(communication between cells) and tight junctions (sealing of adjacent cells). 
Cadherins are calcium-dependent cell adhesion molecules which regulate the 
formation of adheren junctions between cells. Vascular endothelial (VE)-cadherin 
marks the junctions between endothelial cells. It is specifically recognised for its role 
in mediating the organisation of the endothelial layer, the permeability and 
stabilisation of the endothelial barrier via phosphorylation of its tyrosine residue, 
Tyr685 (Gavard, 2014; Sidibé & Imhof, 2014).  
The endothelial dysfunction which drives atherosclerosis results in an imbalance of 
vasodilators and constrictors, specifically a reduction in nitric oxide (NO) 
bioavailability (Gimbrone & García-Cardeña, 2016). Nitric oxide is a key regulator of 
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the endothelial barrier by modulating vasodilation and the influx of small molecules 
such as water, ions and nutrients into circulation. In the absence of NO, the 
endothelial permeability decreases due to wall stiffening caused by calcification from 
atherosclerosis, disabling movement of molecules between the barrier. Conversely, 
during the formation of new blood vessels, the use of VEGF in clinical trials as a 
therapeutic agent led to hyperpermeability of the endothelial layer and caused 
leakage between the blood and vessel wall. VEGF disrupts VE-cadherin by pulling 
cell-cell junctions apart, resulting in a weak endothelial barrier (Hoang et al., 2011). 
Although, In order to induce angiogenesis, signals from VEGF have to increase 
permeability to enable large sized plasma proteins to pass through the barrier to form 
a foundation scaffold for migrating endothelial cells (Senger et al., 1996). Therefore, 
vascular permeability induced by VEGF needs to be highly regulated. It is essential 
that new vessels formed by delivery of growth factors by therapeutic angiogenesis 
can withstand strong forces of shear stress, hydrostatic and fluid pressure as well as 
mediate the influx and outflow of small molecules by maintaining endothelial barrier 
permeability. 
 
1.5 Insulin-like growth factor axis 
The insulin-like growth factor (IGF) family makes a significant contribution to 
reproduction, repair, survival, metabolism and apoptotic pathways. This family 
consists of two growth hormones, named IGF-I and IGF-II, their respective receptors, 
IGF-IR and IGF-2R and binding proteins which regulate the activity of the IGF growth 
factors. In recent years, it has become clear that several components of the axis are 
implicated in vascular pathophysiology and more specifically in angiogenesis. In this 
section, the importance of each of the components of the IGF-axis and how they 
function in order to activate downstream signalling cascades is discussed. 
 
1.5.1 Insulin-like growth factors 
IGF-I and –II are evolutionally highly conserved growth factors, which are important 
in driving growth in-utero and post-natally until adolescence. Growth hormone is 
responsible for IGF secretion from hepatocytes as well as their endocrine functions. 
The majority of plasma IGF-I circulates bound to an IGF binding protein, which 
modulates its biological activity and bioavailability. IGF-I regulates many different 
cellular and physiological processes. IGF-I has been identified as a key molecule 
involved in regulating growth and survival mechanisms in many different cell types, 
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including endothelial cells, smooth muscle cells, endothelial progenitor cells and 
pericytes, which make it a key player in angiogenesis (Bagley et al., 2005; Okura et 
al., 2001; Shigematsu et al., 1999). It is mainly known to function through the 
angiogenic signalling pathways mentioned earlier in this chapter, Akt and ERK (Choi 
et al., 2008; Schiaffino & Mammucari, 2011). IGF-I also plays a significant role in 
metabolic homeostasis by reducing high glucose levels via IGF-I dependent 
activation of the PI3/Akt pathway, activating glycogen synthase activity (Muhič et al., 
2015). 
IGF-I expression fluctuates in different diseased states, suggesting it plays different 
roles upon different stimuli. For example, obese, type 2 diabetic and insulin-resistant 
states affect the normal functionality of IGF-I, also resulting in a reduction in its 
expression (Aguirre et al., 2016; Imrie et al., 2009; Martha et al., 2008). 
IGF-II expression is upregulated during embryonic development and levels drop post-
natally, coupled by an increase in IGF-I levels (Kadakia & Josefson, 2016; Switkowski 
et al., 2017). Although IGF-II shares significant structural homology with IGF-I, post-
natally, IGF-II has been shown to function differently to IGF-I. IGF-II has displayed 
potential in mediating cell migration in hepatocellular cancer and bone marrow cells 
however clear signalling mechanisms which activate these effects remain 
unestablished (Fiedler et al., 2006; Nussbaum et al., 2008). Single nucleotide 
polymorphisms of IGF-II have been shown to be associated with increased 
bodyweight in adult males and increase body mass index (BMI), therefore suggesting 
IGF-II may play a protective role against obesity (Gaunt et al., 2001). 
The pleiotropic effects of IGFs, specifically IGF-I and their involvement in growth and 
metabolism means it is unlikely they could be exploited as potential therapeutics. 
 
1.5.2 Insulin-like growth factor receptors 
IGF signalling is mediated via interactions of IGFs with their cognate transmembrane 
tyrosine kinase receptors, IGF-IR and IGF-IIR. IGF receptors are made up of two α 
and two β subunits, sharing high structural homology with the insulin receptor (IR) 
which also has the same structural conformation. Both IGFs can interact with IGF-IR 
with high affinity, however only IGF-II can bind to the IGF-IIR but the binding of IGF-
II to the IGF-IIR fails to activate intracellular signalling pathways due to the lack of an 
intracellular tyrosine kinase domain (Tian et al., 2016).  
IGF-I shares structural homology to insulin, and between the receptors, IGF-I can 
also bind to IR, blocking insulin-stimulated intracellular signalling and increasing 
insulin resistance (Boucher et al., 2010). The IGF-IR has been widely investigated by 
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Professor Mark Kearney’s group in our laboratory in the context of metabolic 
diseases. One set of α and β subunits from IGF-IR and one set from the IR are able 
to bind together to form a hybrid receptor. Insulin can still bind to this hybrid; however, 
it has a greater affinity for IGF-I, preventing insulin from carrying out its actions, 
resulting in a decrease in insulin sensitivity (Abbas et al., 2011). Mice over-expressing 
IGF-1R endothelial cells display enhanced cell migration. These mice also reduced 
NO bioavailability, however increased endothelial regeneration following arterial 
injury surgery (Imrie et al., 2012). Therefore, the manipulation of IGF-IR and the 
hybrids could be used to promote IGF-I stimulated angiogenic cell mechanisms to 
promote vessel growth and repair. 
 
1.5.3 Insulin-like growth factor binding proteins 
Insulin-like growth factor binding proteins (IGFBPs) are a family of six circulating 
proteins which bind IGFs with high affinity. IGFBPs are approximately 50% 
structurally homologous, with conserved disulphide bonds between cysteine 
molecules in the N and C terminals with molecular weights ranging between 22-
36kDa.  
Their primary function is to modulate the bioactivity of IGF by stimulating or 
suppressing IGF activity (Figure 1.3). Approximately 90% of all IGFs in the system 
circulate bound to an IGFBP, although the number of IGF/IGFBP complexes is reliant 
on the circulating concentrations and half-life of IGFBPs (Twigg & Baxter, 1998). 
IGFBPs have the ability to increase IGF half-life from its unbound form at 5 mins in 
serum to between 90 min and 2 hours if complexed with IGFBP-1 or -2 and up to 16 
hours with IGFBP-3 or -5 (Clemmons, 2012). 
The presence of an 80kDa glycosylated acid-labile subunit (ALS) attached to IGFBP-
3 and -5 stabilises the tertiary complex formed with IGF-I. This enables the whole 
complex with a molecular weight (MW) of 130kDa to circulate in its bound form for 
pro-longed periods of time, however due to its large size the complex is unable to 
cross the endothelium. IGFBP-3 is the most abundant of the IGFBP family in 
circulation; therefore, there are significantly more IGFBP-3/IGF complexes in serum. 
IGFBP-2 is the second most abundant circulating protein; however, IGFBP-2/IGF 
complexes have a extremely short half-life and are rarely found circulating in its 
complex form compared to IGFBP-3, due to the absence of the ALS.  
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The variable central region of IGFBPs provides flexibility to form a pocket to bind IGF 
molecules via the conserved IGF binding sites located on both the N- and C- 
terminus. Several publications highlight that mutation of one of the IGF binding sites 
eliminates all IGF binding ability, confirming the method of sequestering free IGF 
molecules and maintaining the complex via binding to both domains (Perks et al., 
2002; Shen et al., 2012).  
IGFBP-1, 3 and 5 are able to undergo phosphorylation which enhances their affinity 
for IGF, via phosphorylation sites located in the central variable region (Coverley & 
Baxter, 1997; Gupta, 2015; Mishra & Murphy, 2003). IGFBP-3, -and -4 are the only 
IGFBPs which undergo N-linked glycosylation. This linkage is vital for structural 
stability in order to bind IGF in IGFBP-4; however, IGFBP-3 displays the same affinity 
for IGF in its glycosylated and non-glycosylated form. Glycosylation has also been 
highlighted to interfere with interactions between glycosylated IGFBPs and cell 
surfaces. Glycosylated IGFBP-3 displayed restricted cell membrane interactions 
compared to its non-glycosylated form, due to changes in the folding of the protein 
(Firth & Baxter, 1999). IGFBP-5 and 6 have established O-glycosylated sites, with 
glycosylation affecting the activity of these proteins in different ways. IGFBP-5 has 
an increased affinity for heparin in its glycosylated form, suggesting the glycosylation 
interferes with ECM interactions (Forbes et al., 2012; Graham et al., 2007). 
Alternatively, to IGFBP-5, glycosylated IGFBP-6 displays a lack of interactions via its 
heparin binding domain, compared to its non-glycosylated state. Glycosylated 
Figure 1.4 IGFBPs regulation of IGF bioavailability and activity 
IGFBPs promote IGF activity by increasing IGF half-life, increasing the bioavailability of 
IGF in the circulation and directly transporting IGF to its receptor. However, IGFBPs can 
also suppress activity by remaining bound to the IGF and preventing its interaction with its 
IGF-IR or IGF-IIR. 
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IGFBP-6 increases its half-life by reducing proteolytic activity and in turn increasing 
the sequestering time period of IGF molecules. (Marinaro et al., 2000). This confirms 
each IGFBP is unique in its function, with variable factors influencing their final 
effects.  
The non-homologous areas account for interactions independent of IGF binding. 
IGFBP-I and IGFBP-2 are the only binding proteins with the ability to interact with 
integrins via their Arginine-Glycine-Aspartic Acid (RGD) domain, located on the C 
terminus of the protein (Brandt et al., 2015). Most of the IGFBPs have heparin binding 
potential excluding IGFBP-1 and -4 (Boes et al., 2002; Fowlkes et al., 1997). All 
heparin binding domains share a similar motif of BBBXXB within the C terminal or the 
central linker domain of the protein. In the central linker domains of all IGFBP-s, as 
well as crossing into the C terminus of IGFBP-1, 2, 4 and 6, thyroglobulin type 1 
domain (Forbes et al., 2012). The role of this domain is to initiate proteolytic 
degradation of the protein, enabling the release of IGF molecules to continue with 
their designated activity. IGFBP-2, 3 and 5 possess a nuclear localisation signal in 
the variable regions enabling translocation of the complete protein via the importin β 
nuclear transport factor. It has been hypothesised that these IGFBPs activate nuclear 
secreted factors, such as VEGF (Planque, 2006). 
IGFBP-2 is of particular interest to us because it is the only binding protein that can 
bind to variety of cell surface tyrosine kinase receptors as it has an integrin 
recognition site, heparin binding potential, nuclear entry potential, as well as IGF 
binding capability. All of these domains in other proteins are known to activate 
angiogenic-like signalling pathways and therefore we aim to identify if these can be 
exploited for therapeutic potential in IGFBP-2.   
 
1.5.4 IGFBPs in disease 
IGFBPs have been implicated in several pathophysiological processes and diseases. 
A brief overview of the role of IGFBPs in clinical/physiological context is provided in 
this section, followed by a more in-depth discussion of the actions of IGFBP-2 in 
Section 1.8. 
IGFBP-1 and IGFBP-2 have shown strong associations with insulin sensitivity. 
Expression of IGFBP-1 is blunted by insulin, however it acts as a biomarker for type 
1 diabetes due to its upregulated levels (Kabir et al., 2010). IGFBP-1 has been shown 
to enhance insulin sensitivity, which is hypothesised to function through the IGFBP-
1’s RGD domain (Haywood et al., 2017). IGFBP-1 expression levels in VSMCs are 
elevated by activation of an inflammatory response. Interleukin or TNFα stimulated 
P a g e  | 20 
 
 
secretion of IGFBP-1 in response to inflammation has shown to increase cell 
proliferation via IGF and IGF independent mechanisms (Wang et al., 2012). Low 
circulating IGFBP-1 and -2 levels have been associated with diabetes and CVD 
(Heald et al., 2006; Rajwani et al., 2012). Decreased IGFBP-2 levels have been 
associated with enhanced levels of lipoprotein in the plasma and therefore may prove 
to be a biomarker of the onset of atherosclerosis (Carter et al., 2014). Contrastingly, 
IGFBP-4 along with IGFBP-5 expression has been shown to promote the 
pathogenesis of atherosclerosis, due to upregulation of the binding proteins in 
atheroma plaques (Conover et al., 2010; Zheng et al., 1998). Pregnancy-Associated 
Plasma Protein-A (PAPP-A) is the protein responsible for the cleavage of IGFBP-4 
and -5 to release bound IGF molecules. Transgenic mouse model over-expressing 
PAPP-A promoted the development of atherosclerotic regions, suggesting 
atherosclerosis development is stimulated by IGF-I delivery by IGFBP-4, or even 
possibly IGFBP-5 (Harrington et al., 2007). IGFBP-6 expression is mediated by 
hypoxia in vascular endothelial cells but has been shown to inhibit IGF-stimulated 
angiogenesis in sarcoma development (Zhang et al., 2012).  
The role of IGFBP-3 in metabolic diseases is relatively unestablished as the majority 
of its research refers to its role within cancer (Hoeflich et al., 2018). With more than 
90% of all circulating IGFs bound to IGFBP-3, it exerts suppressive effects on cancer 
angiogenesis, across prostate and lung cancer (Mehta et al., 2011; Wang et al., 
2017b). Many cancer types, such as colorectal, breast, gastric and prostate cancer, 
have shown a positive correlation between tumour angiogenesis and the upregulation 
of IGFBPs. Expression of IGFBP-3 elevated levels have shown an association with 
increasing levels of epidermal growth factor receptor in triple-negative breast cancer 
tumours, suggesting they coordinate their bioactivity to promote tumour growth and 
survival (Marzec et al., 2015). IGFBP-2 is the only other binding protein which has 
demonstrated a positive correlation with tumour growth in breast, collateral, prostate 
and pancreatic (Liu et al., 2017; Yau et al., 2015a). IGFBP-1 and -5 are well known 
for their tumour suppressive abilities by inhibiting cancer cell invasion and migration 
(Dai et al., 2014; Sureshbabu et al., 2012). IGFBP-4’s role in cancer development 
remains relatively unclear as it displays multiple effects according to the cancer type 
and stage of tumour growth, however, IGFBP-4 has the potential to exert tumour 
suppressor activity by supressing the growth and survival of colon and prostate 
cancer cells (Damon et al., 1998). However, in a different colon cell line, upregulation 
of IGFBP-4 correlated with cell differentiation (Corkins et al., 2002). 
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This summary highlights that all IGFBPs can induce IGF-independent-mediated 
effects in diseased states. With many disease variables affecting the fluctuation of 
IGFBP expression levels, it is difficult to distinguish clear mechanisms by which 
IGFBPs exert their effects. 
 
1.5.5 IGFBP-related proteins 
In addition to the 6 members of the IGFBP family, in the recent decades, further 
IGFBP related proteins have been discovered, namely IGFBP-rP1-9. These proteins 
share homology with the N-terminal end from IGFBPs-1-6 but display structural 
differences beyond this region, resulting in a lower binding affinity for IGF-I (Kim et 
al., 1997). IGFBP-rP1, also referred to as Mac25 or IGFBP-7 has been gaining much 
interest in the recent years as it also displays insulin binding capabilities, as well as 
IGF, through the conserved cysteines in the N terminal region (Akaogi et al., 1996). 
Research highlights the multiple metabolic roles IGFBP-rP1 may have, however 
mechanisms are not clearly established. The other related IGFBP-rPs have not 
surfaced to play significant roles in the modulation of IGF or IGF-independent 
interactions with metabolism and therefore are rarely the focus of research. 
 
1.6 Insulin-like growth factor binding protein-2 
IGFBP-2 has been reported to have roles in regulating metabolic activity, as well as 
pathophysiological processes in a range of diseased states and cell types. However, 
very few articles have attempted to identify the mechanisms IGFBP-2 functions 
through to exert its cellular effects due to its complex interactions with multiple cell 
surface tyrosine kinase receptors and possibly nuclear entry (Figure 1.5).  
IGFBP-2 is a 36kDa protein and is the second most abundant circulating binding 
protein that can increase the half-life of IGFs. However, IGFBP-2 also exerts several 
IGF-independent effects via its RGD domain, HBD1 and HBD2 sites and its nuclear 
localisation signal. The majority of these IGF-independent interactions have been 
demonstrated to drive cell migration and proliferation, as well as to suppress tumour 
growth in a variety of cancer and non-cancer cell types including glioma, prostate 
cancer cells, VSMCs, osteoblasts and adipocytes. However, extremely limited 
research has been carried out to investigate the actions of IGFBP-2 on vascular 
endothelial cells.   
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1.6.1 Insulin-like growth factor binding 
IGFBP-2, similar to all IGFBPs, is able to increase the half-life of IGFs and it can 
transport IGFs directly to the IGF receptors, in turn enhancing IGF dependent 
mechanisms. The half-life of IGF in the circulation is only extended to a short period 
of between 90 min and 2 hours by IGFBP-2, due to the absence of the ALS in the 
complex formed (Clemmons, 2012). The central variable and flexible region of 
IGFBPs enables IGFBP-2 to mould around IGF-I and –II molecules to ‘sequester’ 
them. The capturing process enables IGFBP-2 to control the activity of IGF by release 
via proteolysis of IGFBP-2 or by remaining in its bound form, in turn inhibiting binding 
to the IGF-IR. IGFBP-2 also requires both IGF binding domains to remain completely 
functional for successful IGF regulation (Demambro et al., 2012).  
This study by Demambro et al., (2012) highlighted a functional IGF binding domain 
is essential to mediate the differentiation of osteoclasts via activation of the Akt 
signalling pathway, which is not stimulated through PTEN dephosphorylation. 
However, IGF/IGFBP-2 interactions are less pronounced compared to IGFBP-2’s IGF 
independent stimulated effects, therefore there is limited research on the activity of 
the IGF binding potential of IGFBP-2. 
 
1.6.2 Receptor Protein Tyrosine Phosphatase-β interactions 
IGFBP-2 HBD1, which is present in the central variable region interacts with the 
tyrosine kinase receptor RPTPβ, located on the cell surface and induces intracellular 
Akt signalling cascades in certain cells, e.g. vascular smooth muscle cells and 
osteoclasts. The mechanism by which IGFBP-2 stimulates RPTPβ is by mediating 
the dephosphorylation of PTEN, activating downstream targets PIP3, PDK, and 
eventually leading to Akt. This IGFBP-2 interaction has been demonstrated to play a 
critical role in many cellular and pathological processes.  
HBD1, although to a lesser extent than HB2 in the C terminal protects against obesity 
be supressing preadipocyte differentiation into adipocytes, suggesting some of this 
activity may be due to RPTPβ (Xi et al., 2013). This initial observation of the inhibition 
of preadipocyte differentiation was reported by (Wheatcroft et al., 2007), however a 
global over-expressing hIGFBP-2 mouse model was used for this study and specific 
signalling via one of IGFBP-2 structural domains was not studied.  
In vitro over-expression of RPTPβ inhibited osteoclast differentiation in the absence 
of IGFBP-2 as inactive RPTPβ is unable to modulate the dephosphorylation of PTEN. 
PTEN in its phosphorylated form prevents the activation of downstream targets 
leading to Akt, hence preventing Akt mediated differentiation. However, with the 
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addition of IGFBP-2, osteoclast differentiation was rescued confirming this 
differentiation is stimulated by IGFBP-2 HBD1. (Xi et al., 2014).  
In pancreatic cancer, the suggested mechanism for the nuclear translocation and 
phosphorylation of NF-κB was through HBD1/ RPTPβ- activated Akt signalling. Cells 
from this malignancy upregulated levels of IGFBP-2 and this was associated with 
tumour growth. Pancreatic carcinoma cells failed to induce the activation of NF-κB 
signalling in response to elevated PTEN levels, confirming this activity was stimulated 
by IGFBP-2/ RPTPβ interactions to stimulate Akt phosphorylation (Gao et al., 2016). 
The importance of IGFBP-2/ RPTPβ’s interaction was supported further by the 
following study. Mice over-expressing a hIGFBP-2 mutant with a non-functional 
HBD1 site, displayed a phenotype with reduced neuronal markers affecting the 
overall function of the brain (Schindler et al., 2017). Anxiety-like characteristics were 
eliminated by 80 weeks of age, suggesting IGFBP-2 activated RPTPβ plays a 
significant role in early brain development. 
From these findings, we can assume IGFBP-2-activation of RPTPβ is critical to cell 
differentiation and activation of certain signalling pathways, indirectly stimulated by 
Akt. Abolishment of IGFBP’s ability to act with the tyrosine kinase receptor via its 
HBD1 domain resulted in complete loss of activity, suggesting there aren’t any 
mechanisms stimulated by IGFBP-2 that can compensate for the loss of Akt 
activation. 
 
1.6.3 Nuclear transport 
IGFBP-2 has been reported to enter the nucleus and participate in transcriptional 
regulation, although the evidence for this is weak. The main mechanism reported is 
nuclear importins are able to translocate IGFBP-2 into the nucleus where it activates 
VEGF and mediates its transport to its receptor, VEGFR2, activating VEGF signalling 
pathways (Azar et al., 2011, 2014). This was hypothesised to be the driving force for 
the enhancement of in vitro endothelial cell tube formation by IGFBP-2 (Das et al., 
2013). There is some controversy over the nuclear localisation of IGFBP-2 reported 
in neuroblastoma cancer cells as cell membranes were permeabilised prior to 
experimental exposure to IGFBP-2 (Azar et al., 2014). It is unclear whether IGFBP-2 
in the extracellular space can cross the cell membrane in a physiological setting. 
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1.6.4 Glycosaminoglycan interactions 
IGFBP-2 mediated glycosaminoglycan interactions are thought to be mediated 
predominantly via HBD2 while HBD1 mediates RPTPβ activation.  Interaction via this 
HBD2 domain is relatively unestablished. Differentiation of pre-adipocytes is inhibited 
more potently by HBD2 than HBD1, as confirmed by mutation of the heparin binding 
domain sites (Xi et al., 2013). Arai et al., (1996) found that heparin binding capability 
of IGFBP-2 is only initiated once IGFs have bound to the binding protein, inducing a 
conformational structural change, and exposing the HBD.  
These interactions may not be as potent as the interactions between IGFBP-2 and 
RPTPβ and therefore effects of this interaction may not be as pronounced. More 
research needs to take place to understand the role of how glycosaminoglycan 
functions with IGFBP-2 and what signalling pathways it specifically activates. 
 
1.6.5 Integrin interactions 
IGFBP-2 has been shown to interact with integrins via its RGD domain which 
modulates cell proliferation and migration mechanisms via activation of MAPK 
signalling pathways. As mentioned briefly in Section 1.5.1, IGF-I activates PI3K/Akt 
to induce cellular glucose uptake. However, IGFBP-2-modulated glucose uptake 
Figure 1.5 Potential Interaction of IGFBP-2 
This diagram displays all the possible interactions IGFBP-2 has been associated with in 
literature to drive intracellular and nuclear signalling. This image has been adapted using 
findings from the publications discussed in this section (1.6). 
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appears to be stimulated by its RGD domain, via an upregulation of FAK and integrin-
linked kinase (ILK), increasing levels of insulin mediated glucose transporter type 4 
(GLUT4) (Reyer et al., 2015). 
Glioma cell proliferation, invasion and migration are driven by the interaction of 
IGFBP-2 with β1 integrin subunit causing the activation of ERK/MAPK signalling 
cascades, confirmed by the knocking down of β1 which resulted in the loss of ERK 
activity (Han et al., 2014). IGFBP-2/α5 interactions have demonstrated a significant 
role in glioma cell mobility by increasing the number of focal adhesions. Mutant RGD 
domain failed to present focal adhesion and lamellipodia-like morphology, which 
promote migration of cells, however this was rescued with the addition of functional 
IGFBP-2 and α5 (Wang et al., 2006). Angiogenic mechanisms in melanoma have 
been suggested to be stimulated by IGFBP-2 via its interaction with αVβ3 (Das et al., 
2013). However, this IGFBP-2/integrin interaction was previously described to 
modulate IGF activity. Breast cancer cells which upregulated αVβ3, when stimulated 
with IGFBP-2, IGFBP-2/αVβ3 interaction in-directly suppressed IGF-I mediated 
migration responses (Pereira et al., 2004). 
Nevertheless, published literature demonstrates IGFBP-2 predominantly exerts its 
cellular activities via the interactions between the RGD domain and the integrins 
α1β1, α5β1 and αVβ3. The majority of these interactions have only been investigated 
in cancer cell lines and the exerted effects may vary between different cell types. 
 
1.6.6 Insulin-like growth factor binding protein-2 in disease 
IGFBP-2 has been implicated in playing a role in several diseased states. This 
section will bring together the published research on the role of IGFBP-2 within 
diseases to help us notice if certain mechanisms are cell type-dependent or disease-
dependent. This will help us understand how IGFBP-2 may function in vascular 
endothelial cells and how it may mediate recovery in response to ischemia. 
Metabolic diseases such as obesity and diabetes influence the concentration levels 
of IGFBP-2 in circulation. In obesity, IGFBP-2 concentrations are down-regulated 
compared to normal circulating levels (Hedbacker et al., 2010). IGFBP-2 was 
reported to prevent pre-adipocyte differentiation and proliferation, protecting against 
the onset of obesity in high fat fed mice and insulin resistance compared to WT 
littermates (Wheatcroft et al., 2007). This has been supported by findings confirming 
IGFBP-2 inhibits development of human visceral adipocytes by reducing expression 
of key lipogenic markers. This activity is thought to be mediated by IGFBP-2’s HBD, 
as stimulation with mutant HBD resulted in reduction of lipid abundance, and 
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therefore restored activation of lipogenesis via FAK and Akt signalling (Yau et al., 
2014). Insulin sensitivity in obese children has been associated with reduced IGFBP-
2 circulating levels which matches the low IGFBP-2 levels associated with type 2 
diabetes (Frystyk et al., 1999; Yau et al., 2018). 
The majority of IGFBP-2 research is carried out in cancer cell lines, as in most of 
them IGFBP-2 expression is upregulated and this correlates with tumour growth. 
IGFBP-2 has recently been shown to promote cell invasion, proliferation and 
migration of glioma cells and breast cancer cells via activation of ERK/JNK mediated 
MAPK and de-phosphorylated PTEN activation of Akt (Foulstone et al., 2013; Han et 
al., 2014).  
Contrastingly to reports of IGFBP-2 being upregulated to tumour progression in 
glioma, IGFBP-2 levels are found to be downgraded in a high-grade glioma. These 
reduced levels were shown to be due to p16, which is usually deleted in cancers. p16 
is well known to down-regulate IGFBP-2 levels but does not halt glioma progression 
(Moore et al., 2009). Fluctuation of IGFBP-2 concentrations in relation to cancer 
stage was also investigated using prostate cancer cells, with IGFBP-2 being elevated 
in affected patients’ plasma (Cohen et al., 1994). Studies with breast cancer cells 
confirmed IGFBP-2 drives growth and survival, and when IGFBP-2 is silenced, this 
effect is lost. Some studies suggest IGFBP-2 stimulated growth and survival of 
cancer cells is via integrin, or reduction in PTEN expression causing inactivation of 
Akt stimulated pathways (Pereira et al., 2004). 
There are few data implicating IGFBP-2 in CVD and the studies that have been 
carried out are conflicting. High concentrations of IGFBP-2 were associated with 
dysfunctional left ventricular ejection fraction (Berry et al., 2015). De Kort et al., 
(2010) identified reduced levels of IGFBP-2 are a marker of increased risk of 
cardiovascular disease in young adults who were born small for gestational age.  
IGFBP-2 demonstrates roles as a protector, an activator and a suppressor of different 
cell processes depending on its stimulus in diseased states. By identifying the 
mechanism that IGFBP-2 drives through endothelial cells to promote angiogenic-like 
characteristics, we could exploit and optimise that particular mechanism with 
additional stimuli to achieve our desired result. 
 
1.7 Summary 
IGFBP-2 remains an understudied binding protein which is known to function through 
its multiple domains to induce intracellular mechanisms via IGF-I, integrin, RPTPβ, 
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glycosaminoglycans interactions or nuclear entry. However, IGFBP-2 has shown 
promise with its effects in obesity and cancer, that it has the potential to regulate 
angiogenic-like mechanisms in endothelial cells. With growth factors failing in clinical 
trials for treatments for PAD, IGFBP-2 currently promotes functional changes in non-
endothelial cell types by which it can promote and suppress their activity, dependent 
on external stimuli. These mechanisms could potentially be exploited in order to 
increase new healthy blood vessel growth in the setting of ischemia.   
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Chapter 2 - Hypothesis and aims 
 
2.1 Hypothesis 
IGFBP-2 can promote the formation of new, healthy blood vessels in ischaemia and 
provide a potential novel treatment for ischemic cardiovascular diseases. 
 
2.2 Aim 
To investigate the mechanisms by which IGFBP-2 promotes angiogenesis in vitro 
and interrogate the potential for IGFBP-2 to promote recovery from ischaemia in vivo. 
 
2.3 Objectives 
• Investigate if increasing IGFBP-2 concentration promotes recovery from 
hindlimb ischaemia in vivo. 
• Determine if local expression of IGFBP-2 is upregulated in ischaemia and 
acts as a driver of angiogenesis. 
• Identify which angiogenic signalling pathways are targeted by IGFBP-2. 
• Interrogate whether angiogenic functionality of endothelial cells is 
upregulated by IGFBP-2. 
• Create individual mutation of the IGF binding, RGD site and HBD/NLS via 
site-directed mutagenesis to identify which structural domain of IGFBP-2 is 
critical to stimulate angiogenic responses. 
• Investigate whether IGFBP-2 modulates permeability of the endothelial 
monolayer. 
 
2.4 Significance and impact 
As described in the introduction, IGFBP-2 has been established to contribute 
significantly to cellular responses in metabolism, growth, diabetes and cancer which 
implies it could be potentially be exploited for therapeutic angiogenesis. However, the 
role of IGFBP-2 within ischemic cardiovascular diseases is unknown. The angiogenic 
potential of IGFBP-2 within ischemia has also not been fully investigated. By 
identifying the underlying mechanisms by which IGFBP-2 regulates angiogenesis, 
we may be able to propose IGFBP-2 as an additional therapeutic strategy for 
ischemic diseases. The development of IGFBP-2 as a therapeutic angiogenic agent 
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would add to current treatment options available, potentially resulting in a decrease 
in morbidity and mortality in patients with ischaemic disorders. 
 
2.5 Ethical implications 
The use of murine models was approved and all procedures were performed 
according to the guidelines set out in the project licences (40/3523, 70/8115, 
P144DDOD6) and awarded personal licence (I6AF7B00B), which have been 
approved by Home Office UK regulation – Animals (Scientific Procedures) Act 1986. 
Annual usage reports were submitted to the Home Office UK summarising the 
severity of all experimental procedures undertaken. All experiments were carried in 
designated rooms within the University of Leeds – Animal Facility or Leeds Institute 
of Cardiovascular and Metabolic Medicine. 
 
2.6 Safeguarding of data 
All data generated were stored according the safeguarding regulations outlined by 
the University of Leeds. The policy covers the confidentiality and the storage of all 
data on university-approved computers and networks.  
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Chapter 3 – General methods 
 
3.1 Cell culture 
All cell centrifugation steps were carried out at 300xg for 5 mins. 
In order to count cells, trypan blue (Life Technologies, 1520061) and a cell counting 
chamber (Hawksley, AC100) were used to count the cells and were then split to 
achieve a cell density of 1x106 (in a T75 flask), 3x105 (in a T25 flask) or 1x104 (per 
well of a 6-well plate (Sarstedt, 83.3920.300). 
Cells were passaged by washing the cell monolayer with Dulbecco’s phosphate 
buffered saline (PBS), pH 7.4, followed by addition of trypsin (Life Technologies, 
25200072). Trypsin activity was deactivated with Dulbecco’s Modified Eagle Media 
(DMEM), containing 10% Fetal Bovine Serum (FBS) and 1% antibiotic-antimyotic 
solution (AAS). 
All cells were incubated at 37ºC with 5% CO2 in a humidified incubator, unless stated 
otherwise. 
 
3.1.1 Human Umbilical Vein Endothelial Cells 
Pooled Human Umbilical Vein Endothelial Cells (HUVECs) (Promocell, C-12208) 
were either cultured in Promocell Endothelial Growth Media 2 (Promocell, C-22011), 
with supplement mix (Promocell, c-39216) and 1% AAS (Invitrogen, 15240) or M199 
endothelial growth media (Sigma-Aldrich, M4530), supplemented with 20% FBS 
(BioSern, FB 1001/500), 2% 1M hepes (Sigma-Aldrich, 83264), 2% sodium pyruvate 
(Sigma-Aldrich, S8636), 0.5% endothelial cell growth supplement (Sigma-Aldrich, 
E2759), 0.5% heparin sodium (1000Units/ml) (LEO Laboratories) and 1% AAS. 
 
3.2 Cell lysis 
Cells were washed twice with ice-cold PBS pH 7.4. Cell extraction buffer (Invitrogen 
FNN0011) (with 0.002% protease (Sigma, P8340) and 0.002% phosphatase (Sigma, 
P0044) cocktail inhibitors) was used to lyse cells. Lysates were purified by 
centrifugation at 13,000 rpm, 4ºC for 15 mins and the supernatant was collected. 
 
3.3 Immunoblotting 
A Bicinchoninic acid (BCA) protein assay kit (Pierce 23225) was used to determine 
the total protein concentration of cell lysates. Samples were mixed with LDS sample 
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buffer and sample reducing agent. Samples were heated for 5 mins at 95ºC, before 
being loaded into wells of a 4-12% Bis-Tris gel (NuPAGE NP0335), with a MW marker 
(Biorad 161-0385). Gel was submerged in diluted MES SDS running buffer (20x) 
(NuPAGE NP002) and run at 180V for 1 hour. 
 
 
 
 
Polyvinylidene difluoride membranes (Millipore) were activated with methanol and 
sandwiched with the gel. Transfer buffer (Table 3.1) was diluted with methanol 
(Fisher Scientific, M/4056/17) and distilled water (dH2O). The transfer was run at 
100V for 45 mins. 
Transferred membranes were blocked in 5% BSA (made up with TBST (table 2)) and 
then incubated in primary antibodies (Table 3.2) for 16-20 hours at 4ºC on an orbital 
shaker. All wash stages were performed with TBST at room temperature (RT). The 
membrane was submerged in secondary polyclonal antibodies (Table 3.3) for 1 hour 
at RT. Anti-western-C marker (Biorad 161-0385) was incubated with the membrane 
for 10 mins followed by final washing steps.  
Immobilon Western Chemiluminescent HRP Substrate (Millipore, WBKLS0500) was 
pipetted over the blot. Imaging software, SynGENE and the SynGENE GBOX were 
used to capture an image of the membrane.  
All membranes were stripped using 2% glycine stripping buffer (0.2M glycine, 0.1% 
SDS, pH2.5). 
 
Solution Contents 
Transfer buffer 0.48M tris base (Fisher Scientific, BP152), 
0.39M glycine (Fisher Scientific, BP381-1) and 
0.1% Sodium dodecyl sulphate (SDS) (Sigma, 
05030) 
Tris-buffered-saline (TBST)  
pH 7.2 
(10x Stock Solution) 
1.7M NaCl, 190mM Tris HCl (Fisher Scientific, 
BP153), 27mM KCl (Fisher Scientific, 
P/4280/60) and 0.1% tween 20 (Sigma, P9416) 
Table 3.1 Transfer and TBST wash buffer recipe 
The components and concentrations used to make transfer buffer for the transfer of the gel 
to the membrane and a 10x stock solution of TBST buffer to wash the membranes ready for 
blocking with the antibody. The 10x TBST stock as diluted to a 1x solution for experiments. 
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Antibody Company Molecular 
Weight (kDa) 
Species Dilution Diluting 
agent 
Phospho-
eNOS 
Cell Signalling 140 Rabbit 1/1000 All 
antibodies 
were diluted 
in 5% BSA 
(Made up 
with TBST) 
(except *) 
eNOS Cell Signalling 140 Rabbit 1/1000 
Phospho-
FAK 
Cell Signalling 125 Rabbit 1/1000 
FAK Cell Signalling 125 Rabbit 1/1000 
Hsp90 Santa Cruz 90 Mouse 1/20000 
Phospho-
Akt 
(Ser473) 
Cell Signalling 60 Rabbit 1/1000 
Anti-Akt BD Biosciences 60 Mouse 1/1000 
Phospho-
PTEN 
Cell Signalling 54 Rabbit 1/1000 
Phospho 
GSK3β 
Cell Signalling 46 Rabbit 1/1000 
p-MAPK Cell Signalling 42-44 Rabbit 1/1000 
*MAPK Cell Signalling 42-44 Mouse 1/1000 *5% Milk 
(Sigma, 
70166) in 
TBST 
β-Actin Santa Cruz 42 Mouse 1/3000 5% BSA in 
TBST IGFBP-2 Santa Cruz 36 Goat 1/1000 
Table 3.2 Primary antibodies for immunoblotting 
List of all the antibodies used in the immunoblotting experiments carried out 
throughout this thesis. The table consists of the company which the antibody was 
sourced from, the expected molecular weight and diluting agent used for signalling 
studies. 
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Table 3.3 Secondary polyclonal antibodies 
List of secondary antibodies sourced from Jackson ImmunoResearch Laboratories and the 
dilution used to help visualise the primary antibody on the membrane. 
 
 
3.4 Biotinylated IGF-I ligand blotting 
LDS sample buffer and lysis buffer were added to varying concentrations of 
commercially sourced recombinant IGFBP-2. Reducing agent was not added and the 
samples were not heated prior to being loaded on a 4-12% Bis-Tris gel with the 
molecular weight marker. The gel was run, and the transfer was carried out using the 
same conditions as the immunoblotting process in 2.3.4. Membranes were blocked 
in 5% BSA/TBST (as mentioned in Section 2.3.4) for 1 hour at room temperature. 
Biotinylated IGF-1, produced by Dr Paul Cordell was made to a 1:1000 dilution using 
5% BSA/TBST and incubated with the membrane for 2 hours at room temperature. 
The membrane was washed 3x10 min with TBST. Streptavidin was diluted 1:5000 in 
5% BSA/TBST and incubated with the membrane for 1 hour. The membrane was 
washed 2x10 min before being imaged in the same manner as stated in Chapter 3.3. 
Membranes were stripped and probed for IGFBP-2 using the immunoblotting method 
 
 
 
  
Antibody Dilution 
Donkey anti-mouse Prepared to a 1:5000 dilution in 5% milk powder with 
TBST Donkey anti-rabbit 
Donkey anti-goat 
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Chapter 4 - Investigating the effect 
of over-expression of IGFBP-2 on 
recovery from hind limb ischemia 
in vivo 
 
4.1 Background 
There has been fairly limited research regarding IGFBP-2s involvement in 
angiogenesis. IGFBP-2 has been associated to promote many angiogenic-like 
characteristics such as invasion, migration, proliferation and survival (Foulstone et 
al., 2013; Han et al., 2014; Liu et al., 2017). In addition, due to the complexity of 
IGFBP-2s structure and multiple interactions, there is much uncertainty regarding the 
predominant mechanism responsible for these actions. The majority of research on 
IGFBP-2s potential in enhancing angiogenic-like characteristics has been carried out 
on cancer cells, and has not been investigated in a cardiovascular context (Azar et 
al., 2011; Patil et al., 2016). Many publications have reported IGFBP-2s protective 
mechanisms against the onset of obesity and therefore it is plausible these protective 
characteristics may be exerted upon an ischemic insult (Wheatcroft et al., 2007; Yau 
et al., 2015b). 
In order to determine whether IGFBP-2 does play a role within ischemia-induced 
angiogenesis and whether this role can be exploited for therapeutic potential, it is 
necessary to identify the specific mechanisms through which it functions. As this has 
not previously been researched at an in vitro or in vivo level, the starting point of this 
project is to identify if IGFBP-2 plays a vascular angiogenic type role to aid recovery 
from ischemia in a mouse model. This would give us the validation to investigate the 
mechanisms activated further for the use of IGFBP-2 on a translational medicine 
level. As our main aim is to use IGFBP-2 as a potential therapeutic for PAD, we will 
be using an in vivo representative surgical model, hind limb ischemia (HLI) (Niiyama 
et al., 2009). Observing how over-expression of IGFBP-2 on a global and endothelial-
specific level can help to restore perfusion to the lower limbs that have been starved 
of a blood supply, will enable us to determine if IGFBP-2 does play a role in 
angiogenesis. 
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4.1.1 IGFBP-2 in vivo models 
Currently, the only IGFBP-2 in vivo animal models used to develop IGFBP-2 research 
are global mIGFBP-2 knock out (KO) and global hIGFBP-2 over-expression mice.  
Initial characterisation of the KO IGFBP-2 mouse highlighted IGFBP-1, -3 and -4 
levels were elevated in response to the absence of IGFBP-2 (Wood et al., 2000). This 
suggests there is a particular requirement for IGFBP-2 in regular homeostasis as the 
family of IGFBPs attempt to compensate for the loss of activity. The communication 
mechanisms between IGFBP-2 and the family of IGFBPs are relatively 
unestablished, however limited publications have highlighted IGFBP-2 and -3 
function in combination to modulate IGF-I actions (Alkharobi et al., 2016). The KO 
IGFBP-2 model is mainly known for its gender-specific differences in bone 
development, with male mice demonstrating reduced proliferation of osteoblasts and 
osteoclasts compared to their female counterparts. They also identified the absence 
of IGFBP-2 caused a significant increase in PTEN levels compared to global over-
expressing IGFBP-2 mice, confirming IGFBP-2 can regulate Akt signalling via 
modulation of PTEN. (DeMambro et al., 2008). 
The first global hIGFBP-2 over-expressing murine line was produced and 
characterised by Hoeflich et al., (1999). This mouse model displayed a reduced 
carcass weight in globally over-expressing hIGFBP-2 transgenic mice compared to 
WT littermates. Further research carried out by Wheatcroft et al., (2007) on a global 
over-expressing hIGFBP-2 mouse line identified its protective nature, preventing the 
onset of obesity and insulin resistance following a high fat diet. IGFBP-2 directly 
prevented fat development by suppressing the proliferation and differentiation of 
adipocytes, resulting in protection against weight gain. Thus, again highlighting 
IGFBP-2 is able to exert protective properties to restore regular health, specifically in 
regard to cardiovascular disease.  
 
4.1.2 Recovery from hind limb ischemia 
HLI surgery is a commonly used in vivo angiogenesis experimental procedure, in 
which the blood flow to the lower leg is disrupted, resulting in an immediate 
inflammatory response. As there is no evidence of IGFBP-2 driving an angiogenic 
response or vessel growth directly, it is very difficult to hypothesise the effect IGFBP-
2 over-expression may have on recovery. However, IGFBP-2 has been reported to 
be essential to embryonic vascular development in vertebrates (Wood et al., 2005).  
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Arteriogenesis, as discussed in Chapter 1, is the first mechanism to be activated in 
response to a restriction in blood supply. A build-up of shear stress from the blood 
flow attempts to relieve the pressure by causing the enlargement of vessels or 
collateral artery formation (Duvall et al., 2004). Collateral vessel circulation is an 
alternative network of smaller sized vessels which can compensate for a blockage in 
artery in order to relieve the blood pressure and transport the blood to its end location 
(Figure 4.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene profiling following ligation of the penile artery in rats resulted in an ateriogenic 
recovery response; however IGFBP-2 was not involved as expression levels 
remained unchanged from before and after ligation (Lin et al., 2001) 
As arteriogenesis is induced by shear stress and not hypoxia, it is the initial mode of 
recovery following HLI, before an inflammatory response is signalled. In contrast, 
angiogenesis is induced by hypoxia and drives the formation of small capillaries 
(Shireman, 2007). Therefore, angiogenesis would begin to occur later on in the 
recovery process. IGFBP-2 has been reported to regulate HIF-1α expression in 
neuroblastoma tumour metastasis and later findings have confirmed the interaction 
between IGFBP-2 and HIF-1α are critical for the growth of glioblastoma cells (Azar 
et al., 2011; Lin et al., 2015). Activation of VEGF, a potent inducer of angiogenesis, 
is modulated by IGFBP-2 to induce an angiogenic-type response in HUVECS in vitro 
(Das et al., 2013). This suggests IGFBP-2 begins to induce a response before 
Figure 4.1 Arteriogenesis mechanism 
Small capillary sized collateral vessels remain closed between healthy blood 
vessels. Blockage in the artery onsets arteriogenesis and causes the expansion 
of collateral vessels into larger sized arterioles to restore perfusion via the 
alternative artery. Adapted from Iwasawa et al., (2016). 
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angiogenesis has begun, as it may be responsible for expression of the angiogenesis 
induction factor, HIF-1α and VEGF in ischemia. It is important to note that IGFBP-2 
is upregulated in ischemic brain, probably as a result of hypoxia (Fletcher et al., 
2013). Therefore, there is evidence that it might be playing a role in driving recovery 
from ischemia. Fletcher et al., (2013) also suggested a proposed mechanism that 
IGFBP-2 may transport IGF-I directly to the ischemic site and upregulate IGF-I 
pathways to rescue the blood flow as confirmed by an upregulation of IGF-I, 
correlating with upregulation of IGFBP-2 72 hours after stroke. 
Therefore IGFBP-2 levels may also be elevated in response to PAD. To determine if 
IGFBP-2 drives arteriogenesis and/or angiogenesis mechanisms, we need to identify 
how long it takes IGFBP-2 to induce a response to the ischemic environment and 
how it functions in order to restore perfusion. 
 
4.1.3 Summary 
Although IGFBP-2 has never previously been known to directly promote 
angiogenesis, its upregulation has been positively correlated with tumour growth, via 
enhancement of mechanisms such as invasion, migration and proliferation. IGFBP-2 
global KO and over-expressing mouse models have highlighted its role in mediating 
cell proliferation and differentiation in vivo, as well as displaying a protective nature 
in compromised health states. 
Therefore IGFBP-2 has the potential to enhance the restoration of perfusion following 
HLI. The endothelial-specific over-expression of IGFBP-2 model will confirm if 
IGFBP-2 mediates endothelial cell migration and proliferation to drive an arteriogenic 
and angiogenic recovery response. 
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4.2 Experimental objectives 
We aim to identify if IGFBP-2 plays an angiogenic reparative and a protective role in 
the context of PAD using in vivo murine models. This is important because we need 
to prove IGFBP-2s ability as a potential therapeutic angiogenic acute treatment in a 
clinical setting. Using in vivo models will also clarify IGFBP-2 does not cause the 
same negative angiogenic outcome caused by VEGF and functions through a VEGF-
independent mechanism. Therefore, these findings would provide a foundation and 
reasoning to investigate IGFBP-2s role in angiogenesis further. The research in this 
chapter was carried out using the objectives listed:   
• Investigate the local expression of IGFBP-2, in relation to VEGF in ischemic 
limbs in wild-type mice. 
• Investigate the effects of the global over-expression of hIGFBP-2 and the 
endothelial-specific over-expression of hIGFBP-2 on perfusion recovery 
responses following the use of a PAD in vivo model, HLI. 
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4.3 Materials and Methods 
4.3.1 Generation of gene modified mice 
Global over-expressing hIGFBP-2 model 
Dr Paul Crossey (Kings College London) produced this globally over-expressing 
hIGFBP-2 transgenic (TG) mouse model (Wheatcroft et al., 2007). The mice were 
purchased from The Jackson Laboratory where they had been banked after 
generation (stock number 008222). 
The complete IGFBP-2 transgene, at a total MW of 39kb was extracted from a human 
cosmid clone Pronuclear microinjection was used to deliver the gene into FVB/N 
embryos. These transgenic mice were generated via backcrossing and continuously 
bred with C57BL/6J mice for a minimum of 9 generations. The C57BL/6J mice have 
been recommended as the non-carrier control/wild-type (WT) for hIGFBP-2 mice due 
to it sharing a 94% background with them. The line of mice globally overexpressing 
human IGFBP-2 has been maintained at the University of Leeds Animal Unit.  
 
Endothelial-specific over-expressing hIGFBP-2 model 
The flox hIGFBP-2 mouse was produced by Genoway in 2017. A Rosa26 approach 
was used to create the knock-in of hIGFBP-2. Genoway ‘knocked’ in a targeting 
vector containing hIGFBP-2, promoter and STOP cassette into the mouse’s own 
Rosa26 locus. The Conditional hIGFBP-2 over-expression is driven by the Chicken 
β-Actin (CAG) promoter. However, there is a STOP casette in between the promoter 
and the protein therefore expression only takes place once the STOP casette has 
been excised. LoxP sites are placed either side of the STOP casette which can be 
catalysed by Cre recombinase, removing the STOP cassette, stimulating hIGFBP-2 
over-expression (Figure 4.2). 
An inducible VE-Cadherin Cre-recombinase mouse was a kind gift provided by Dr 
Ralf Adams. This mouse is inducible due to the estrogen receptor present after the 
cre-recombinase cassette. This receptor is only activated once stimulated by 
tamoxifen injections. In its inactive state, cre-recombinase is not expressed. Due to 
the VE-Cadherin, cre-recombinase is only expressed in endothelial cells once 
induced by tamoxifen. This recombinase mouse was bred with the floxed mouse 
generated by Genoway, resulting in a TG positive pup with both mouse genotypes 
(Figure 4.3).  
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Figure 4.2 A schematic outline for the generation of the hIGFBP-2 flox mouse 
The sequence within the hIGFBP-2 flox mouse has a CAG promoter, with a STOP cassette 
surrounded by two LoxP sites, with the hIGFBP-2 gene following after, in the distal position. 
 
Figure 4.3 Inducible endothelial-specific over-expression hIGFBP-2 mouse 
Inducible VE-cad cre-recombinase mouse was crossed with the hIGFBP-2 flox mouse to 
generate a mouse flanked with loxp sites around a STOP cassette preventing hIGFBP-2 
and cre recombinase which is controlled by the estrogen receptor. Once induced by 
tamoxifen, the estrogen receptor drives cre-recombinase expression in endothelial cells, 
resulting in excision of the STOP cassette and over-expression of hIGFBP-2, driven by the 
CAG promoter 
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4.3.2 Tamoxifen injections 
Mice were kept in a tamoxifen only room for safety reasons. Tamoxifen (Sigma-
Aldrich,85266) was diluted into solution using corn oil (Sigma-Aldrich, C8267) to 
10mg/ml. 100µl of this solution was injected intraperitoneally on alternate sides for 5 
consecutive days. Injected mice were left for 7 further days in the tamoxifen only 
room to ensure tamoxifen would not be toxic to other colleagues. 
 
4.3.3 Genotyping  
To confirm over-expression of human IGFBP-2 in both mouse models compared to 
the wild-type littermates, DNA was extracted from ear notches. A HOTSHOT method 
was used to extract the DNA (Truett et al., 2000). The notches were incubated in an 
alkaline lysis solution (25mM NaOH, 0.2mM EDTA pH 12.0) and heated at 95ºC for 
20 min. Neutralisation reagent (40mM Tris-HCL pH5) was added. Samples were 
stored short term at 4ºC or long term -20ºC. Genotypes were confirmed using 
polymerase chain reaction (PCR) as referred to in Section 4.3.3.1.  
End products were run on a 1.5% agarose gel prepared with agarose (Sigma, A9539) 
and TAE buffer (40mM Tris Base (Fisher Scientific, BP152), 20mM Acetic Acid 
(Sigma, 506007), 1mM of 0.5M EDTA (Sigma, E9884)). Ethidium bromide (Sigma, 
E1510) was added to the gel before set. The gel was submerged in TAE buffer; PCR 
products were loaded with a 100bp MW ladder (New England Biolabs, N0467S) and 
run for 1 hour at 100V. The gel was imaged using SynGENE GBOX. 
From mid-2017, all mice ear notches, including ear notches collected from the, 
hIGFBP-2 TG line, VE-hIGFBP-2 heterozygous and homozygous line were sent to 
an external genotyping service, TransnetYX. 
 
4.3.3.1 Primer and PCR cycle data for the TG hIGFBP-2 line 
PCR for the TG hIGFBP-2 mouse was carried out using the primers in the table 4.1. 
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Primer 5’ Label Sequence 5’ → 3’ 
BP-2 Forward CCT GTG CAG CAG CTT CTC GCT GAG 
BP-2 Reverse CCC AGG CTG GCA CCA TGC TCA CCT G 
BP-2 Control 
Forward 
CAA ATG TTG CTT GTC TGG TG 
BP-2 Control 
Reverse 
GTC AGT CGA GTG CAC AGT TT 
Table 4.1 TG hIGFBP-2 genotyping primers 
Primer sequences which amplify the TG hIGFBP-2 global over-expressing gene during 
genotyping PCR. 
 
 
Each reaction was made up of 12.5μl Bio mix red PCR Mastermix (Bioline 
BIO25006), 0.5µl 10μM each primer, 1μl DNA and 9.5μl DNA/RNA free H2O. The 
PCR cycle used is listed in table 4.2.  
 
PCR Stage Number of 
Cycles 
Time Temperature 
Initial Denaturation 1 5 min 95°C 
Denaturation 35x 1 min 95°C 
Annealing 1 min 65°C 
Extension 1 min 72°C 
Final Extension 1 10 min 72°C 
End 1 ∞ 4°C 
Table 4.2 TG hIGFBP-2 genotyping protocol 
PCR cycle used to amplify DNA products in order to determine the genotype of the TG 
hIGFBP-2 gene or the WT littermate. 
 
 
4.3.3.2 Primer sequences for the VE-hIGFBP-2 heterozygous and 
homozygous mice lines 
PCR for the VE-hIGFBP-2 heterozygous and homozygous mice were carried out by 
TransnetYX using primers in the table 4.3: 
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Primer Primer Sequence 5’ to 3’ PCR product size 
  Wild-
type 
allele 
Inducible 
Knock-in 
allele 
182053creWHE1 CTCCCAAAGTCGCTCTGAGTTGT
TATCA 
778 bp 245 bp + 
7378 bp* 
182054creWHE1 CGATTTGTGGTGTATGTAACTAAT
CTGTCTGG 
0034-KIn-
ROSAGX6044 
GCAGTGAGAAGAGTACCACCATG
AGTCC 
Table 4.3 VehiHom genotyping primers 
Primer sequences which amplify the Cre and Flox inducible region during genotyping PCR. 
 
4.3.4 Animal husbandry and breeding 
Cages were housed in the animal unit within the University of Leeds. Temperature, 
humidity and light conditions were controlled at 21ºC and humidity at 55%, with 12 
hour light cycles. All mice were fed a standard chow diet and provided drinking water. 
Breeding cages were assembled using 1 male and 2 female mice at approximately 7 
weeks of age, consisting of TG and WT phenotypes to establish hIGFBP-2 colonies. 
C57/BL6 females were also mated with TG males. Breeding cages were re-
established when reproduction rates were slow, birth of small sized litters or if the 
parental mice were becoming too old (8 months of age). 
Offspring were weaned 3 weeks after birth and housed in cages to a maximum of 6 
pups per cage and according to the sex of siblings. Cages consisting of mice above 
6 weeks of age only housed a maximum of 5 mice per cage. An ear notching system 
was used to label the mice in each cage. Female mice were culled under the schedule 
1 act at weaning unless females were required to replenish breeding cages.  
 
4.3.5 Culling of mice 
Mice were culled by two methods: the use of a CO2 chamber or by cardiac puncture. 
100% CO2 is released into the chamber with the mice for 6mins at a flow rate of 
approximately 20% per min. The release was repeated to ensure death. Mice were 
placed under anaesthetic using Isoflurane (IsoFLo) and cardiac puncture was used 
to obtain a terminal blood flow. Dislocation of the neck was carried out after both 
methods to confirm death. 
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4.3.6 Weight measurements 
Mice were weighed on a weekly basis and before and after tamoxifen injections, 
using standard weighing scales. Weight measurements were collected in grams.  
 
4.3.7 General Anaesthesia 
All mice were individually placed in an anaesthetic chamber. A constant flow of 
oxygen was maintained at 2L/min. Isoflurane was directed to the chamber, putting 
mice into an unconscious state after 2/3mins. Mice were then moved onto the nose 
cone, where the unconscious mouse was secured in place onto a heated surgical 
table set at 37ºC. The isoflurane rate was also reduced to 2.5-3%, with the oxygen 
flow maintained. A scavenger system was present to remove all toxic components 
from the isoflurane system to be removed from the environment. If mice were to be 
recovered following surgery, mice were removed to an environment free from 
isoflurane and placed on a heated surface, set at 37ºC. Mice typically recover from 
the anaesthetic within 5mins. 
 
4.3.8 Hind limb ischaemia 
Mice (8/9 weeks of age) were shaved below the abdomen on the front side in 
preparation for surgery on the following day. Surgery was carried out on a heated 
surface at 37ºC by Dr Nadira Yuldasheva. Lubrithal eye gel (Dechra) was applied to 
the eyes to prevent them drying out or contracting conjunctivitis during surgery before 
securing the mouse in place. Buprenorphine, an analgesic drug was injected via 
intraperitoneal injection and skin was washed with 3% Hydrogen Peroxide. 
Microscope (Ziess, OPM 1-FC) was used between x7.2 and x30 magnification 
(dependent on the view required) to create a small incision in the left hind limb area. 
The fat was removed in order to expose the femoral artery, vein and nerve. After 
separation of the femoral artery from the vein and nerve, sutures (using 8.0 vicryl 
suture) were placed at the proximal and distal ends of the artery, leaving a space of 
approximately 1mm between the sutured ends of the femoral artery, disrupting the 
arterial blood supply. The 1mm section of artery between the sutures was cut out. 
Isotonic saline solution (0.9% NaCl) was used to prevent tissues from drying out. The 
incision was closed using 8.0 vicryl suture and continuous stitching. Post-surgery 
saline solution was injected intraperitoneally to ensure the mice did not suffer from 
dehydration and leg exercises were carried out to help restore regular leg movement. 
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Mice were placed in a cage on a 37ºC surface until expected mobility and awareness 
was observed. 
 
4.3.8.1 Laser Doppler imaging and analysis 
Mice were anaesthetized using 5% isoflurane in oxygen. This was reduced to 1.8% 
as the mouse was placed on the stage. Double sided tape was used to stick feet in 
a position which can enable laser Doppler imaging. The calibrated Moor Instruments 
(Axminster, Devon) laser imager was started and took images from the toes to the 
abdomen, highlighting areas of blood flow in warm colours such as red. Reduced 
blood flow results in colder colours such as blue. Mice were left to recover from the 
anaesthetic on a heated table.  
Analysis was carried out using MoorLDI V6 to measure blood flow changes. Using 
the polygon tool, an outline was drawn around the foot and leg up, just past the knee 
(Figure 4.3). The statistics tool is able to calculate the blood flow within the leg from 
the flux image in a numeric form. The left leg (ischemic) is normalised against the 
right leg (non-operated) to account for any variables that affect each mouse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Example of the Laser Doppler analysis tool 
An outline is drawn around the leg from just above the knee of both the non-operated (1) and 
ischemic (2) legs. The Moor Instruments Analysis Tool was then used to calculate the blood flow 
in that area. 
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4.3.9 Muscle Harvest 
Mice were placed under general anaesthesia following 24 hours after HLI. Cardiac 
puncture was used obtain a terminal blood sample. Surgical tools were used to collect 
the Gastrocnemius, Soleus and Tibialis muscles from both legs. Muscles for PCR 
were immediately incubated into liquid nitrogen and later stored at -80 ºC for long 
term storage. 
 
4.3.10 Cell culture 
All cells were lysed in exactly the same manner as stated in Chapter 3.2. Lysates 
were used for immunoblotting (materials and methods can be found in Chapter 3.3). 
 
4.3.10.1 Primary isolation of Pulmonary Endothelial Cells (PECs) 
Lungs from wild-type (WT) and transgenic (TG) globally over-expressing IGFBP-2 
mice were broken up using scalpel blades and collagenase, prepared in Hanks 
Balanced Salt Solution (HBSS). The collagenase and lung mixture was incubated at 
37ºC for 45 mins. The precipitate was broken up further using a cannula and 
strippette, in order to ensure a single cell suspension. The mixture was then put 
through a 40mm sieve, following a wash with 5% BSA in PBS pH 7.4.  
Collagenase solution was removed by centrifugation and pellet was washed with the 
BSA/PBS wash. Following another centrifugation at 1200rpm for 5 mins, the pellet 
was suspended in a small volume of BSA/PBS wash and incubated with CD146 
(LSEC) microbeads (Miltenyi Biotec, 130-092-007) for 20 mins at 4ºC. The incubated 
mixture was centrifuged at 4000rpm for 5 mins. BSA/PBS wash was dropped through 
the MS column attached to the MACs magnet separator. The pellet containing the 
beads and sample was resuspended in BSA/PBS wash and put through a sieve, 
leading the washed MS column. Once the sample had entered into the column, 5 
washes of BSA/PBS followed. The column was removed of the magnet and BSA/PBS 
wash was added to flush out all the contents in the column.  
For all cells purified with a second column, the output is incubated with fresh LSEC 
beads again and put through the column again. Washes were carried out in the same 
manner. 
Samples were centrifuged at 4000rpm for 5 mins and the pellet was resuspended in 
ECGM MV2 media (Promocell, C-22221), supplemented with supplement mix 
(Promocell, C-39226), 10% FBS and 1% AAS. Cells were plated onto 0.1% gelatin 
coated plates. After 1.5hour incubation at 37ºC and 5% CO2, cells were washed with 
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PBS and fresh media was added. This was repeated the following day. Half media 
changes were carried out every other day. 
 
4.3.11 IGFBP-2 ELISA 
Blood was collected from a vein in the leg of the murine model and spun for 6000xg 
for 10mins at room temperature. The top plasma layer was collected into another 
tube. Plasma was diluted 1:200 using buffer A provided in IGFBP-2 ELISA kit 
(Abcam, ab215082). The remaining protocol was carried out according to the IGFBP-
2 ELISA handout in the kit. The concentration of IGFBP-2 was determined in ng/ml 
using the standard curve calculated. 
 
4.3.12 Real-time PCR 
Below are the steps which need to be taken to obtain cDNA from tissue samples to 
use in real-time PCR to test for expression of species-specific genes. 
 
4.3.12.1 RNA Extraction 
Tri reagent and ball bearings were added to muscle samples and degraded by 
mechanical force using a tissue lyser. Samples were centrifuged at 15,000xg for 10 
mins. Supernatant was transferred into a new eppendorf. Phenol chloroform was 
added, and samples were centrifuged at 15,000xg for 15 mins. The top layer which 
contains the RNA was pipetted into a fresh tube and isopropanol was added to each 
sample. The tubes were centrifuged at 15,000xg for 10 mins. Supernatant was 
discarded, and the pellet was washed with 70% ethanol. The wash step was repeated 
before samples were left to air dry. Pellets were then resuspended in DNA/RNA free 
H2O. The RNA was validated using a Nanodrop to determine the 260/230nm ratio 
and 260/280nm ratio. Only RNA samples which had a 260/230nm value over 2 and 
a 260/280nm value of approximately 2 were used, as these values signified nucleic 
acid and RNA purity. 
 
4.3.12.2 DNAse I Treatment 
In order to remove contamination of DNA from the RNA extraction, a master mix of 
DNase I buffer and DNase I was made from a DNA removal kit (Invitrogen, AM1906). 
This was pipetted into each RNA sample and incubated at 37ºC for 1 hour. DNase 
inactivation reagent was added and incubated at room temperature for 5 mins. 
Samples were spun at 10,000xg for 1 min. RNA was transferred into a fresh tube. 
RNA concentration was determined using a Nanodrop. 260/230nm and 260/280nm 
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ratios were also used to validate the purity of the sample, as described in Section 
4.3.12.1. 
 
4.3.12.3 Reverse transcription 
A high-capacity RNA to cDNA kit (Invitrogen, 4388950) was used for this conversion. 
RNA was diluted to a weaker concentration with DNA/RNA free H2O, so that 2ng of 
RNA is present in a maximum volume of 9µl. 10µl of 2x RT Buffer mix, 1µl of 20x RT 
Enzyme mix and up to 9µl of RNA sample, made up to a total reaction volume of 20µl 
with DNA/RNA free H2O. The cycle in table 4.4 was used for reverse transcription. 
 
Step Temperature (ºC) Time (min) 
1 37 60 
2 95 5 
3 4 ∞ 
 
Table 4.4 Reverse transcription cycle 
This table reports the steps which make up the reverse transcription cycle, highlighting the 
incubation times at certain temperatures in order to obtain cDNA. 
 
 
4.3.12.4 Real-time PCR reaction 
Primers were sourced from Bio-rad (Table 4.5) and their optimised protocol was used 
to produce the reaction mixture. mGAPDH was used as the housekeeping gene for 
all reactions. 
Primer Catalogue 
hIGFBP-2 qHsaCED0043615 
mIGFBP-2 qMmuCID0006519 
mVEGF-A qMmuCED0040260 
mGAPDH qMmuCED0027497 
 
Table 4.5 Real-time Bio-rad primers  
Bio-rad primers used for real-time PCR, in order to observe changes in gene expression with 
hIGFBPP-2, mIGFBP-2, mVEGF-A and mGAPDH and their catalogue numbers.  
 
 
cDNA was dissolved to a useable concentration using DNA/RNA free H2O. Per 
reaction in a 96 well plate, 1µl PrimePCR Assay (primer), 10µl Bio-Rad SYBR Green 
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Supermix, 1-4µl cDNA (equivalent to 200ng) was added. Variable volumes of 
nuclease-free water are added to make a total volume of 20µl. All samples were run 
in duplicate. The real-time cycle was performed using a thermal cycler, using the 
following cycle (Table 4.6). 
 
 
PCR Stage Number of 
Cycles 
Time Temperature 
Polymerase Activation 
and Initial Denaturation 
1 30 sec 95°C 
Denaturation 35x 10 sec 98°C 
Annealing/Extension 30 sec 60°C 
Metal-Curve Analysis 1 5 sec 95°C 
 
Table 4.6 Real-time PCR cycle 
The different stages, including the cycle times and temperature which make up the entire 
real-time PCR cycle. 
 
The raw cycle threshold (Ct) values were collected and the mGAPDH was subtracted 
from the gene of interest Ct values providing a difference value (ΔCt). The following 
formula was used to calculate the relative quantification (RQ), representing the total 
expression of a gene: RQ = 2-ΔCt x 100. 
 
4.3.13 Ethical Implications 
All experimental procedures were performed under the UK Home Office regulations 
as approved in the project licence (403523/P144DDOD6) and personal licence 
(I6AF7B00B). Mice were checked and weighed on a weekly basis to ensure a healthy 
status. Any mice with weights lower than 80% of the weights of their fellow siblings, 
due to unknown reasons were culled and not used for experimental procedures. Mice 
displaying irregular phenotypes were also removed from experiments. 
 
4.3.14 Data analysis 
MoorLDI V6 was used to carry out analysis following HLI. GeneTools was used to 
perform densitometry analysis of the bands on each western blot. Unpaired t-tests 
were used to test for significance. Error bars represent SEM. 
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4.4 Results 
4.4.1 Effect of global over-expression of hIGFBP-2 on recovery in 
perfusion following HLI  
Although this global over-expressing transgenic (TG) mouse model has been 
characterised previously in our laboratory, it is important to confirm the genetic 
modification is present to a significant level (Wheatcroft et al., 2007). 
DNA extracted from mouse ear notches confirmed WT and global over-expression 
hIGFBP-2 (TG) genotypes (Figure 4.5 A). Results from the hIGFBP-2 ELISA kit 
confirmed significant over-expression of hIGFBP-2 in plasma from the TG mice 
compared to WT mice (Figure 4.5 B). There was no difference in weight between WT 
and TG mice. However, female TG mice were significantly smaller than male TG 
mice (Figure 4.5 C). Laser Doppler imaging visualised the improvement in perfusion 
after HLI surgery on a weekly basis for 28 days (Figure 4.6 A). The blood flow from 
ischemic limb compared against non-ischemic limb was significantly enhanced at day 
7 in the TG mice compared to the WT mice (Figure 4.6 B). However, there was not 
an overall difference in perfusion to the ischemic limb between the TG and WT mice 
after 28 days of recovery (Figure 4.6 C) 
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Figure 4.5 Characterisation of hIGFBP-2 TG mice 
(A) Agarose gel (1.5%) stained with ethidium bromide has 5µl of DNA (2µg) loaded following 
RT-PCR extracted from ear notches in the mice with hIGFBP-2 forward and reverse primers, 
which amplify the hIGFBP-2 gene. Lane 1: Molecular weight (MW) marker; Lane 2: Positive 
control, TG hIGFBP-2 confirmed mouse (MW = 300bp); Lane 3: Negative control, non-TG 
hIGFBP-2 mouse line; Lane 4: C57blk mouse control; Lane 5: Water; Lane 6: WT hIGFBP-
2 mouse; Lane 7 TG hIGFBP-2 mouse (MW = 300bp). The lighter band in the non-positive 
samples at a MW = 290bp represents mIGFBP-2. 
(B) Plasma collected from blood taken from the leg of a mouse was run on an hIGFBP-2 
ELISA kit. Final hIGFBP-2 concentrations in the samples were calculated in ng/ml. Error bars 
show SEM (*=p<0.02, n= WT=7, TG=7). (C) Mice, WT and TG from male and female litters 
were weighed (in kg) at 8 weeks of age. Error bars show SEM (*=p<0.05, n= Male WT=5, 
Male TG=4, Female WT=4. Female TG=4). 
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Figure 4.6 hIGFBP-2 causes a significant enhancement in perfusion following HLI 
at day 7 
(A) Representative images of Laser Doppler imaging carried out on mice on a weekly 
basis following HLI surgery in WT and TG mice from 7-28 weeks. (B) Perfusion in the 
ischemic and non-operated legs was measured using Laser Doppler imaging and Moor 
Instruments Review tool. After taking account of the area of the leg measured, ischemic 
perfusion values were normalised against the non-operated (non-ischemic) perfusion 
values, providing a ratio displayed in the graph. Error bars show SEM (*=p<0.04, n= WT-
13, TG=14). (C) Area under both curves, WT and TG was calculated from Figure 4.6B 
using Prism GraphPad. The AUC values are displayed in this graph. (p=0.096, n= WT-
13, TG=14). Error bars show SEM 
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4.4.2 Signalling in PECs over-expressing hIGFBP-2  
A common problem that occurs with PEC isolations is obtaining a mixed population 
of fibroblasts and endothelial cells. Fibroblasts as the modulator of endothelial cell 
proliferation and therefore have a more pronounced proliferative and invasive nature 
which is able to over-populate an endothelial cell culture (Eckermann et al., 2011). A 
positive correlation between IGFBP-2 levels and fibroblast differentiation has already 
been established resulting in high expression levels of mIGFBP-2 (Park et al., 2015). 
The antibody used to identify presence of IGFBP-2 in cell lysates is unable to 
distinguish between mouse and human IGFBP-2 therefore, mixed population of 
fibroblasts and PECs abolished over-expression of IGFBP-2 in TG compared to WT. 
However, second column purification resulting in pure endothelial cells displayed a 
significant enhancement in IGFBP-2 expression in TG PECs compared to WT (Figure 
4.7). Over-expression of hIGFBP-2 in TG endothelial cells before ischemia did not 
enhance Akt or eNOS phosphorylation, compared to total levels (Figure 4.8).  
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Figure 4.7 PECs confirm TG genotype 
(A) Representative images taken using an optical microscope at a 40x magnification (scale 
100µm) display mixed cultures of fibroblasts and endothelial cells before and following a 2nd 
separator column. (B) 40µg protein from WT and TG PEC lysates, pre-2nd column run, was 
loaded onto the western blot, probing for goat polyclonal anti-IGFBP-2 (MW=36kDa) and, the 
loading control, murine monoclonal anti-β-Actin (43kDa). Blots were stripped and reimaged to 
confirm no presence of attached primary antibodies between probing for IGFBP-2 and β-Actin. 
Densitometry was measured using Genetools and IGFBP-2 levels were normalised against the 
loading control. Error bars show SEM (n= WT=3, TG=3). (C) 40µg protein from WT and TG 
PEC lysates, post-2nd column run, was loaded onto the western blot, probing for goat polyclonal 
anti-IGFBP-2 (MW=36kDa) and, the loading control, murine monoclonal anti-β-Actin (43kDa). 
Blots were stripped and reimaged to confirm no presence of attached primary antibodies 
between probing for IGFBP-2 and β-Actin. Densitometry was measured using Genetools and 
IGFBP-2 levels were normalised against the loading control. (*=p<0.001, n= WT=3, TG=3). 
Error bars show SEM. 
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Figure 4.8 hIGFBP-2 over-expression in PECs does not phosphorylate Akt or eNOS 
Representative images of immunoblots which were carried out using 40µg protein from WT 
and TG PEC lysates, post-2nd column run. Blots were imaged after being stripped to check 
no substrate or antibody remained bound between probing with different antibodies. (A) 
Probed for rabbit polyclonal anti-phospho Akt (MW=60kDa) and murine polyclonal anti-Akt 
(MW=60kDa) and, the loading control, murine monoclonal anti-β-Actin (43kDa). Lane 1 
consists of WT PEC lysates, lane 2 contains TG PEC lysates. (n= WT=3, TG=3). (B) Probed 
for rabbit polyclonal anti-phospho eNOS (MW=140kDa) and rabbit polyclonal anti-eNOS 
(MW=140kDa) and, the loading control, murine monoclonal anti-β-Actin (43kDa). Lane 1 
consists of WT PEC lysates, lane 2 contains TG PEC lysates. (n= WT=3, TG=3). 
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4.4.3 mVEGF levels after HLI  
Laser Doppler images 24 hours after surgery confirm restriction of blood flow to the 
lower leg (Figure 4.9 A). Images were taken of the harvested muscles, the 
gastrocnemius, soleus and tibialis (Figure 4.9 B).  
Real-time PCR of hIGFBP-2 in WT and TG muscles confirmed hIGFBP-2 was only 
present in the TG soleus muscle (Figure 4.10 A). mIGFBP-2 levels increased in the 
TG soleus following ischemia compared to non-operated (Figure 4.10 B). hIGFBP-2 
levels were significantly elevated in TG ischemic soleus and tibialis compared to their 
non-operated control (Figure 4.10 C).  
mIGFBP-2 levels were elevated in ischemic gastrocnemius, soleus and tibialis 
muscles in WT mice (Figure 4.11 A). mVEGF levels did not correlate with upregulated 
levels following ischemia in the WT or TG mice muscles (Figure 4.11 B & C). 
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Figure 4.9 Muscles harvested 24 hours after HLI surgery 
(A) Laser Doppler images captured loss of blood flow to the leg from before surgery 
to after 24 hours after HLI surgery. The surgery was only carried out on the left leg 
of each mouse as highlighted by the arrows. The right leg remained a non-operated 
control. (B) Images of the gastrocnemius, soleus and tibialis muscles were 
captured after harvest. The final images on this panel show the positioning of the 
tibialis, which is the muscle on the lower limb on the front side of the leg, and the 
gastrocnemius, which is located on the back of the leg. The soleus sits in the 
middle of the gastrocnemius muscle on the back side of the leg. 
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Figure 4.10 IGFBP-2 is located in specific muscles following HLI in TG mice 
Real-time PCR was used to determine human and mouse IGFBP-2 levels, normalised to murine 
GAPDH across 3 different muscle types, gastrocnemius, soleus and tibialis, by genotype and 
by ischemic vs non-ischemic limbs. The controls were non-operated limbs from the relative 
operated mouse. (A) hIGFBP-2 levels were tested in gastrocnemius, soleus and tibialis 
muscles, which were harvested from WT and TG mice from the operated limb. hIGFBP-2 levels 
were normalised to murine GAPDH levels. (*=p<0.01, gastrocnemius WT vs TG p=0.09, n=7 for 
each condition). Error bars show SEM. (B) mIGFBP-2 levels were tested in gastrocnemius, 
soleus and tibialis muscles which were harvested from TG mice from the non-operated (control) 
and operated (ischemic) limbs. mIGFBP-2 levels were normalised to murine GAPDH levels. 
(*=p<0.01, gastrocnemius ischemic (operated) vs soleus ischemic (operated) p=0.08, soleus 
ischemic (operated) vs tibialis ischemic (operated) p=0.07, n-10 for each non-operated 
condition, n=7 for each ischemic condition). (C) hIGFBP-2 levels were tested in gastrocnemius, 
soleus and tibialis muscles which were harvested from TG mice from the non-operated (control) 
and operated (ischemic) limbs. hIGFBP-2 levels were normalised to murine GAPDH levels. 
(*=p<0.02, n=10 for each condition). Error bars show SEM.   
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Figure 4.11 mIGFBP-2 up-regulation in response to ischemia does not correlate with 
VEGF-A expression 
Real-time PCR was used to determine the levels of murine IGFBP-2 and murine VEGF-A, 
normalised to mouse GAPDH in WT and TG, non-operated and ischemic muscles, 
gastrocnemius, soleus and tibialis. The controls were non-operated limbs from the relative 
operated mouse. (A) mIGFBP-2 levels were tested in gastrocnemius, soleus and tibialis 
muscles, which were harvested from WT mice from the control (non-operated) and ischemic 
(operated) limb. mIGFBP-2 levels were normalised to murine GAPDH levels. (Tibialis 
control vs ischemic p=0.08, n=7 for each condition). Error bars show SEM. (B) mVEGF-A 
levels were tested in gastrocnemius, soleus and tibialis muscles, which were harvested 
from WT mice from the control (non-operated) and ischemic (operated) limb. mVEGF-A 
levels were normalised to murine GAPDH levels. (Gastrocnemius n=7, soleus n=3, tibialis 
n=5). (C) mVEGF-A levels were tested in gastrocnemius, soleus and tibialis muscles, which 
were harvested from TG mice from the control (non-operated) and ischemic (operated) limb. 
mVEGF-A levels were normalised to murine GAPDH levels. (Gastrocnemius n=6, soleus 
n=3, tibialis n=6). Error bars show SEM. 
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4.4.4 Effect of endothelial-specific expression of hIGFBP-2 on recovery 
in perfusion following HLI 
The induction of hIGFBP-2 expression in the inducible models of the endothelial-
specific hIGFBP-2 over-expressing homozygous mouse (VehiHom) colony after 
tamoxifen injections was confirmed by immunoblotting probing for IGFBP-2 in 
cultured PECs from WT and VehiHom TG mice (Figure 4.12 A). The generation of 
this mouse was described in Section 4.3.1. Upregulation of hIGFBP-2 was confirmed 
in plasma from VehiHom mice using a hIGFBP-2 ELISA (Figure 4.12 B). 
There was no significant different in weight between WT and VehiHom mice in males 
(Figure 4.13 A) or in females (Figure 4.13 B). Tamoxifen injections did not cause any 
difference to weight in WT or VehiHom mice (Figure 4.13 C). Laser Doppler analysis 
after HLI surgery confirmed a significant enhancement in perfusion at day 14 in 
VehiHom mice compared to WT mice, however there was no overall difference in 
perfusion recovery over 28 days between both genotypes (Figure 4.14). Both the TG 
global over-expressing mouse and VehiHom mouse increased perfusion to a similar 
point at day 28 of recovery after HLI surgery (Figure 4.15). 
 
 
 
 
Figure 4.12 hIGFBP-2 is over-expressed in VehiHom TG mice following tamoxifen 
injections 
(A) Representative images of immunoblots which were carried out using 40µg protein from 
WT and VEhiHom homozygous PEC lysates. Blots were cut at 60kDa to probe for goat 
polyclonal anti-IGFBP-2 (MW=36kDa) and murine monoclonal Hsp90 (MW=90kDa). Lane 
1 consists of VE-Cre hIGFBP-2 lox WT homozygous and lane 2 consists of the VehiHom 
mouse. Densitometry measured using Genetools compared IGFBP-2 levels normalised to 
Hs90 levels. (*=p<0.001, WT n=6, VehiHom n=6). Error bars show SEM. (B) Plasma 
collected after tamoxifen injections from WT and VehiHom mice were tested for IGFBP-2 
expression levels, using a hIGFBP-2 ELISA kit. (*=p<0.001, WT n=6, VehiHom n=6). Error 
bars show SEM. 
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Figure 4.13 Endothelial-specific hIGFBP-2 over-expression or tamoxifen injections do not 
affect weight 
The mouse weight was measured on a weekly basis after being weaned at 3 weeks up until 7 weeks 
of age. (A) Graphical representation of the weight of male mice. Mice were randomly selected for 
weighing. One mouse was chosen per litter from the WT and TG (VehiHom) mice (n=3). Error bars 
show SEM. (B) Female mice were randomly selected from individual litters and weighed on a weekly 
basis from weaning age (3 weeks) (n=3). Error bars show SEM. (C) WT and VehiHOM mice were 
weighed before and after 5 days of receiving tamoxifen injections (n=9). Error bars show SEM. 
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Figure 4.14 Perfusion in response to HLI was significantly enhanced in 
VehiHom mice at day 14 
(A) Representative images taken from Laser Doppler imaging showing the change 
in perfusion over 28 days in WT and VehiHom mice. (B) Analysis using the Moor 
Instruments Review tool provided a value representing the blood flow, normalised 
to leg area. Perfusion values of ischemic (operated) limbs were compared against 
non-ischemic (non-operated) limbs (*=p<0.02, WT n=9, VehiHom n=8). Error bars 
represent SEM. (C) The area under the curve from Figure 4.14 B was calculated for 
WT and VehiHom mice (WT AUC vs VehiHom AUC p=0.065, WT n= 9, TG n=8). 
Error bars show SEM. 
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Figure 4.15 Comparative outcome between global and endothelial-
specific hIGFBP-2 over-expressing mouse models 
(A) Representative images of Laser Doppler imaging carried out on TG 
global hIGFBP-2 over-expressing mice on day 0, immediately following HLI 
surgery and day 28 after recovery. (B) Representative images of Laser 
Doppler imaging carried on VehiHom mice, after HLI surgery on the left leg 
and after 28 days of recovery. (C) HLI surgery was carried out on hIGFBP-
2 globally over-expressing mice and VehiHom endothelial-specific over-
expressing hIGFBP-2 mice at day 0. Occlusion of blood flow in the left leg, 
measured by Laser Doppler imaging, was compared to the non-operated 
(non-ischemic) limb. Recovery was measured at day 28 by comparing the 
restoration of blood flow to the operated limb vs the non-operated limb. 
Graphical representation of final recovery achieved at day 28 from day 0 in 
hIGFBP-2 over-expressing mice and VehiHom mice (hIGFBP-2 n=14, 
VehiHom n=10). Error bars show SEM. 
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4.5 Discussion 
4.5.1 Global over-expression of hIGFBP-2 displays potential playing a 
role in the recovery from HLI 
As there is currently ambiguity regarding IGFBP-2s specific role in angiogenesis, it 
was important we were able to see potential on an in vivo level before committing 
effort to try and find a mechanism to support all the characteristics exerted by IGFBP-
2 in published literature. This in vivo model proved over-expression of hIGFBP-2 on 
a global scale did not cause any detrimental effects to overall health and especially 
did not drive tumour development in these mice as confirmed following the full harvest 
of organs.  
Before beginning any surgical procedures on these mice, no differences in body 
weight between the TG and WT models were observed, suggesting good health. All 
mice matched the expected weight for their age point. It was significantly clear male 
mice were larger in size than female mice; however, this is a common phenomenon 
in mammals. For ease of surgery, male mice were used due to their larger size.  
After comparing ischemic to non-ischemic limbs to measure to progress of perfusion 
after HLI surgery, a significant enhancement in recovery was observed at day 7 in 
the TG mice in comparison to its WT littermates. This early difference suggests 
IGFBP-2 may play a role in remodelling of the pre-existing vasculature via 
arteriogenesis, rather than angiogenesis (Shireman, 2007). Forces provided by shear 
stress from the blood flow will initiate collaterals to open up to aim to restore the blood 
flow, however for arteriogenesis to take place, the endothelial layer still needs to 
reform to enable the opening up effect. IGFBP-2 has been referenced to promote 
proliferation and migration of a range of cell types, including glioma, vascular smooth 
muscle and neural stem cells (Deng et al., 2017; Han et al., 2014; Shen et al., 2015). 
Although these mechanisms have not been established in endothelial cells, it is 
plausible to hypothesise IGFBP-2 may mediate arteriogenesis activity via enhancing 
proliferation and migration of the endothelial cells in the inner layer of the vessel. 
The theory that IGFBP-2 induces arteriogenesis rather than angiogenesis is 
supported even further; TG mice fail to display a significant difference in overall 
recovery of perfusion in comparison to the WT mice at day 28. The over-expression 
of hIGFBP-2 seems to drive an immediate effect in enhancing recovery at an earlier 
rate and returns back to the normal WT recovery level. Angiogenesis, involving the 
formation of new blood vessels is a process that will take much longer than a week 
as it requires the upregulation of many growth factors and the recruitment and 
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communication between many cells, which make up the vessel wall (Limbourg et al., 
2009). It is an extremely regulated process to ensure the blood flow is restored to the 
right location. One possible reason for why we may not see an increased effect in the 
TG mice post day 14 is due to the upregulation of growth factors such as VEGF, 
PDGF, FGF which have been secreted due to inflammatory signals. These growth 
factors may silence the effects of IGFBP-2, as they are extremely potent angiogenic 
promoters. Also, as we see the graph plateau, it suggests the recovery has reached 
its maximal point, and therefore even if we continued adding further IGFBP-2, we 
may not see an effect. 
Therefore IGFBP-2 influencing arteriogenesis, rather than angiogenesis is a more 
positive outlook in regard to recovery from PAD than our original hypothesis. It is 
essential IGFBP-2 does not cause a significantly enhanced angiogenic response, as 
with VEGF it led to the formation of unstable blood vessels. We want IGFBP-2 to 
enhance the recovery immediately at a faster rate to the maximum level matching the 
normal end recovery outcome (to the WT level). Superficially enhanced or further 
vessel growth may result in formation of an unstable network and in turn display the 
negative side effects which have been associated with VEGF (Reardon et al., 2011).  
 
4.5.2 PECs over-expressing IGFBP-2 fail to activate the Akt/eNOS 
pathway 
PECs were isolated from the mice, which did not undergo HLI surgery, to confirm the 
gene modification of over-expression of IGFBP-2 in the TG model compared to the 
WT. The protocol had to be optimised to ensure we obtained a pure sample. 
Contamination by fibroblasts elevated total mIGFBP-2 levels in WT samples to a 
matching level with the TG sample containing both m and hIGFBP-2. IGFBP-2 has 
been reported to promote proliferation and differentiation of fibroblasts explaining the 
increased expression of IGFBP-2 (Brandt et al., 2015; Park et al., 2015). Once 
cultured cells displayed a more endothelial-like phenotype, after comparing cell 
images with previous images of positively stained endothelial cells, IGFBP-2 over-
expression was confirmed in the TG mouse compared to the WT. Contrastingly to 
published research, into in vitro signalling changes observed by western blotting 
showed IGFBP-2 over-expression had no effect on Akt phosphorylation or activation 
of the downstream target eNOS (Mehrian-Shai et al., 2007; Xi et al., 2016). However, 
it is unknown if IGFBP-2 only functions in a compromised environment, it may explain 
why we do not observe any signalling changes before the induction of ischemia.  
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4.5.3 hIGFBP-2 and mIGFBP-2 in the TG model is located to the specific 
muscles 
Although previous characterisation of the TG over-expression model highlighted 
IGFBP-2 over-expression in the muscle, only skeletal muscle has been interrogated 
(Hoeflich et al., 1999). We have identified that hIGFBP-2 global over-expression is 
modulated according to muscle type, pre-surgery, with the soleus displaying a 5-fold 
enhancement in hIGFBP-2 levels compared to the gastrocnemius and tibialis muscle. 
A possible explanation for why the soleus retains a larger abundance of hIGFBP-2 is 
that the soleus is the inner most muscle and is surrounded by a larger capillary 
network than the gastrocnemius and the tibialis are. Supporting this, mIGFBP-2 
levels are elevated in the TG model in response to ischemia but the majority of the 
mIGFBP-2 is directed to the soleus over the other two muscles. Non-operated and 
ischemic muscle types were interrogated for hIGFBP-2 levels again to observe if 
ischemia affected the increased concentration of hIGFBP-2 in the soleus. 
Interestingly, the levels of hIGFBP-2 in the ischemic soleus had increased just less 
than 10-fold compared to non-operated limbs, but there was also a significant 
increase in hIGFBP-2 levels in the tibialis ischemic limb compared to its non-operated 
control. It has been reported that necrosis as a result of a poor/restricted blood supply 
to the limb effects the lower muscle groups, the gastrocnemius, soleus and tibialis in 
particular (Shireman, 2007). However, when observing the muscle types 
independently of each other, the tibialis and soleus muscle were the most affected, 
whereas the effect of necrosis to the gastrocnemius was variable (Shireman & 
Quinones, 2005). IGFBP-2 is well known for its role as a protector in regards to 
metabolic syndromes (Carter et al., 2014; Wheatcroft et al., 2007). Therefore, it may 
be possible hIGFBP-2 is drawn to a location where it is required to act as a protector 
to prevent further muscle damage as a result of femoral ligation. 
 
4.5.4 mIGFBP-2 expression is elevated due to ischemia but does not 
correlate with mVEGF expression 
We have found evidence that suggests IGFBP-2 expression is mediated by ischemia 
in a model of PAD. Although not significant due to high variability, there is an evident 
trend that 24 hours after the induction of ischemia, mIGFBP-2 expression is elevated 
in comparison to non-operated muscles in WT mice. This trend was seen across all 
lower limb muscle types. This supports the idea that IGFBP-2 does play an immediate 
role and is immediately required to possibly drive arteriogenesis to rescue perfusion.  
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The high variability displayed could be a result of the mice already having a collateral 
vessel network in place, which can compensate for the sudden restriction in blood 
flow. The already present collateral vessel network may suppress the full activity or 
requirement for IGFBP-2 to help rescue perfusion to the ischemic limb. 
It is also important to note the upregulation of mIGFBP-2 or hIGFBP-2 in ischemic 
limbs did not correlate with mVEGF-A expression in WT or TG mice, contradicting 
findings from Das et al., (2013), that IGFBP-2 promotes the activation of VEGF. 
Interestingly, mVEGF-A expression in the ischemic muscle types remained the same 
as non-operated muscles. However, this may be because hypoxia, as an 
inflammatory marker drives the activation of VEGF (Krock et al., 2011; Ramakrishnan 
et al., 2014). 24 hours may not be enough time to induce an inflammatory response 
large enough to induce VEGF expression. VEGF is also known as a more potent 
regulator of angiogenesis, rather than arteriogenesis specifically, suggesting VEGF 
may start functioning later on in the recovery process (Hoeben et al., 2004). 
Additionally, collateral vessel growth via arteriogenesis does not require VEGF as a 
stimulus, therefore suggesting VEGF was not upregulated following ischemia as 
there may already be a collateral network in place. 
 
4.5.5 Endothelial-specific over-expression of hIGFBP-2 plays a role in 
recovery from HLI 
VehiHom mice were shown to over-express IGFBP-2 in cultured PECs and in plasma 
using a hIGFBP-2 ELISA. There was no difference in weight gain over time between 
the VehiHom and WT littermates and weight was not affected after 5 days of 
tamoxifen injections. There were no obvious differences in phenotype between the 
genotypes and deemed in a healthy state to undergo surgery. 
Findings from the endothelial-specific hIGFBP-2 over-expressing mouse support the 
theory that IGFBP-2 is directly involved in mediating arteriogenesis endothelial 
remodelling as an enhancement in recovery was observed at an early stage of the 
recovery process. Comparison of the ischemic limb to the non-ischemic limb 
displayed a significant enhancement in rescue of perfusion at day 14 in the VehiHom 
in comparison to the WT mice after HLI surgery. The path of recovery mimics what is 
observed with the global TG over-expresser of hIGFBP-2, in that recovery after 21 
days begins to plateux, therefore reaching its maximum recovery point. This suggests 
perfusion is restored predominantly through arteriogenesis (in the first 14 days), 
rather than angigogenesis, however, to support this claim, we would have to study 
the changes to the collateral network in the mice. 
P a g e  | 68 
 
 
A sudden drop from the increase at day 14 to day 21 is observed. A possible 
explanation may be that inflammatory signals may be released to promote rapid 
expression of angiogenic growth factors such as VEGF, elevating perfusion rates to 
a significant level at day 14. VEGF is well established to drive uncontrollable vessel 
growth, resulting in a burst of perfusion. At day 21, the delivery of growth factors may 
have been achieved causing a suppression of the enhancement to a regular level. 
However, IGFBP-2 has been referenced to exert apoptotic effects in human 
teratocarcinoma cells by blocking IGF-II survival (Granérus et al., 2001) It can also 
mediate the effects of IGF-I-stimulated survival signalling pathways via modulation of 
tumour suppressors such as p53 (Grimberg et al., 2006). It may be possible that 
IGFBP-2 senses the increase in perfusion at day 21 and modulate the angiogenic 
effects that are being exerted by endogenous growth factors instead of promoting 
them further.  
Although we are trying to identify IGFBP-2 as a promoter of angiogenesis, if IGFBP-
2 is able to regulate its effects, it may display more potential as a therapeutic than 
VEGF, which results in uncontrollable enhancement of growth and signalling 
pathways. 
 
4.5.6 Study Limitations 
It is important to note both TG models express more than double the concentration 
of IGFBP-2 present in humans and therefore are enhanced to a super-physiological 
level in the mice. Although all characteristics have displayed only minor differences 
in phenotype between the gene modified and WT mice, it is difficult to establish if the 
over-expression could be having adverse effects in the experimental procedures we 
are using. However, In vitro proliferation experiments carried out by other researchers 
have displayed no difference in activity using 1000ng/ml IGFBP-2 compared to 
500ng/ml (Uzoh et al., 2011).  
Another limitation observed regarding the use of IGFBPs is that IGFBP-1 and IGFBP-
3 function at an enhanced ability when promoting a recovery response in a pro-
inflammatory induced state (Aziz et al., 2018; Jiang et al., 2014).  Therefore, we may 
observe a more pronounced effect with IGFBP-2 if induced at a later time point after 
HLI surgery, at a point where backup collateral vessels have failed to restore blood 
flow and necrosis has begun to take place. In a clinical setting, we believe IGFBP-2 
would be the last source of treatment before amputation is the only solution. As we 
have inducible hIGFBP-2 over-expressing endothelial-specific models in place, we 
could test the theory of waiting until the post-operative limb begins to show signs of 
P a g e  | 69 
 
 
necrosis, remaining within the guidelines of severity set out by the Home Office 
before inducing IGFBP-2 expression. An inducible global over-expressing hIGFBP-2 
could also be used in this instance. This will determine if IGFBP-2 contributes to the 
formation of a new collateral vessel network from the pre-existing vessels, as the pre-
existing collaterals will have failed to compensate the loss of perfusion.  
The largest limitation of this study is that due to time constraints we were unable to 
quantify blood vessel density by histology, angiography or microCT. Therefore, we 
cannot confirm that angiogenesis, arteriogenesis or any type of new blood vessel 
formation occurred. However, as a segment of the femoral artery was cut, it is unlikely 
the increase in blood flow may purely be due to vasodilation, suggesting 
angiogenesis of some form must also take place. We did plan on carrying out 
immunohistochemistry to investigate the vascularity of the peripheral muscles using 
endothelial markers (e.g. CD31 to detect capillaries) and assess angiogenesis and 
adductor muscle using smooth muscle markers (e.g. smooth muscle actin to detect 
arteries and arterioles) to assess arteriogenesis. However, unfortunately due to time 
constraints, we were not able to complete these planned experiments. 
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4.6 Concluding remarks 
For the first time we have highlighted IGFBP-2 levels are elevated 24 hours after 
ischemia in the lower mice limbs, representing a murine model of PAD. The 
enhancement in IGFBP-2 does not increase VEGF expression levels, suggesting 
IGFBP-2 exerts in actions in an ischemic setting independent of VEGF. PECs over-
expressing hIGFBP-2 fail to show a difference in Akt or eNOS phosphorylation. We 
have also shown over-expression of IGFBP-2 on a global and endothelial-specific 
level plays a role in enhancing perfusion at early stages of recovery following HLI. 
Using published information regarding recovery after HLI, we believe IGFBP-2 drives 
arteriogenesis activity immediately; however, its role as a pro-angiogenic agent still 
remains unestablished. The enhanced recovery plateaus to a normal level, 
corresponding to the WT suggesting over-expression of IGFBP-2 does not drive 
uncontrollable vessel formation. 
To identify if IGFBP-2 drives arteriogenesis or angiogenesis of new collateral 
formation, we could stain the collateral vessels and use a 3D CT imaging system to 
display differences in recovery of perfusion at different time points. For clinical 
relevance, HLI should be carried out on mouse models, which result in necrosis 
rather than complete recovery and induce IGFBP-2 expression to observe its 
rescuing properties. 
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Chapter 5 - Effects of IGFBP-2 on 
pro-angiogenic signalling in 
endothelial cells 
 
5.1 Background 
Findings from Chapter 4 confirmed IGFBP-2 does play a role in recovering perfusion 
following an ischemic insult at day 7 in the recovery process. We also showed IGFBP-
2 is slightly elevated 24 hours after induction of ischemia in WT mice. The only 
mechanism investigated in vascular endothelial cells suggested that IGFBP-2 
stimulated activation of VEGF signalling is responsible for enhancement in in vitro 
angiogenic responses (Das et al., 2013). However, we were unable to replicate any 
correlation between elevated IGFBP-2 levels and VEGF levels in response to 
ischemia. Therefore, we can deduce IGFBP-2 may be exerting angiogenic-like 
characteristics through other angiogenic signalling pathways. In order to understand 
how IGFBP-2 may be exerting the angiogenic-like activity we have seen in the 
previous chapter, we need to investigate the angiogenic signalling cascades 
activated by IGFBP-2. 
IGFBP-2 has been associated to promote its angiogenic-like characteristics, such as 
migration and proliferation through a variety of signalling mechanisms, which differ 
between different cell types used for in vitro experiments. A summary of these 
published findings is discussed in Section 5.1.1. However, as endothelial cells are at 
the forefront of the initial angiogenesis stages, it is important we understand how 
IGFBP-2 may mediate their survival, migration and proliferation. 
 
5.1.1 IGFBP-2 and angiogenic signalling 
The Akt/PI3K is the most common signalling cascades which determine cell viability, 
motility and regular homeostasis (Karar & Maity, 2011). It is well established 
activation of IGF-I signalling also results in elevation of Akt phosphorylation (Assefa 
et al., 2017). IGFBP-2-stimulated Akt is also mediated via interaction between the 
HBD and RPTPβ, modulating the de-phosphorylation of PTEN, an upstream target 
of Akt activation. De-phosphorylation of PTEN results in an open conformation with 
an exposed and active phosphatase domain which rapidly enhances the degradation 
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of PTEN, causing an upregulation of Akt phosphorylation (Ross & Gericke, 2009). 
Knock-out models of IGFBP-2 resulted in down-regulation of Akt phosphorylation in 
mouse embryo fibroblasts, while PTEN tyrosine phosphorylation increased (Mehrian-
Shai et al., 2007). Therefore IGFBP-2 is possibly regulating Akt signalling cascades 
via HBD interactions.  
In an esophageal adenocarcinoma cell line, activation of the MAPK pathway, as well 
as Akt was shown to modulate the IGFBP-2 stimulated cell proliferation, migration 
and invasion (Myers et al., 2015). The association of elevated IGFBP-2 levels and 
increased MAPK signalling has been reported in the growth and survival of many 
cancer cell lines such as epithelial carcinoma and glioma cells (Yoshino et al., 2006). 
Recent advances have suggested the MAPK-induced migration is dependent on 
IGFBP-2 integrin interactions with β1 or α5 subunits by enhancing ERK and JNK 
activation (Han et al., 2014; Mendes et al., 2010; Wang et al., 2017c). IGFBP-2s 
interaction with the tumour suppressor, p53 is responsible for inhibiting IGF-induced 
ERK activation. Low levels of IGFBP-2 also promote cell growth by suppressing p53’s 
ability to down-regulate IGF-I stimulated-activation of ERK/MAPK signalling pathway. 
(Grimberg et al., 2006) 
Via the cell adhesion modulators, β-catenin and integrin, IGFBP-2 mediates the 
inactivation of GSK3β by modulating Akt and FAK signalling. IGFBP-2-stimulated Akt 
suppresses GSK3β’s ability to degrade β-catenin, which in turn prohibits the Wnt 
signalling pathway to regulate cell migration and death (Atkins et al., 2012). 
Stabilisation of β-catenin is necessary for Wnt signalling. Cell surface integrin actions 
stimulated by IGFBP-2 also mediate the activation of GSK3β via FAK 
phosphorylation. However, IGFBP-2 stimulated-FAK functions in a contrasting 
manner by enhancing phosphorylation of GSK3β, driving stabilisation of β-catenin 
and activation of Wnt signalling (Patil et al., 2016).  
Therefore, the cross-talk between IGFBP-2 binding domains determines the 
activation of the Akt, MAPK and FAK signalling pathways. All these pathways are 
well known to drive angiogenic responses, suggesting IGFBP-2 may directly 
influence angiogenesis via one or more of its interactions (Figure 5.1). 
 
 
 
 
 
 
P a g e  | 73 
 
 
 
 
 
 
5.1.2 Suppression of IGFBP-2 signalling activity 
Although all the previous publications highlight IGFBP-2s role in promoting IGF-I 
induced stimulation of angiogenic signalling pathways such as Akt, IGFBP-2 has the 
Figure 5.1 Proposed mechanisms of IGFBP-2 IGF-independent activation of 
angiogenic signalling pathways 
Published articles have shown how IGFBP-2 IGF-independently can activate FAK, Akt and 
MAPK to stimulate characteristics such as survival, migration and proliferation in non-
endothelial cell types. This schematic highlights which signalling molecules can be responsible 
for IGFBP-2 angiogenic-like characteristics. (Adapted from Han et al., 2014; Mehrian-Shai et 
al., 2007; Patil et al., 2016. 
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potential of suppressing IGF-I signalling via by sequestering IGF molecules and 
inhibiting their transport to their receptors (Kiepe et al., 2002). Regarding in vitro 
experiments, this could be important as a set concentration is added to cell growth 
media for in vitro culture, and potentially disrupt the overall affect our added IGFBP-
2 may have on signalling. 
Heparin is a common component added to media to facilitate the transport of growth 
factors in the media. However, IGFBP-2 has two functional heparin binding domains. 
Blockage of these sites may also prohibit HBD-driven signalling activation.  
Another problem that may suppress the activity of IGFBP-2 is the presence of 
additional growth factors in the media such as VEGF, FGF and PDGF. These growth 
factors are potent stimulators of angiogenesis alone and therefore may competitively 
down-regulate IGFBP-2s potential to drive angiogenic signalling. As mentioned 
previously, IGFBP-2 has been reported to modulate VEGF activity (Azar et al., 2011). 
IGFBP-2s interaction with αVβ3 may also regulate FGF activity in vitro (Rusnati et 
al., 1997).  
Therefore, these growth factors may distract IGFBP-2s role to activate angiogenic 
signalling in HUVECs, resulting in down-regulation of the binding protein’s true effect. 
Optimisation steps have been carried out in this chapter to eliminate any interference 
caused by these additional media components. 
 
5.1.3 IGFBP-2 and endothelial cells 
With the majority of IGFBP-2s potential role in angiogenesis being interrogated in 
endothelial cells, there are very limited numbers of publications that report how 
IGFBP-2 may modulate signalling within endothelial cells, specifically vascular 
endothelial cells. Investigating IGFBP-2 stimulated mechanisms which drive 
endothelial cell angiogenic-like characteristics may develop our understanding of 
how IGFBP-2 can be used therapeutically to promote endothelial remodelling during 
arteriogenesis or angiogenesis. 
IGFBP-2 has been previously shown to enhance HUVEC tube formation via inducing 
VEGF signalling and in turn Akt activation (Das et al., 2013). Upregulation of IGFBP-
2s integrin interaction with α5β1, via IGFBP-2 over-expression in HUVECs has 
shown potential in promoting adhesion of HUVECs to endothelial progenitor cells 
(Feng et al., 2015). Migration of HUVECs is incrementally elevated as concentrations 
of circulating IGFBP-2 rise, stimulated via activation of the IGF-IR (Png et al., 2012). 
A further study using a highly anti-proliferative agent caused the suppression of 
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angiogenic-like characteristics via suppression of Akt activation, which correlated 
with a reduction in IGFBP-2 levels in HUVECs (Bhutia et al., 2016).  
Although it is clear IGFBP-2 activates Akt phosphorylation in HUVECs, no studies 
have referenced the role of IGFBP-2s HBDs or IGFBP-2 stimulated activation of other 
angiogenic signalling pathways in HUVECs. eNOS signalling occurs downstream of 
Akt but is a key molecule involved in regulation of the vascular environment by 
modulating the generation of nitric oxide. As mentioned in the introduction (Chapter 
1), NO presents protective roles to prevent the onset of cardiovascular disease by 
maintaining contractility of the vessel wall, preventing high blood pressure, platelet 
aggregation and vascular tone (Naseem, 2005). These are key variables which need 
to be maintained following the formation of new blood vessels, therefore if IGFBP-2 
presents an angiogenic role, its involvement in the regulation of eNOS is important. 
 
5.1.4 Summary 
IGFBP-2s interaction with angiogenic signalling molecules is determined by cell type 
and interaction type via its domains. However, the limited research carried out in 
HUVECs suggests IGFBP-2 stimulated Akt phosphorylation may lead modulation of 
endothelial functions. To determine which angiogenic-like mechanisms IGFBP-2 
specifically activates in HUVECs, we will be exploring the effect of IGFBP-2 on all the 
signalling pathways it has currently been associated with. 
 
 
 
5.2 Experimental Objectives 
In this chapter, we aim to understand the effects of IGFBP-2 on pro-angiogenic 
signalling pathways in endothelial cells in vitro. Endothelial cells are the primary cells 
which induce the angiogenic signalling cascades in vivo and provide the structural 
framework for the formation of a new vessel. Investigation of the angiogenic signalling 
mechanisms activated by IGFBP-2 was carried using the objectives below: 
• Investigate the cellular effects of IGFBP-2 in HUVECs on angiogenic 
signalling pathways. 
• Identify the variables that may affect the function of IGFBP-2 on angiogenic 
signalling 
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5.3 Materials and Methods 
5.3.1 Cell Culture 
Standard cell culture protocol was carried out using the method stated Chapter 3.1. 
HUVECs were cultured using the protocol in Chapter 3.1.1 .The following cells were 
grown specifically for the experiments in this chapter. 
 
C2C12 myoblasts 
C2C12 myoblasts (original source: Professor Michelle Peckham), were grown in 
DMEM (Invitrogen, 61965-026) supplemented with 10% FBS and 1% AAS. To enable 
differentiation into myotubes, cells were washed in PBS (Invitrogen 14190250) and 
incubated in differentiation media (DMEM containing 5% FBS and 1% AAS). Cells 
were serum-starved overnight in DMEM + 1% AAS prior to lysing.  
 
HepG2 Cells 
HEPG2 refers to human liver carcinoma cells (purchased from Public Health England 
Culture Collections), were cultured in Minimum Essential Medium Eagle (MEME) 
(Sigma-Aldrich M5650) with 10% FBS, 1% AAS and 2mM L-Glutamine (Life 
Technologies, 25030081). Prior to lysing, the cells were incubated in serum-free 
medium (MEME + 1% AAS + 2mM L-Glutamine) overnight. 
 
INS832/13 Pancreatic Cells 
INS832/13 cells sourced from a rat cell line (kindly gifted by Professor Christopher 
Newgard) were cultured in RPMI media (Table 5.1). Cells were serum-starved in a 
low glucose salt solution (Table 5.1) prior to being lysed. 
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Table 5.1 Solutions used to culture Ins832/13 pancreatic cells 
Table highlighting the components and concentrations of components required for the media 
to culture of Ins823/13 pancreatic cells. 
 
 
Human Saphenous Vein Endothelial Cell (HSaVEC) lysates 
HSaVECs (a kind gift from Dr Karen Porter) were derived from patients without 
diabetes undergoing coronary artery bypass graft surgery at Leeds Teaching 
Hospitals NHS Trust. Lysates had been stored at -80ºC in NuPage LDS sample buffer 
(4x) (Life Technologies, NP007) and NuPage sample reducing agent (10x) (NP0009). 
Previously determined protein concentrations of the samples were used for 
immunoblotting. 
 
Mouse Pulmonary Endothelial Cell (PEC) lysates  
PECs (a kind gift from Dr Hema Viswambharan) were cultured from wild-type 
C57BL6/J mice. Lysates were sonicated and purified by centrifugation at 13,000 rpm 
for 15 mins at 4ºC. 
 
5.3.2 Immunoblotting 
Cell lysing and immunoblotting was carried out according to the protocols noted in 
Chapter 3.2/3.3. 
 
5.3.3 Treatment of HUVECs with additional stimulants  
HUVECs were serum-starved for 2 hours in serum-free endothelial cell growth 
medium (M199) (M199 medium (Sigma-Aldrich, M4530) (supplemented with 1% 
Solution Contents 
RPMI media (Sigma-
Aldrich R8758) 
10% FBS, 1% AAS, 10mM HEPES (Life Technologies, 
15630056), 1mM sodium pyruvate (Life Technologies, 
11360070) and 0.05mM 2-mercaptoethanol (Sigma-
Aldrich M6250) 
Low Glucose Salt 
Solution 
pH 7.2 
144mM NaCl (Fisher Scientific, S/3160/63), 1.16mM 
MgSO4 (Fisher Scientific, M65), 4.7mM KCl (Fisher 
Scientific, P/4280/60), 2.5mM CaCl2 (Fisher Scientific, 
C77), 1.2mM KH2PO4 (Fisher Scientific P285), 
25.5mM NaHCO3 (Fisher, Scientific, S/4920/60), 
20mM HEPES and 0.2% bovine serum albumin (BSA) 
(Cell Signalling, 9998) 
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AAS, ECGS (Sigma-Aldrich E2759), 10mM Hepes, 1mM Sodium Pyruvate and 
2500U Heparin) before being stimulated with other proteins. Basal control wells were 
replaced with fresh serum-free media at the time of the stimulation. In some 
experimental studies, the stimulant was pipetted directly into the well of the serum-
free media which had remained in the plate for 2 hours. 
 
Treatment of HUVECs with recombinant IGFBP-2 
Cells were stimulated with recombinant IGFBP-2 (Abcam, ab63223 (reconstituted in 
sterile-filtered water), IGFBP-2 (R&D Systems, 674-B2-025 (reconstituted in PBS)), 
diluted in serum-free M199 obtaining final concentrations between the range of 1-
1000ng/ml, was added for a minimum stimulation period of 10, 15 or 30 min. For time-
dependent changes 200ng/ml IGFBP-2 and incubated for the time points, 15, 30, 45, 
60 and 75 min, prepared in serum-free M199 was used as a stimulant. 
 
Treatment of HUVECs with hIGF-1 
Cells were stimulated with IGF-1 (R&D Systems, 291-G1 (reconstituted in sterile 
PBS)), diluted in serum-free M199 for 15 min at concentration of 10-50ng/ml. 
 
Treatment of HUVECs with VEGF-A 
VEGF165A (Promocell, C-64423), (reconstituted in H2O)), diluted in serum-free M199 
was used for a stimulation period of 10-20 min. The concentration of VEGF165A used 
was 30ng/ml for all experiments as a positive control.  
 
5.3.4 Data Analysis 
GeneTools was used to perform densitometry analysis of the bands on each western 
blot. Unpaired t-tests were carried out to test data for statistical significance. All error 
bars represent standard error of the mean (SEM). Some preliminary studies only had 
n=2 due to time and funding constraints and therefore statistical tests were not carried 
out on these samples. 
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5.4 Results 
5.4.1 IGFBP-2 from different sources 
We initially sourced recombinant human IGFBP-2 from 2 different sources, murine 
cell (R&D) and insect cell (Abcam) to investigate in vitro angiogenic signalling and 
activity in future experiments. The functionality of these proteins was tested using 
IGF ligand blot. Akt signalling was also used to test functionality because IGFBP-2 
has already been shown to stimulate Akt activation via its interaction with IGF-IR or 
via VEGF signalling (Das et al., 2013; Png et al., 2012). 
hIGFBP-2 from an insect cell source failed to display IGF-I binding capability using 
the IGF binding blot, whereas murine sourced hIGFBP-2 bound biotinylated IGF-I 
(Figure 5.2). However, both IGFBP-2s were able to phosphorylate Akt to the same 
extent in HUVECs (Figure 5.3). 
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Figure 5.2 IGFBP-2 sourced from Insect cells does not possess IGF binding ability 
Preliminary study 
(A) Non-denatured R&D murine recombinant IGFBP-2 and Abcam insect recombinant 
IGFBP-2 (100ng and 500ng) were loaded onto a 4-12% Bis Tris gel and transferred onto 
a membrane. The blot was incubated with blocked with 5% BSA and incubated with 
biotinylated IGF-I. Streptavidin was used to visualise bound IGF-I. Positive bands 
appear at functional IGF binding sites (36kDa). The blot was stripped, imaged to confirm 
no residue remained bound to the blot and probed with a polyclonal goat anti-IGFBP-2 
antibody (MW=36kDa) to confirm presence of IGFBP-2. Blot lane 1 = R&D murine 
IGFBP-2 500ng, lane 2 = R&D murine IGFBP-2 100ng, lane 3 = Abcam insect IGFBP-
2 500ng, lane 4 = Abcam insect IGFBP-2 100ng. (B) Graphical representation of the 
densitometry calculated displays the intensity of elevated IGF binding levels in R&D 
murine IGFBP-2 at 500ng and 100ng compared to Abcam Insect IGFBP-2 using 
Genetools to measure the blot densitometry in the IGF ligand blot (n=2). (C) 
Densitometry of the bands from the blot probed with polyclonal goat anti-IGFBP-2 
antibody were presented graphically to show the levels of IGFBP-2 in each lane (n=2). 
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Figure 5.3 IGF-independent interactions are responsible for IGFBP-2 
stimulated Akt activation  
(A) HUVECs were treated with varying concentrations of R&D murine IGFBP-2 and 
Abcam insect IGFBP-2 (1-200ng/ml) for 15 minutes. 20µg protein was collected 
from the stimulated HUVEC lysates and analysed using immunoblotting. The blots 
were probed for rabbit polyclonal anti-phospho Akt (MW=60kDa) and murine 
polyclonal anti-Akt (MW=60kDa) and, the loading control, murine monoclonal anti-
β-Actin (43kDa). The blots were stripped after incubation with the phospho-
antibody and checked for bound residue. Once confirmed that no residue was 
bound, the blots were probed with the total Akt antibody. (B) Densitometry carried 
out from the blots displayed in 5.3A in a graphical form show both the change in 
Akt phosphorylation in HUVECs following stimulation with R&D and Abcam IGFBP-
2 (1-200ng/ml) (R&D; n=6, *<p=0.01) (Abcam; n=3, *<p=0.05). Error bars represent 
SEM. 
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5.4.2 Endogenous IGFBP-2 expression across different cell types 
Previous literature has highlighted changes in IGFBP-2 activity between different cell 
types. The majority of changes in IGFBP-2 activity are influenced by the levels of 
IGFBP-2 present, as shown by the use of knock out and over-expressing in vitro 
models (Shen et al., 2012). Therefore, a range of available endothelial cells, 
HUVECs, PECs and HSaVECs were collected to observe how IGFBP-2 levels 
fluctuated between different tissues. HEPG2, liver carcinoma cells were sourced as 
a positive control on two fronts; all IGFBPs are predominantly expressed by the liver 
and IGFBP-2 levels are upregulated in many cancers. C2C12, again serve as a 
positive control as they have already been reported to endogenously express high 
levels of IGFBP-2 in response to serum starving (Sharples et al., 2010). INS-
Pancreatic cells have been used in many studies regarding insulin resistance. As we 
know IGFBP-2 protects against insulin resistance, it would be interesting to see how 
this may affect IGFBP-2 endogenous expression by the cells. 
Our results showed that HUVECs endogenously expressed the most IGFBP-2, 
however other endothelial cells did not replicate this. Endogenous expression of 
IGFBP-2 in non-endothelial cell types was varied (Figure 5.4). 
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Figure 5.4 Endogenous expression of IGFBP-2 in PEC, HEPG2, C2C12, Ins and 
HSaVEC cells 
(A) Images captured during the culturing of cells at a 40x magnification using an optical 
zoom microscope. (B) Cell lysates were collected from PEC, HEPG2, C2C12, Ins cells and 
HsaVEC lysates. 40µg protein was added for each sample/cell lysate. The blots were 
probed for goat polyclonal anti-IGFBP-2 (MW=36kDa) and, the loading control, murine 
monoclonal anti-β-Actin (43kDa). The blots were stripped after incubation with the IGFBP-
2 antibody and checked for bound residue. Once confirmed that no residue was bound, the 
blots were probed with the loading control. Densitometry was measured using Genetools 
(n=5, *<p=0.02). Error bars represent SEM. 
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5.4.3 Serum in media affects IGFBP-2 activity 
Very little research has been carried out on HUVECs using IGFBP-2 as a stimulant, 
especially in regards to in vitro angiogenic signalling and activity (Das et al., 2013; 
Feng et al., 2015; LI et al., 2018). Therefore, we needed to optimise the in vitro 
conditions, which create a HUVEC environment where the angiogenic-like 
characteristics of IGFBP-2 can be observed.  
Media compositions can affect the growth of cells as well as influence the effect of 
stimulants. As stated in the background (Chapter 5.1) heparin, IGF-I and other growth 
factors all have ability to affect IGFBP-2 activity. Cells were compared using a high 
serum media (20%) (M199), which is used universally in our laboratory and a low 
serum media (2%) (EGM2).  
Cells grown in 20% serum following serum starvation displayed a change in 
morphology, presenting a rigid cell shape and cells floating to the surface (Figure 
5.5). Following stimulation with IGFBP-2, Akt and MAPK phosphorylation was more 
pronounced in HUVECs which didn’t retain their endothelial cell phenotypes (Figure 
5.6). 
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Figure 5.5 Serum-starving influences cell morphology, depending on 
media used to culture cells - Preliminary study 
Images taken at a 40x magnification using an optical zoom microscope of 
(A) HUVECs grown until confluency in M199 media (supplemented with 
20% serum) or EGM2 (supplemented with 2% serum) media. (B) After 
changing the media to serum-free media (no serum or endothelial growth 
factors/supplement) for 2 hours for HUVECs grown in both different 
mediums. Images were magnified using ImageJ. 
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Figure 5.6 Different serum concentrations in cell media influences signalling outputs - 
Preliminary study 
Serum-starved HUVECs grown in either EGM2 (2% serum) or M199 (20% serum) were 
stimulated with 500ng/ml IGFBP-2 or 30ng/ml VEGF for 20 mins. (A) 20µg of protein from the 
stimulated HUVEC lysates was loaded onto an immunoblot and probed for rabbit polyclonal 
anti-phospho Akt (MW=60kDa), murine polyclonal anti-Akt (MW=60kDa), rabbit polyclonal 
anti-phospho-MAPK (MW=44/42kDa) and the loading control, murine monoclonal anti-β-Actin 
(43kDa). The blots were stripped after each incubation and confirmed that no residue was 
bound before the next antibody was used. Lane 1-3 = HUVECs grown in EGM2 media, lane 
4-6 = HUVECs grown in M199 media. Lane 2 and 5 were stimulated with 500ng/ml IGFBP-2, 
Lane 3 and 6 stimulated with 30ng/ml VEGF. (B) Graphical representation of the densitometry 
of pAkt/Akt, normalised to β-Actin (n=2). (C) Graphical representation of the densitometry of 
pMAPK normalised to β-Actin (n=2).  (D) Graphical representation comparing the densitometry 
of pAkt/Akt and p-MAPK, normalised to β-Actin in non-stimulated (SF) and VEGF-stimulated 
samples in both mediums (n=2).  
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5.4.4 Heparin affects IGFBP-2 signalling activity 
Heparin is added to most cell growth media to help the delivery of growth factors. The 
effect of heparin in the media and its possible interference with the HBDs in IGFBP-
2 was also verified by observing the changes occurred with Akt and MAPK 
phosphorylation. Akt phosphorylation and MAPK phosphorylation was blunted in the 
presence of heparin. (Figure 5.7).  
Figure 5.7 Heparin suppresses IGFBP-2 stimulated activity - Preliminary study 
(A) Representative images of immunoblots with 20µg of protein from cell lysates of HUVECs 
grown in EGM2 (2% serum) or M199 (20% serum), in the presence (+) and absence (-) of 
heparin and stimulated with IGFBP-2 (BP2) (500ng/ml) or VEGF (30ng/ml) for 20 minutes. The 
blots were probed for rabbit polyclonal anti-phospho Akt (MW=60kDa) and murine polyclonal 
anti-Akt (MW=60kDa), rabbit polyclonal anti-phospho-MAPK (MW=44/42kDa), murine 
polyclonal anti-MAPK (MW=44/42kDa) and the loading control, murine monoclonal Hsp90 
(MW=90kDa). All these sections were cut separately with phospho-proteins being probed for 
first, following the total equivalent, with the blots being stripped in between. Between each 
stripping stage, the blots were imaged to ensure no residue remained (B) Densitometry of 
phospho-Akt and -MAPK changes in HUVECs grown in EGM2, in the presence or absence of 
heparin, stimulated with or without IGFBP-2 (n=2). (C) Densitometry of phospho-Akt and -
MAPK changes in HUVECs grown in M199, in the presence or absence of heparin, stimulated 
with or without IGFBP-2 (n=2).  
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5.4.5 IGF and ECGS influences cellular expression of IGFBP-2 
Endothelial cell growth supplement (ECGS) contains many growth factors such as 
FGF, PDGF and VEGF, which also may indirectly or directly affect the role IGFBP-2 
may play, specifically IGF. IGF-I concentrations may influence IGFBP-2 expression 
and therefore interfere with the known concentration of IGFBP-2 added to stimulate 
a response (Clemmons et al., 1992). ECGS and IGF-I in combination and alone 
increased endogenous expression of IGFBP-2 in HUVECs (Figure 5.8).  
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Figure 5.8 IGF-1 and ECGS stimulation significantly enhances cellular IGFBP-2 
expression 
HUVECs were stimulated with IGF-I (10-50ng/ml) for 10 minutes in the presence (+) and 
absence (-) of endothelial cell growth supplement (ECGS) following serum starvation or 
remained in full media (20% serum). (A) 20µg protein was loaded from non-stimulated and 
stimulated cell lysates. Blots were first probed for goat polyclonal anti-IGFBP-2 (MW=36kDa) 
and the loading control, murine monoclonal al anti-β-Actin (43kDa). Following stripping 
between antibody probing, the blots were imaged to ensure no residue remained. (B) 
Densitometry of IGFBP-2 levels normalised to β-Actin, comparing full media HUVECs, serum-
starved HUVECs, following stimulation with IGF-I for 10 minutes, in the presence or absence 
of ECGS (n=2, *<p=0.03). Error bars represent SEM. (C) Graph comparing IGFBP-2 levels, 
normalised to β-Actin in the absence of ECGS, following stimulation with IGF-I (10ng/ml and 
50ng/ml) (n=2, *<p=0.05). Error bars show SEM. 
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5.4.6 Cell confluency affects IGFBP-2 stimulated Akt phosphorylation 
Cells at different stages of confluency activate different growth and survival signalling 
pathways, as growth signalling pathways would be activated when populating an 
area, whereas apoptotic signalling pathways will be triggered during over confluence. 
We need to ensure the changes in signalling pathways influenced by confluence do 
not affect the role of IGFBP-2 in in vitro angiogenic signalling pathways. IGFBP-2 
stimulated Akt phosphorylation is muted at 50% confluence state but the 
enhancement returns at 100% and over-confluency (Figure 5.9). 
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Figure 5.9 Confluence states influences the activity of IGFBP-2 
HUVEC were stimulated with IGFBP-2 (500ng/ml) for 20 mins and lysed at 50%, 100% or over-
confluent (24 hours after 100% confluency) states. (A) Images of HUVECs at the different 
confluence states before being stimulated with IGFBP-2 (500ng/ml) were taken at a 40x 
magnification using an optical zoom microscope. (B) 20µg of protein was obtained from HUVEC 
lysates and used for immunoblotting analysis. Blots were probed for rabbit polyclonal anti-
phospho-Akt (MW=60kDa), murine polyclonal anti-Akt (MW=60kDa) and the loading control, 
murine monoclonal Hsp90 (MW=90kDa). Blots were stripped and checked for residue in 
between probing for phosphor and total levels of Akt. Lane 1 and 2 are HUVECs at 50% 
confluency, lane 3 and 4 are HUVECs at 100% confluency and lane 5 and 6 are HUVECs at 
over-confluency. Lane 2, 4 and 6 are stimulated with IGFBP-2 and 1, 3 and 5 are their 
representative controls. Densitometry of the bands on the blots measured show Akt 
phosphorylation changes in response to stimulation with IGFBP-2 at different confluence states 
(50%, 100% and over-confluent) (n=2, *<p=0.03). Error bars represent SEM. 
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5.4.7 IGFBP-2 stimulated Akt phosphorylation in HUVECs 
Having optimised HUVEC culture conditions to ensure they do not interfere with the 
IGFBP-2 used to stimulate signalling cascades, we can optimise the concentrations 
and time stimulations required to induce effects on certain angiogenic pathways. 
Physiological concentrations of IGFBP-2 in healthy humans range from 
approximately 250ng/ml to 600ng/ml (Lin et al., 2009).  
HUVECs stimulated with lower concentrations and concentrations within the human 
plasma range demonstrated 200ng/ml achieved the maximum level of IGFBP-2 
stimulated Akt phosphorylation (Figure 5.10) Time-dependent stimulation showed 
IGFBP-2 maximal Akt phosphorylation was achieved within 15 mins. 
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Figure 5.10 IGFBP-2 significantly activates Akt phosphorylation 
HUVECs were stimulated with IGFBP-2 (1-500ng/ml) for 15 mins or for 15 mins 
intervals up to 75 mins. 20µg of protein from cell lysates was loaded onto western 
blots. The blots were probed for rabbit polyclonal anti-phospho Akt (MW=60kDa) and 
murine polyclonal anti-Akt (MW=60kDa) and the loading control, murine monoclonal 
anti-β-Actin (43kDa). Blots were stripped between being probed for phospho and total 
Akt. (A) HUVECs were stimulated with IGFBP-2 (1-200ng/ml) for 15 mins. 
Densitometry from the blots shows the change in Akt phosphorylation occurred as a 
result of stimulation with IGFBP-2 of increasing concentrations (n=6, *<p=0.01). (B) 
HUVECs were stimulated with IGFBP-2 (200-500ng/ml) for 15mins. Densitometry of 
the blots shows the change in Akt phosphorylation vs total levels of Akt in response to 
stimulation with increasing concentrations of IGFBP-2 (n=5, *<p=0.01). (C) HUVECs 
were stimulated with IGFBP-2 (200ng/ml) for 15-75 mins in 15 min intervals. 
Densitometry shoes the change in Akt phosphorylation, compared to total Akt levels in 
response to increasing stimulation times with IGFBP-2 (n=5, *<p=0.01). Error bars 
represent SEM. 
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5.4.8 IGFBP-2 stimulated ERK/MAPK phosphorylation in HUVECs 
Along with the Akt pathway being the most reported pathway to be influenced by 
IGFBP-2 via IGF-I, integrin and PTEN interactions, ERK/MAPK activation is also 
stimulated by IGFBP-2 (Myers et al., 2015; Shen et al., 2012). p44/42 MAPK was 
activated in response to 500ng/ml IGFBP-2 (10 min stimulation) (Figure 5.11). The 
incubation time was lowered to 10 mins instead of 15 mins because following 
optimisation, incubation time at 15 mins did not give us a consistent activation effect. 
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Figure 5.11 IGFBP-2 enhances MAPK activation  
Serum-starved HUVECs were stimulated with varying concentrations of IGFBP-2 (10-
500ng/ml) for different time periods (10-30mins) or with the positive control (30ng/ml; 
10min). 20µg protein cell lysates in blots were probed for rabbit polyclonal anti-phospho-
MAPK (MW=44/42kDa), murine polyclonal anti- MAPK (MW=44/42kDa) and the loading 
control, murine monoclonal anti-β-Actin (43kDa) or murine monoclonal Hsp90 
(MW=90kDa). Blots were stripped and checked for bound residue between phospho-, total-
MAPK and β-Actin. (A) Representative image of the immunoblot with HUVECs stimulated 
with IGFBP-2 (10-500ng/ml; 10min) or VEGF (30ng/ml; 10min) and probed for phospho-
MAPK, total-MAPK and β-Actin. Graph shows change in MAPK phosphorylation compared 
total MAPK levels and normalised to β-Actin levels in response to stimulation with increasing 
IGFBP-2 levels (n=3, *<p=0.05). (B) Representative image of immunoblot with HUVECs 
stimulated with IGFBP-2 (200-500ng/ml; 20min) or VEGF (30ng/ml; 10min). Graph shows 
change in MAPK phosphorylation compared total MAPK levels and normalised Hsp90 levels 
in response to stimulation with increasing IGFBP-2 levels (n=3, *<p=0.01). (C) 
Representative image of immunoblot with HUVECs stimulated with IGFBP-2 (500ng/ml; 10-
30min). Graph shows change in MAPK phosphorylation compared total MAPK levels and 
normalised Hsp90 levels in response to stimulation with IGFBP-2 (500ng/ml) for 10, 20 or 
30mins (n=3, *<p=0.01). Error bars represent SEM. 
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5.4.9 IGFBP-2 does not stimulate eNOS phosphorylation 
IGFBP-2 has rarely been implicated to interact with eNOS until recent years. In 
HUVECs, down-regulated levels of IGFBP-2 have been associated with a decrease 
in insulin-stimulated Akt and in turn eNOS (LI et al., 2018). If IGFBP-2 directly 
modulates endothelial remodelling as hypothesised from Chapter 4, IGFBP-2 may 
also affect eNOS expression. However, in HUVECs IGFBP-2 did not show any 
evidence of mediating eNOS phosphorylation (Figure 5.12). 
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Figure 5.12 IGFBP-2 fails to enhance eNOS phosphorylation 
Serum-starved HUVECs were stimulated with varying concentrations of IGFBP-2 (10-400ng/ml) 
for different time periods (10-20mins) or with the positive control (30ng/ml; 10min). 20µg protein 
from cell lysate were used on blots which were probed for rabbit polyclonal anti-phospho eNOS 
(MW=140kDa), rabbit polyclonal anti-eNOS (MW=140kDa) and the loading control murine 
monoclonal anti-β-Actin (43kDa). Blots were stripped and checked for bound residue between 
probing for phospho and total levels. (A) Representative image of the immunoblot with HUVECs 
stimulated with IGFBP-2 (10-400ng/ml; 20min). Graph shows change in eNOS phosphorylation 
compared total eNOS levels and normalised to β-Actin levels in response to stimulation with 
increasing IGFBP-2 levels (n=4). Error bars show SEM. (B) Representative image of immunoblot 
with HUVECs stimulated with IGFBP-2 (500ng/ml; 10 or 20min) or VEGF (30ng/ml; 10 or 20min). 
Graph shows change in eNOS phosphorylation compared total eNOS levels and normalised β-
Actin levels in response to stimulation with IGFBP-2 levels at different stimulation times (10 or 
20min) (n=2). 
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5.4.10 IGFBP-2 does not activate FAK, GSK3β or PTEN 
FAK was investigated due to many published articles linking an association between 
increased IGFBP-2 concentrations and activation of the FAK pathway (Liu et al., 
2017; Yau et al., 2014). However, for the first time we are exploring this link in an 
endothelial cell (Figure 5.13). The phosphorylation of other potential angiogenic-
signalling molecules shown to interact with IGFBP-2 such as GSK3β and PTEN were 
interrogated to help identify the predominant signalling pathway driving IGFBP-2s 
influence over angiogenic-like characteristics. In HUVECs, IGFBP-2 failed to activate 
FAK and GSK3β signalling, or PTEN phosphorylation (Figure 5.13). 
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Figure 5.13 IGFBP-2 does not activate other angiogenic signalling molecules 
Serum-starved HUVECs were stimulated with varying concentrations of IGFBP-2 (10-
500ng/ml) for different time periods (10-60mins). 20µg protein from cell lysate were 
used on blots which were probed for rabbit polyclonal anti-phospho FAK 
(MW=125kDa), rabbit polyclonal anti-FAK (MW=125kDa), rabbit polyclonal anti-
phospho GSK3β (46kDa), rabbit polyclonal anti-phospho Akt (60kDa), rabbit 
polyclonal anti-phospho PTEN and the loading control, murine monoclonal anti-β-Actin 
(43kDa). Blots were stripped and checked for bound residue between probing for 
phospho, total levels and the loading control. (A) Representative image of the 
immunoblot with HUVECs stimulated with IGFBP-2 (10-500ng/ml; 15min), probing for 
changes in FAK phosphorylation changes, compared to total FAK levels. (B) 
Representative image of the immunoblot with HUVECs stimulated with IGFBP-2 
(500ng/ml; 10-60min). Graph shows change in FAK phosphorylation compared to total 
FAK levels and normalised to β-Actin levels in response to stimulation with IGFBP-2 
for stimulation times at 10 or 15min intervals, up to 60min (n=3). Error bars represent 
SEM. (C) Representative image of the immunoblot with HUVECs stimulated with 
IGFBP-2 (10-500ng/ml; 15min), probing for changes in GSK3β phosphorylation 
changes. (D)  Representative image of the immunoblot with HUVECs stimulated with 
IGFBP-2 (10-500ng/ml; 15min), probing for changes in PTEN phosphorylation 
changes, using phosphorylation of Akt as a positive control (as identified previously). 
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5.5 Discussion 
5.5.1 Endothelial cell types endogenously express varying 
concentrations of IGFBP-2 
From earlier studies, changes in IGFBP-2 induced signalling were dependent on 
levels within different cells. Therefore, it is important to identify which cells 
endogenously express higher levels of IGFBP-2 as these cells are most likely to be 
involved in modulating angiogenic-like characteristics. This is confirmed by cells, 
specifically cancer cells, such as small cell lung cancer cells and breast cancer cell 
lines, which express elevated levels of IGFBP-2 also display an enhancement in cell 
growth, survival, proliferation and migration (Hoeflich & Russo, 2015; Yazawa et al., 
2009). 
Our findings showed HUVECs expressed the largest abundance of endogenously 
expressed IGFBP-2 compared to all cell types, suggesting they play a more 
significant role in cell migration and proliferation. We investigated the over-expression 
of IGFBP-2 on cells that are highly proliferative in their regular phenotype as these 
are types of cells which will respond to angiogenic signals rapidly.  
Bovine aortic endothelial cells have previously been shown to express IGFBP-2 
levels, displaying an intense band following northern blotting and RT-PCR (Moser et 
al., 1992). Interestingly, PECs and HSaVECs produce very small amount of IGFBP-
2 in comparison to HUVECs and other non-endothelial cell types. However, this 
correlates with their growth in in vitro culture. 100,000 HUVEC cells are able to reach 
confluency in approximately 3 days, however PECs and HSaVECs proliferate at a 
distinctively slower rate as observed in our laboratory.  
Strangely, HEPG2 cells also generate significant less IGFBP-2 than HUVECs, even 
though IGFBP-2 is expressed into circulation from liver cells. C2C12 myoblasts 
express IGFBP-2 in a small abundance when not put in a state of inflammation due 
to low serum concentration (Sharples et al., 2010). INS-Pancreatic cells presented a 
significantly elevated expression of IGFBP-2 in comparison to the C2C12 cells. Many 
in vitro and in vivo studies have confirmed IGFBP-2 does play a role in maintaining 
metabolic homeostasis. As these are insulin producing cells and they have a large 
presence in modulating metabolism, IGFBP-2 may be expressed by the cell in order 
to regulate metabolic changes.  
These findings validate our use of HUVECs for our exploration of IGFBP-2s 
angiogenic potential. Their highly proliferative characteristic may be driven by the 
upregulation of IGFBP-2 we observe. In addition, IGFBP-2 down-regulation or low 
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IGFBP-2 levels cause negative effects on angiogenic signalling which is opposite to 
the effect we are aiming to investigate (Gao et al., 2016; Liu et al., 2017). 
 
5.5.2 IGFBP-2 activates Akt signalling independent of IGF binding in 
HUVECs 
Previous in vitro studies exploring the effect of IGFBP-2 on HUVECs have all 
highlighted activation of a potent angiogenic signalling molecule, Akt. The 
mechanisms reported to drive this activation were through IGF-I signalling or integrin 
interactions.  
We commercially sourced two recombinant IGFBP-2 proteins retrieved from different 
sources, one from insect cells (Abcam) and one from murine cells (R&D). The use of 
both recombinant IGFBP-2s have been published, however no citations have been 
reported on the Abcam product site (Chua et al., 2016; Huynh et al., 2008). Both 
recombinant proteins were validated using its IGF functional ability to inhibit IGF-
stimulated growth responses. However, we failed to display functional binding of 
biotinylated IGF-I to non-denatured IGF binding sites in the Abcam recombinant 
IGFBP-2 sourced from insect cells. Immunoblotting using an IGFBP-2 antibody 
confirmed the protein was recognised as IGFBP-2. The recombinant protein sourced 
from murine cells displayed IGF binding capacity of the biotinylated IGF-I. From this, 
we can deduce, post-translational modifications in the IGFBP-2 sourced from insect 
cell hosts may define its selection of binding to IGF-I. To study this further, we would 
need to assess for changes in post-translational modifications, such as 
phosphorylation and glycosylation changes, between the different species hosts of 
IGFBP-2. 
Further investigation into the functionality of these recombinant proteins was carried 
out on a signalling level. Published data confirmed IGFBP-2 regulates Akt 
phosphorylation in serum-starved HUVECs to drive survival and migration 
responses, therefore we used the Akt signalling pathway to determine the effect a 
non-functional IGF binding IGFBP-2 had on Akt phosphorylation compared to the 
complete functional protein (Bhutia et al., 2016). Interestingly, both recombinant 
IGFBP-2s dose-dependently enhanced Akt activation in HUVECs. Thus, suggesting 
IGFBP-2 induced Akt phosphorylation is via an IGF-independent mechanism. This 
potential has been highlighted in IGFBP-2 KO mice that were injected with a HBD 
peptide. The peptide resulted in the upregulation of IGF-I stimulating an 
enhancement in Akt signalling (Kawai et al., 2011). Therefore, other domains within 
IGFBP-2 may indirectly influence IGF-I levels without requiring IGF binding potential. 
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Although the non-binding IGF did not affect Akt signalling, we cannot confirm the 
other domains are functional and what adverse effect the non-functioning site may 
have on further angiogenic signalling and assay studies. Therefore, the complete 
functional recombinant protein sourced from murine cells was used for all further 
experiments. 
Maximum Akt phosphorylation stimulated by IGFBP-2 was achieved using a 
concentration 200ng/ml in serum-starved HUVECs. Elevated Akt phosphorylation 
plateaued following stimulation with concentrations above 200ng/ml to 500ng/ml. It is 
difficult to establish why Akt phosphorylation may plateau, however IGFBP-2 
bioavailability and functionality may be dependent on circulating IGF concentrations. 
Time-dependent stimulation of IGFBP-2 (200ng/ml) highlighted immediate activation 
of Akt by IGFBP-2 occurred within 15 mins, matching published results (Das et al., 
2013). This enhanced response to Akt activation also plateaued with stimulations for 
increasing periods of time over 15 mins. 
Excess IGF-I prevents IGFBP-2 from exerting its inhibitory functionality on the effect 
of follicle-stimulating hormone, which it would normally exert in low IGF circulating 
concentrations (Zhou et al., 2013). If IGF-I circulating concentrations are able to affect 
IGFBP-2s bioactivity, it is possible IGFBP-2 may also rely on the bioavailability of 
integrins or heparin to exert its actions. Therefore, the plateau effect could be due to 
a restricted bioavailability of any of these molecules stimulating IGFBP-2-dependent 
Akt phosphorylation to its maximum possible level or affinity of interaction, as IGFBP-
2 may be competing with other IGFBPs. 
 
5.5.3 IGFBP-2 activates MAPK phosphorylation in HUVECs 
IGFBP-2 stimulated MAPK activation through ERK and JNK has been associated in 
many cancer cell lines to enhance cellular migration and proliferation. MAPK 
signalling induced by IGFBP-2 has never been interrogated in HUVECs. Although 
most cells stimulated with IGFBP-2 activate MAPK via both ERK and JNK, IGFBP-2 
stimulated JNK was shown to be specifically involved in mediating glioma cell 
migration only. (Han et al., 2014; Mendes et al., 2010). However, angiogenesis 
involves a combination of cell proliferation and migration, therefore in the initial 
signalling studies we focused on the activation of ERK1/2 (Wang et al., 2017c). 
Stimulation with the lower concentration of IGFBP-2 200ng/ml that can induce Akt 
phosphorylation activates p44/42 MAPK phosphorylation at a slower rate, therefore 
longer incubation times were required. A time-dependent stimulation with IGFBP-2 
highlighted p44/42 MAPK phosphorylation occurs at 20 mins, compared to the Akt 
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activation which as been confirmed at 15 mins. These distinct differences between 
IGFBP-2 stimulated Akt and p44/42 MAPK suggest different interaction mechanisms 
are responsible for the activation of each pathway.  
The activation of the p44/42 MAPK pathway by IGFBP-2 displays distinct differences 
compared to its Akt activation, suggesting they function through different interactions. 
The most reported interactions shown to drive IGFBP-2 stimulated MAPK activation 
is through integrins, specifically the subunits β1 and α5 (Holmes et al., 2012). 
Whereas IGFBP-2 induced Akt is thought to function via modulation of IGF-I or 
interactions between HBD1 and RPTPβ. Thus, providing an explanation to the 
different conditions required to stimulate each pathway. 
 
5.5.4 IGFBP-2 stimulation has no effect on eNOS phosphorylation in 
HUVECs 
eNOS is a highly important regulator of vascular integrity, especial during and after 
angiogenesis in the formation and maintenance of healthy blood vessels. IGFBP-2 is 
recently being associated with an increase in NO via activation of Akt in osteoblasts, 
hepatocellular carcinoma cells and HUVECs, however there is limited information 
(Hung et al., 2017; LI et al., 2018; Xi et al., 2016).  
We have already established IGFBP-2 does activate Akt in serum starved HUVECs, 
however we have not interrogated downstream activation of targets below Akt in the 
signalling cascade. IGFBP-2 failed to upregulate eNOS phosphorylation under a 
variety of different conditions. (LI et al., 2018) observed a reduction of IGFBP-2 to 
correlate with a reduction in eNOS phosphorylation in an insulin-resistant state. 
However, with an overnight treatment of IGFBP-2, eNOS activation increased. 
IGFBP-2s protective properties were discussed in Chapter 4, which suggests that 
maybe cells need to be in a compromised state before we identify significant changes 
in angiogenic signalling stimulated by IGFBP-2. From these findings we can deduce, 
in regular homeostasis, IGFBP-2 does not influence eNOS phosphorylation. 
Therefore, we need to interrogate which other downstream targets of Akt may be 
activated via IGFBP-2 stimulation. 
 
5.5.5 IGFBP-2 fails to enhance activation of other associated angiogenic 
signalling molecules in HUVECs 
IGFBP-2 has been reported to modulate the effects of GSK3β and in turn β-catenin, 
via activation of FAK signalling in breast cancer and glioma cells (Patil et al., 2016; 
Sehgal et al., 2013). Both, dose- and time-dependent stimulation failed to upregulate 
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FAK or GSK3β phosphorylation to a significant level in HUVECs. As this mechanism 
has only been investigated in cancer cells, it may only be limited to highly invasive 
and proliferative cell lines. 
IGFBP-2 has been reported to drive Akt phosphorylation via interactions between its 
HBD1 in the variable region and RPTPβ (Shen et al., 2012). Active and stable RPTPβ 
mediates the de-phosphorylation of PTEN. When in de-phosphorylated form, PTEN 
can undergo degradation, which in turn stimulates Akt stimulation. To determine if 
PTEN phosphorylation was reduced in response to stimulation with IGFBP-2, serum 
starved HUVECs were stimulated with different doses of IGFBP-2 (10-500ng/ml). 
However, as IGFBP-2 shown enhancement of Akt phosphorylation, PTEN 
phosphorylation levels failed to correlate. Thus suggesting IGFBP-2 stimulated Akt 
phosphorylation is induced by another interaction independent from RPTPβ and 
PTEN mediated activation.  
 
5.5.6 Study limitations 
As mentioned in the introduction, Chapter 5.1.2, components in the media such as 
serum and endothelial cell growth supplement contain many additional growth factors 
and molecules that can inhibit the effect of IGFBP-2. A distinct difference in 
endothelial cell phenotype was observed when cells were serum starved from 20% 
serum media (M199), resulting in irregular cell morphology. IGFBP-2 stimulated Akt 
and p44/42 MAPK phosphorylation was significantly more pronounced in the M199 
media with the compromised cells than cells grown in low serum media (EGM2). This 
finding correlates with IGFBP-2s potential to rescue diseased states to a 
healthy/regular level, as seen in the case of insulin resistance and osteoblast 
differentiation (Hedbacker et al., 2010; Xi et al., 2014).  
Another limitation which was highlighted due to the ability of IGFBPs to sequester 
IGF molecules, preventing IGF mediated mechanisms was that heparin in the media 
could present the same problem regarding blockage of the HBDs (Kiepe et al., 2002). 
In the presence of heparin, responses were evidently less pronounced in relation to 
IGFBP-2 stimulated Akt and p44/42 MAPK phosphorylation. This finding suggest 
heparin binding may play a role in causing the IGFBP-2 stimulated activation of Akt 
and MAPK. Heparin was removed from all further experiments to ensure it does not 
interfere with the function of IGFBP-2s HBD. 
As mentioned previously in Chapter 5.1.2, growth factors could interfere with the 
activity of IGFBP-2. VEGF, FGF, PDGF and IGF are all present in the supplement 
and are extremely potent activators of angiogenesis, therefore any angiogenic-like 
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stimulation may be induced signalling exerted by these factors. Serum starved 
HUVECs were stimulated with increasing concentrations of IGF-I, in the presence 
and absence of ECGS. The supplement alone significantly elevated IGFBP-2 
expression levels, however IGF-I at 10ng/ml also caused an increase in IGFBP-2 
expression. Thus, increasing the overall bioavailability of IGFBP-2 in circulation. As 
we only wanted to see the effect of a known concentration of IGFBP-2 we added, all 
cells were serum-starved before experiments to ensure removal of the growth factors 
expressed by cells and in the media. The serum starving media contained no serum 
or added supplements which may adversely increase cellular IGFBP-2 expression. 
During growth to confluence, cells activate different signalling pathways to induce 
proliferation and migration. Cells at different stages of confluency were stimulated 
with IGFBP-2 (500ng/ml). Surprisingly, at a 50% confluency state, when proliferation 
and migration signalling pathways would be activated to populate empty areas, 
stimulation with IGFBP-2 failed to enhance phosphorylation of Akt compared to its 
basal control. However, at a 100% confluency state or when cells were left 24 hours 
after 100% confluency (an over-confluent state), proliferation and migration signalling 
would be down-regulated and contact inhibition begins to take place, resulting in cell 
death. Contact inhibition results in some cells become senescent and floating to the 
surface (Sun, 2014). When IGFBP-2 was used as a stimulant in both of these states, 
an increase in Akt phosphorylation was observed. This supports the rescue theory of 
IGFBP-2 that when abnormal signals are released by compromised environments 
such as insulin resistance or reduced osteoblast differentiation, IGFBP-2 aims to 
restore regular levels (Hedbacker et al., 2010; Xi et al., 2014). In the case of cell 
confluency, IGFBP-2 may cause an enhancement in Akt phosphorylation to promote 
the survival of existing cells or growth of new cells to compensate for the cells that 
are dying (Chen et al., 2013). As cell confluency also influences the effect of IGFBP-
2, it is essential cells are used at the same confluency state for each experiment in 
order to make a fair comparison of true IGFBP-2 stimulated effects. 
 
 
5.6 Concluding remarks 
We have identified IGFBP-2 stimulates Akt and p44/42 MAPK phosphorylation but 
fails to activate FAK signalling and in turn GSK3β phosphorylation in HUVECs. 
Activation of both the Akt and MAPK pathways via stimulation with different 
conditions, such as 200ng/ml IGFBP-2 significantly enhances Akt phosphorylation 
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but fails to activate p44/42 MAPK at this concentration and Akt phosphorylation takes 
place within 15 mins. However, IGFBP-2 stimulated phosphorylation of p44/42 MAPK 
takes a longer period of approximately 20 mins. These differences highlight two 
different mechanisms via IGFBP-2 may be responsible for activating the Akt and 
MAPK signalling cascades. The mechanisms responsible for the activation of these 
pathways will be further investigated using mutant variants of IGFBP-2 possessing 
non-functional domains. It is clear, MAPK relies on integrin interactions but Akt is 
possibly driven by IGF-I or HBD interactions. However, our investigation into 
recombinant IGFBP-2 from different sources and upstream targets suggest other 
interactions may be responsible for IGFBP-2 stimulated Akt phosphorylation in 
HUVECs. 
A non-functional IGF binding domain did not affect IGFBP-2-stimulated Akt 
phosphorylation, suggesting IGFBP-2 relies on IGF-independent mechanisms to 
stimulate Akt. However, stimulation with IGFBP-2 failed to reduce PTEN 
phosphorylatyion levels, therefore the central HBD interactions do not promote 
IGFBP-2 stimulated Akt activation in HUVECs. IGFBP-2 failed to induce 
phosphorylation of a downstream target of Akt that plays a significant role in 
maintenance of the vascular network, eNOS. Other downstream targets activated by 
Akt and involved in angiogenesis should be interrogated to determine how the role of 
IGFBP-2 stimulated Akt activation can be exploited therapeutically. 
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Chapter 6 - Influence of IGFBP-2 
on angiogenic properties of 
endothelial cells in vitro 
 
6.1 Background 
We have established IGFBP-2 is elevated in response to ischemia and enhances 
perfusion at early stages of recovery following hind limb ischemia in Chapter 4. This 
was supported by the upregulation of Akt and p44/42 MAPK phosphorylation in 
HUVECs, in Chapter 5. In published literature, IGFBP-2s angiogenic potential in 
functional studies using HUVECs remains fairly limited. 
Angiogenesis is the formation of new blood vessels from pre-existing vessels. We 
have hypothesised from findings from Chapter 4, IGFBP-2 may stimulate more 
arteriogenic type responses rather than angiogenesis. Although both mechanisms 
are induced by different stimuli, they both involve endothelial adhesion, migration and 
proliferation. Arteriogenesis uses these mechanisms to induce endothelial 
remodelling of the pre-existing collaterals.  
Once angiogenic signals, such as VEGF, are sensed the pericyte layer which 
encloses the endothelial monolayer detaches from the vessel wall due to degradation 
of junctional molecules such as VE-cadherin. This causes vascular 
hyperpermeability, enabling plasma membranes to install a temporary ECM 
consisting of plasma proteins such as fibrinogen, collagen, fibronectin and 
glycosaminoglycans (Rhodes & Simons, 2007). This provides the foundation scaffold 
which endothelial cells migrate onto to form the vessel endothelial monolayer, once 
an endothelial cell is transformed into a tip cell to promote sprouting. Although 
migration is a vital mechanism promoting the migration of the endothelial tip cell onto 
the temporary ECM during sprouting, the cells are still initially attached to the pre-
existing vessel, offering stability to the tip cell via FAK and integrin signalling 
(Cavalcanti-Adam et al., 2007). IGFBP-2 stimulated angiogenesis has the potential 
to function through angiogenic signalling as well as interacting with the ECM surface 
via glycosaminoglycan interactions through its HBD. This summary highlights the 
roles of endothelial cell adhesion, migration and proliferation in angiogenesis. 
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6.1.1 Adhesion  
In regards to angiogenesis, adhesion is usually presented as a negative effect. This 
is due to the anchoring mechanisms which down-regulate cell migration and 
proliferation. However, as described in the angiogenesis mechanism above, integrin 
signalling has to mediate cell adhesive properties to promote endothelial cell 
migration along the temporary ECM, driven by the endothelial tip cell and ensure their 
survival until maturation has been achieved (Figure 6.1). Cell adhesion is also critical 
for regulating cell morphology by regulating actin organisation and junction formation 
between adjacent cells (Folkman & Moscona, 1978). 
FAK is a tyrosine kinase involved in adhesion signalling to promote cell-ECM 
adhesion and is regulated via integrin interactions, specifically with the subunit β1 
(Schaller et al., 1995). It was confirmed IGFBP-2 cell surface binding to fibronectin 
was specifically mediated by α5β1, however this ECM binding led to the inactivation 
of FAK, as well as p44/42 MAPK (Schütt et al., 2004).  Thus suggesting integrin 
signalling determines IGFBP-2s role in cell adhesion, as well as migration. This 
inactivation of FAK has to be critically regulated as endothelial-specific deletion of 
FAK disrupted blood vessel development, due to a lack of adhesion (Shen et al., 
2005). The majority of research associating IGFBP-2s role within cell adhesion 
reports it promotes de-adhesion of cells. This has been observed in breast cancer 
and glioma cells (Beattie et al., 2015; Chua et al., 2016).  
Activation of ERK/MAPK signalling is induced by the binding of endothelial cells via 
α5β1 integrin to a fibronectin coated surface (Sudhakar et al., 2003). This was also 
observed with IGFBP-2 possibly enhancing interactions between integrin α5, 
increasing glioma cell adhesion. Activation of this mechanism resulted in activation 
of the JNK/MAPK pathway (Mendes et al., 2010). 
Cell adhesion molecules (CAMs) are glycoproteins on the cell surface which mediate 
cell-ECM and cell-cell interactions. An association between IGFBP-2 levels and the 
expression of CAMS such as ICAM-1, ITGAL and CDC42 has been discovered, 
which correlated with other published data confirming the upregulation of cell 
adhesion genes such as integrin α5 in response to over-expression of IGFBP-2 (Song 
et al., 2003; Wang et al., 2003) 
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These findings highlight IGFBP-2 does play a role in regulating cell adhesion via its 
integrin actions, specifically via α5. However, it is unknown what effect IGFBP-2 may 
have on cell adhesion in driving angiogenic responses to rescue an ischemic 
environment. 
 
Figure 6.1 Critical cell adhesion stages in angiogenesis 
This image represents different stages of angiogenesis from the tip cell formation to 
maturation of endothelial cells. Thus, highlighting the importance of adhesion to the pre-
existing vessel to start the sprouting process and to stabilise the migrating column by 
adhering to surrounding ECM promoted by focal adhesions. Adapted from Francavilla et 
al., (2009). 
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6.1.1.1 Integrins 
Integrins are heterodimer transmembrane receptors that facilitate cell adhesion 
properties between cells and the ECM. They are composed of different combinations 
of non-covalently bonded α and β subunits. 
Once integrins located on the cell surface bind to RGD sites on the ECM, a 
conformational change takes place resulting in separation of α and β subunits. The 
separation creates α and β integrin cytoplasmic tails. These tails are recognised by 
cytoplasmic proteins which once bound increase integrin affinity and also activate 
integrin-mediated intracellular signalling cascades. (Morse et al., 2014). As integrin 
affinity increases, more binding to the ECM causes integrins to form focal complexes 
and eventually focal adhesions, connecting the intracellular actin cytoskeleton to the 
ECM) (Legate & Fassler, 2009). The maturation of focal complexes into fibrillar 
adhesions is only apparent when binding of integrin α5β1 to fibronectin occurs 
(Geiger & Yamada, 2011). Once the actin has connected to the ECM, outside-in 
signalling activation occurs, leading to the recruitment of signalling components such 
as FAK, ILK and Src kinases. (Harburger & Calderwood, 2009) 
The RGD site in IGFBP-2 has been reported to act via the integrins αVβ3, α1β1 and 
α5β1 (Hamidouche et al., 2010; Han et al., 2014; Kawai et al., 2011). However, 
IGFBP-2s interaction with each of these integrins activates different signalling 
cascades and functionality. Interestingly, interactions between IGFBP-2 and αVβ3 
have been reported to negatively modulate IGF-I mediated effects (Miyako et al., 
2009). It appears that interaction with this domain may be dependent on IGFBP-2s 
other domains, as in smooth muscle cells, activation of the HBD induced αVβ3 
integrin mediated signalling (Kawai et al., 2011). IGFBP-2 and its interaction with α5 
is critical to cell mobility, acting via activation of JNK mediated MAPK phosphorylation 
(Mendes et al., 2010; Wang et al., 2006). However, its interaction with the subunit β1 
also promotes MAPK phosphorylation via activation of ERK (Han et al., 2014).  
The integrin mediated role that IGFBP-2 may play in angiogenesis needs to be further 
interrogated as not only do the integrins modulate adhesion, but also cell migration. 
The association between IGFBP-2 and αVβ3 has been investigated to a limited 
extent; however αVβ3 has been identified as a mediator of angiogenesis due to its 
ability to find to a variety of ECMs and molecules, including fibrin, fibronectin and von 
Willebrand factor (Bischoff, 1997). 
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6.1.2 Proliferation and migration 
Proliferation and migration of endothelial cells are mechanisms which are critical for 
angiogenesis, both co-ordinately working together. As stated previously, cell 
adhesion via integrin binding to the ECM is the initial phase of angiogenesis that 
causes the stimulation of growth and motility signalling cascades. A VEGF-activated 
endothelial cell adhered to the pre-existing vessel matures into a tip cell and begins 
migration mechanisms to drive the endothelial tip cell to the temporary ECM. Stalk 
cell proliferation then takes place providing stability to the migrating column (Norton 
& Popel, 2016).  
IGFBP-2 upregulated levels were first identified in cancer and further research 
highlighted a correlation between elevated IGFBP-2 levels and tumour growth, 
suggesting IGFBP-2 has a role in cancer angiogenesis. Since this discovery, the 
effect of IGFBP-2 on proliferation and migration angiogenic mechanisms has been 
researched extensively in cancer and non-cancer cell lines. 
In a majority of cancers, IGFBP-2 is highly expressed and correlates with cancer cell 
angiogenic mechanisms. To truly observe if IGFBP-2 is responsible for the 
mechanisms that promote the growth and development of tumours, IGFBP-2 is 
commonly silenced using siRNA. In pancreatic cancer and acute myeloid leukaemia 
cells, IGFBP-2 played a significant role in cell migration and survival. A knockdown 
of IGFBP-2 inhibited cell migration and promoted apoptosis, which corresponded with 
a decrease in Akt phosphorylation induced by increased PTEN levels (Chen et al., 
2013; Liu et al., 2017). Cell proliferation and survival was also supressed in breast 
cancer epithelial cells following silencing of IGFBP-2. However, the suppression was 
rescued via treatment of an RGD-containing disintegrin, suggesting the RGD domain 
within IGFBP-2 is responsible for cell proliferation and survival. (Foulstone et al., 
2013).  
IGFBP-2 stimulated activation of these mechanisms was also observed in non-
cancer cell types. In adjuvant arthritis synovial cells, IGFBP-2 enhanced cell 
proliferation and migration via wound closure, and enhancement of the ERK 
signalling cascade (Wang et al., 2017a). Human dermal fibroblasts over-expressing 
IGFBP-2 also displayed enhanced migration, specifically via the α5β1 (Brandt et al., 
2015). 
IGFBP-2 appears to use a combination of its domains to influence the integrin 
signalling, Akt, and ERK signalling pathways to drive proliferation and migration 
mechanisms. Therefore, IGFBP-2 may be using these mechanisms in vivo to 
contribute to the enhancement in perfusion we observed in HLI in Chapter 4. 
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6.1.3 Summary 
It is clear IGFBP-2 plays a regulatory role in cell adhesion, migration and proliferation 
in many cells types, however IGFBP-2 stimulated activation of the mechanisms has 
only once been investigated in HUVECs which suggested VEGF was responsible for 
increases in in vitro endothelial cell tube formation (Das et al., 2013). The majority of 
the angiogenic mechanisms appear to be modulated by integrins, Akt or MAPK 
signalling pathways. In this chapter we interrogated the effect of IGFBP-2 on each 
mechanism independent of each other in order to determine how IGFBP-2 may be 
exploited to achieve growth of healthy vessels via therapeutic angiogenesis in a 
clinical setting. 
 
 
 
6.2 Experimental objectives 
In this chapter, we aim to investigate the effects of IGFBP-2 on pro-angiogenic 
properties in HUVECs in vitro. IGFBP-2 has exerted many angiogenic-like 
characteristics in a variety of cell types, however this has been rarely been examined 
in endothelial cells. Endothelial cells initiate and drive the angiogenic response via 
adhesion, migration and proliferation of cells in order to create the base scaffolding 
for the formation of the remaining vessel. Investigation of the angiogenic mechanisms 
promoted by IGFBP-2 was carried out using the objectives below: 
• Determine what effect stimulation with IGFBP-2 may have on HUVEC 
adhesion to ECMs.  
• Investigate the effect IGFBP-2 may exert on HUVEC motility via migration and 
proliferation, and migration alone. 
• Investigate the effect IGFBP-2 may have on driving mechanisms to promote 
HUVEC tube formation.  
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6.3 Materials and Methods 
In all assays, recombinant IGFBP-2 commercially bought from R&D Systems, 
sourced from murine cells and does possess IGF binding capability as confirmed by 
us was used. 
 
6.3.1 Cell adhesion assay 
A cell pellet consisting of HUVECs (after centrifugation at 300xg for 5 mins) was 
resuspended in either ECGM with 20% FBS (+ve control) or serum-free ECGM 
(treated and -ve control). 
50,000 HUVECs were seeded into each well of a 24-well, 2% gelatin (Sigma, 69391), 
100µg/ml Collagen IV (Merckmilipore, CC076) or fibronectin coated plate (Corning, 
354411). Positive control wells contained ECGM + 20% FBS; negative control wells 
contained serum-free ECGM and treated cells contained 200ng/ml or 500ng/ml 
IGFBP-2 in serum-free ECGM. The plate was incubated for 30 mins in a humidified 
incubator at a temperature of 37ºC and 5% CO2. The surface was washed three times 
with PBS, pH 7.4 to remove non-adherent cells. Images were taken at 5 different 
points within the well at a 40x magnification. Adhered cells were counted using the 
cell counter tool in ImageJ. 
 
6.3.2 Scratch wound assay 
Wells of a 96-well gridded plate (Essen, 4379) were coated with 0.1%, 1% or 2% 
gelatin. 40,000 HUVECs were seeded into each coated well with Promocell media 
(with growth supplement mix and 1% AAS). Cells were pre-treated with 200 or 
500ng/ml IGFBP-2 for 20 hours. Cells were then starved with ECGM + 1% FBS (and 
endothelial cell growth supplement) for 4 hours. 200 or 500ng/ml IGFBP-2 was added 
to treated wells during the serum-starvation period.  
Wound maker 96 (Essen Bioscience) created a uniform scratch across the surface. 
Wells were washed twice with PBS (containing Ca2+ and Mg2+). Conditioned media 
was made with the basal media (ECGM (2% FBS and ECGS)) and 200 or 500ng/ml 
IGFBP-2. The positive control contained ECGM with 5% FBS and ECGS. Images 
were taken at 2 points of the scratch at a 40x magnification before the plate was 
incubated, and after the 13/16-hour incubation period on the optical zoom 
microscope. Incucyte images were taken at a 10x magnification. The closure area 
was measured using the polygon tool to draw around the edge of the empty area in 
Image J. Time course experiments were placed in the Incucyte imager, placed in an 
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incubator at optimum cell conditions. Images were retrieved and analysed for wound 
closure and cell density using IncucyteZoom software Wound Assay tools. The tool 
is able to locate the original wound gap and measure the closure in wound with over 
time (Figure 6.2). 
 
Migration only scratch wound assay 
Mitomycin C (Sigma, M4287) was prepared to 0.5mg/ml in filtered H2O. 50,000 
HUVECs were seeded in each well. 0.5µg/ml mitomycin C was added to each well, 
20 hours prior to making the scratch and was also added to every media change.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Incucyte wound closure review tool 
Screenshot of scratch wound assay tool used to measure wound with changes using 
IncucyteZoom software. The software highlighted the confluent area of cells (orange), the 
initial scratch (blue) and the change in scratch area over time (yellow). The wound tool 
calculates the area of the initial scratch (blue region) and subtracts the area of the final scratch 
(yellow) to provide the change in wound closure value. 
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6.3.3 Tube formation assay 
Thawed Matrigel (Corning, 354230) was set at 37ºC for 30 mins. For certain 
conditions, equal concentrations of IGFBP-2 to the amount of IGFBP-2 added into 
the media were also added into the Matrigel before it was set. Cells were trypsinised 
and washed with PBS, pH 7.4. After centrifuging the cells at 300xg for 5 mins, the 
pellets were resuspended in ECGM + 1% FBS.  
100,000 HUVECs were seeded into each well with conditioned media. The positive 
control wells consisted of ECGM + 10% FBS, basal wells consisted of ECGM + 1% 
FBS and the treated well consisted of basal media + 200, 500 or 1000ng/ml IGFBP-
2. The plate was incubated for 8 hours. The empty areas created when formed tubes 
meet at ‘nodes’ and sprout off again to create a network, are known as meshes 
(DeCicco-Skinner et al., 2014) (Figure 6.3). The optical microscope was used to 
capture images at a 40x magnification. The Incucyte was used to capture a time 
course of tube formation at a 10x magnification. Images were captured at 9 different 
points in the well. 
 
 
Figure 6.3 Tube formation network  
In this image, the mesh that we measure for tube formation assays has been highlighted. 
Khoo et al., (2011) analysed different methods of quantifying Matrigel tube formation and 
highlighted the measurement of branches and nodes can also be used for quantification. Our 
group decided to measure mesh area as we would like to observe the network that if formed. 
Cells are able to form branches and nodes in the absence of growth factors, however 
stimulation from growth factors is needed to create a strong network, which is what we are 
trying to measure.  
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6.3.4 Data Analysis 
ImageJ Cell Counter tool was used to count the number of cells in each image for the 
cell adhesion assay. ImageJ Area tool was used to measure the area between 
scratch wounds using the gridded plate. Incucyte Zoom Wound Closure Review Tool 
was used to measure images taken using the Incucyte for the scratch wound assay. 
Image J Cell Counter tool was used to count the number of meshes in a pre-
determined area. Unpaired t-tests were used to test for significance. Error bars 
represent SEM. 
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6.4 Results 
6.4.1 Effect of IGFBP-2 on HUVEC adhesion 
IGFBP-2 is well known to promote de-adhesion activity in cancer cell lines (Alkharobi 
et al., 2016; Holmes et al., 2012). In contrast, vascular endothelial cells require strong 
interactions with the surrounding ECM as they lose stability provided by the pre-
existing vessel as they begin to sprout away (Francavilla et al., 2009) 
Firstly, incubation times to allow cell adhesion to occur need to be optimised. 
Integrins are widely known to be responsible for the initial attachment to ECM 
surfaces. However, once cells have started spreading, they are able to activate other 
growth and survival pathways which may also include expression of cell adhesion 
molecules. The optimum time to observe cell adhesion before cells have started 
spreading was 30 mins. (Figure 6.4). 
Extracellular matrices composed of collagen, gelatin and fibronectin were used to 
interrogate the effect IGFBP-2 has on HUVEC adhesion. These are some of the most 
well established ECMs present in humans, with collagen being the most abundant in 
humans (Frantz et al., 2010). Gelatin and fibronectin, also major ECMs in the human 
body are commonly used as an agent to adhere cells to surfaces in in vitro culture. 
The presence of RGD sites in most ECMs makes it important to identify which one 
least interfered with IGFBP-2s effect on cell adhesion. All ECMs displayed the same 
abundance of HUVEC adherence, however the adhesion response in stimulation to 
IGFBP-2 was highest in fibronectin (Figure 6.5). 
As we previously identified in Chapter 5, 200ng/ml IGFBP-2 can stimulate Akt 
signalling, however 500ng/ml is required to activate p44/42 MAPK. Therefore, we 
tested stimulation with both of these concentrations. 200ng/ml and 500ng/ml were 
efficient concentration of IGFBP-2 to enhance HUVEC adhesion to fibronectin (Figure 
6.6).  
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Figure 6.4 HUVEC adhesion incubation time  
50,000 HUVECs were placed onto a 100µg/ml fibronectin coated surface, in duplicate, for 
different time periods, 20, 30 and 40 mins. Non-adhered cells were washed away with 3x 
washes of room-temperature PBS. (A) Representative images at a 40x magnification after 
non-adhered cells had been removed. Snapshots were magnified using ImageJ for ease of 
visualisation. Blue arrows highlight adhered cells which have not started spreading. Red 
arrows highlight adhered cells which have started spreading. (B) Number of cells adhered to 
the fibronectin surface were counted using ImageJ at 5 different points in a well at varying 
incubation times, 20, 30 and 40 min (*=p<0.01, **p<0.001; n=4). Error bars represent SEM. 
(C) The number of elongated cells, as highlighted by the red arrows in 6.4A, adhered to the 
fibronectin surface for an incubation time of 30 or 40 mins (*=p<0.01; n=4). Error bars show 
SEM. 
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Figure 6.5 Increased number of IGFBP-2 stimulated cells adhere to Fibronectin 
50,000 HUVECs were plated onto different ECMs, in duplicate, 100µg/ml collagen, 
2% gelatin or 100µg/ml fibronectin for 30 min. Surfaces were washed 3 times to 
remove non-adhered cells. (A) Representative images at a 40x magnification using 
an optical microscope, of cells adhered in the absence (serum-free) and presence 
of IGFBP-2 (200ng/ml; 30min) across different ECMs. (B) Cells were counted using 
ImageJ at 5 random points in the well of the cells adhered to collage, gelatin or 
fibronectin, in stimulation to IGFBP-2, with their representative controls (SF, serum 
free) (*=p<0.001; n=4). Error bars represent SEM. 
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Figure 6.6 HUVEC adhesion is not enhanced following stimulation with increasing 
IGFBP-2 concentrations 
50,000 HUVECs were incubated on a 100µg/ml fibronectin matrix, in duplicate for 30 minutes 
with varying media conditions, with IGFBP-2 (200/500ng/ml) or 20% serum (+ve). Non-
adhered cells were washed off using PBS after the 30 min incubation period. Cells were 
counted using the cell counter tool on Image J at 5 random spots in the well. (A) 
Representative images, taken at a 40x magnification, using an optical microscope of 
HUVECs following stimulation with IGFBP-2 (200ng/ml; 30min) or the positive control (20% 
serum; 30min) on a fibronectin coated surface. Graph compares adhered HUVECs counted, 
following stimulation with IGFBP-2 and positive control (+ve) (*=p<0.0001, n=5). (B) 
Representative images of HUVECs following stimulation with IGFBP-2 (500ng/ml; 30min) or 
the positive control (20% serum; 30min). Cells were counted using ImageJ at 5 random spots. 
The graph compares HUVECs adhered, following IGFBP-2 (500ng/ml) stimulation and 
positive control (20% serum) stimulation to a fibronectin-coated surface (*=p<0.0001, n=3). 
Error bars represent SEM. 
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6.4.2 IGFBP-2-stimulated HUVEC wound closure 
In vitro wound closure is a representation of cell migration and proliferation that can 
be altered depending on stimulants. Not only are migration and proliferation key 
mechanisms that promote angiogenesis, but also the majority of current research 
regarding IGFBP-2s angiogenic-like actions is their potential in enhancing these two 
mechanisms (Brandt et al., 2015; Liu et al., 2017) 
Our laboratory had previously optimised a HUVEC scratch wound assay protocol, 
creating a uniform scratch across all wells using the wound maker. 2% gelatin was 
originally optimised to be used to coat the plastic surface to aid HUVEC adherence 
in the previous protocol. However, gelatin contains a high abundance of RGD sites 
which may compete with IGFBP-2s action (Xing et al., 2015). Therefore, lower 
concentrations of gelatin were tested to not affect cell wound closure. The use of 
0.1% gelatin to coat the surface instead of 2% had no significant effect on the wound 
closure outcome (Figure 6.6 A). Using Incucyte Zoom, we recorded the change in 
wound width every 4 hours to determine the optimum end time to measure a 
significant difference in wound closure between the negative and positive controls. 
The earliest time to see a significant difference was 12 hours. (Figure 6.6 B).  
The effect of stimulations with different concentrations of IGFBP-2 (optimised in 
Chapter 5 with Akt and MAPK signalling) was examined using the optical microscope 
to image gridded areas of the well. Wound closure was only observed in response to 
500ng/ml IGFBP-2 and not 200ng/ml (Figure 6.7).  
Mitomycin C, a well-known anti-proliferative agent was used to block all proliferation 
activity, resulting in scratch wound closure occurring due to migration only. A time 
course was carried out using the Incucyte Zoom to identify the optimum time to 
observe a significant change between negative and positive controls and the effect 
IGFBP-2 may have on this wound closure response. IGFBP-2 significantly enhanced 
migration only wound closure in HUVECs (Figure 6.8). 
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Figure 6.7 Gelatin concentration and incubation time affect wound closure 
readouts 
40,000 HUVECs were plated into each well of a 96 plate in triplicate and the monolayer 
was scratched on different gelatin concentrations (0.1%, 1% or 2%) and stimulated with 
or without 5% serum (positive control), or with IGFBP-2 (500ng/ml). Wound closure was 
measured after 15 hours from before and after images, or at 5-hour intervals up to 20 
hours using the IncucyteZoom. (A) This graph compares wound closure of the scratched 
monolayer of HUVECs stimulated with the positive control, compared to the non-
stimulated vehicle on different gelatin concentrations (0.1, 1 or 2%) (**=p<0.0001, 
*=p<0.001; n=3). (B) Scratched monolayer of HUVECs was either non-stimulated or 
stimulated with IGFBP-2 (500ng/ml) or positive control (5% serum). Change in wound 
width was recorded over 20 hours using the IncucyteZoom (*=p<0.02; n=3). Error bars 
represent SEM. 
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Figure 6.8 500ng/ml IGFBP-2 enhances HUVEC wound closure  
40,000 HUVECs were plated into each well of a 96 plate in triplicate. Monolayer was scratched 
on 0.1% gelatin and stimulated with IGFBP-2 (200 or 500ng/ml) or positive control (5% serum) 
for 13 or 16 hours. Images were captured at a 40x magnification. Change in wound closure was 
measured using the polygon tool in Image J. (A) Representative images of the width of a well of 
HUVEC monolayer stimulated with 200ng/ml IGFBP-2 or positive control, following the scratch 
and after a 16-hour incubation period. Graph compares wound closure over 16 hours in response 
to stimulation with IGFBP-2 (200ng/ml) or positive control (5% serum) (*=p<0.02; n=2). (B) 
Representative images of initial and after (13-hour incubation) of scratched HUVEC monolayer, 
stimulated with IGFBP-2 (500ng/ml) or positive control (5% serum). Graph compares wound 
closure over 13 hours, in response to no stimulation and stimulation with IGFBP-2 (500ng/ml) 
and positive control (*=p<0.01, **=p<0.001; n=4). Error bars represent SEM. 
 
 
5% Serum (+ve) 
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Figure 6.9 The presence of Mitomycin C does not affect IGFBP-2’s ability to enhance 
wound closure 
40,000 HUVECs were plated into each well of a 96 plate in triplicate and the monolayer was 
scratched on 0.1% gelatin and stimulated mitomycin C (0.5µg/ml) and with IGFBP-2 (500ng/ml) 
or positive control (5% serum) for up to 20 hours. (A) Using the IncucyteZoom, change in wound 
width was measured every 5 hours, up to 20 hours, of HUVECs scratched, in response to 
stimulation with mitomycin C and IGFBP-2 (500ng/ml) or positive control (*=p<0.01; n=5). (B) 
Representative images of initial and after (16-hour incubation) of scratched HUVEC monolayer, 
in the presence of mitomycin C, stimulated with IGFBP-2 or positive control at a 40x 
magnification, using an optical microscope. Graphical representation compares HUVEC wound 
closure area, measured using ImageJ polygon tool, following a scratch, in the presence of 
mitomycin C, non-stimulated (basal) and following stimulation with IGFBP-2 and the positive 
control (*=p<0.001; n=4). Error bars show SEM. 
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6.4.3 Effect of IGFBP-2 on HUVEC tube formation 
Tube formation is an in vitro representation of the formation of an endothelial network 
that takes place to form the scaffolding during angiogenesis. A combination of 
adhesion, migration and proliferation is used for endothelial cells to create a mesh-
type like structure in Matrigel matrix.  
Using the optimised IGFBP-2 concentrations to induce a signalling response in 
Chapter 5, 200ng/ml IGFBP-2 failed to enhance HUVEC mesh tube formation, 
however tube formation was significantly enhanced following stimulation with 
500ng/ml IGFBP-2 (Figure 6.10). Mesh formation was counted at end point of 8 hours 
as previous literature stated maximum tube formation occurred at approximately 8 
hours (Roberts et al., 2015). Longer periods of time result in breakage of the network, 
displaying a lack of tube formation.  
During the assay, the cells form tubes within the Matrigel in order to have access to 
the growth factors present in the matrix. Therefore, adding IGFBP-2 into the Matrigel 
may have an enhanced effect on tube formation, as the cells may not have complete 
access to IGFBP-2 added to the media alone, however this did not enhance tube 
formation further. Concentrations of IGFBP-2 outside the regular range did not 
stimulate tube formation further. (Figure 6.11).  
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Figure 6.10 500ng/ml IGFBP-2 is required to enhance tube formation 
100,000 HUVECs plated onto Matrigel in conditioned media, in duplicate and incubated for an 8-
hour period. (A) Image (taken at a 40x magnification, using an optical microscope) and graphical 
representation compares IGFBP-2 (200ng/ml; 8h)-stimulated and positive control (10% serum)-
stimulated tube mesh formation, counted using ImageJ tools (*=p<0.01; n=2). (B) Representative 
images captured after 8 hours, at a 40x magnification using an optical microscope. Graph shows 
HUVEC tube mesh formation non-stimulated and stimulated with IGFBP-2 (500ng/ml; 8h) and 
positive control (10% serum; 8h) (*=p<0.001; n=5). The number of tube meshes formed were 
counted using the Cell Counter tool on Image J. All meshes counted had a strong (not broken) 
tube outline. Error bars represent SEM. 
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Figure 6.11 Adding IGFBP-2 into the Matrigel failed to enhance tube formation. 
Varying concentrations of IGFBP-2 (200, 500, 1000ng/ml) were added into the Matrigel before 
it was set at 37ºC and HUVECs were plated on. The same concenration of IGFBP-2 added 
to the matrigel was also added into the conditioned media. 100,000 HUVECs plated onto 
Matrigel in conditioned media and incubated for an 8-hour period. (A) Representative images 
(taken at a 40x magnification, using an optical microscope) of tube formation following no 
stimulation (basal) and stimulation with IGFBP-2 (200, 500 or 1000ng/ml) in the media and 
Matrigel. The graph compared the number of tube meshes formed (counted using ImageJ) 
for each of the conditions (*=p<0.02, n=3). (B) HUVEC tube mesh formation was in response 
to stimuation with IGFBP-2 (500ng/ml) in the media alone and in the Matrigel and media. The 
number of meshes formed were counted using ImageJ.The graph shows non-stimulated and 
IGFBP-2 tube mesh formation (n=3; p=not significant). Error bars show SEM. 
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6.5 Discussion 
6.5.1 Stimulation with IGFBP-2 enhances HUVEC adhesion to fibronectin 
As previously discussed in the background (Chapter 6.1), adhesion is required; 
however, adhesion should not inhibit migration or proliferation of cells in 
angiogenesis. 
It was important to optimise the incubation time we were observing cell adhesion at. 
At 40 mins, some endothelial cells had become elongated due to changes in actin 
caused by the connection to the ECM. This suggests focal adhesions or fibrillar 
adhesions may have formed, resulting in possible recruitment of signalling 
components. It was important we attempted to catch cells at the same stage of 
adhesion to ensure activation of other signalling cascades did not affect IGFBP-2 
activity. An optimum time of 30 mins was used as cells had adhered to the surface, 
possibly through integrin interactions, however no cells had begun showing a change 
in morphology. 
Initially we hypothesised the RGD domains within the ECM would compete against 
the RGD domains in IGFBP-2. We cannot be certain the RGD domains in the ECM 
do not play a role in the adhesion of HUVECs to the surface, however, with the 
addition of IGFBP-2 for 30mins, the number of cells adhered to the surface 
significantly increased across collagen IV, gelatin and fibronectin coated surface, 
compared to their individual controls. Enhancement in HUVEC adhesion with 
200ng/ml and 500ng/ml suggests IGFBP-2s integrin interactions will be causing the 
activation of Akt and MAPK signalling pathways, using the findings from Chapter 5. 
This finding of IGFBP-2 enhancing HUVEC adhesion was surprising because IGFBP-
2 is known to cause de-adhesion of most cells by preventing integrins on the cell 
surface binding to RGD sites in the ECM. An explanation for this maybe IGFBP-2 
presents a positive feedback mechanism. It has been reported integrin binding to 
ECM increases the affinity for more integrin and ECM interactions (Morse et al., 
2014). Once IGFBP-2 has bound to a cell via its RGD domain, it may cause an 
increase in affinity for more integrins to become exposed at the cell surface. In 
glioblastoma, IGFBP-2 has been highlighted to activate the expression of α5 integrins 
(Wang et al., 2003). Therefore, IGFBP-2 potentially could be increasing the number 
of integrin/ECM possible interactions, resulting in an enhancement in cell adhesion.  
It would be interesting to use live cell imaging and labelling of the integrins to observe 
if this mechanism explains the IGFBP-2 stimulated enhancement in HUVEC 
adhesion to fibronectin.  
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6.5.2 Exogenous IGFBP-2 elevates HUVEC migration and proliferation 
rates 
IGFBP-2 is well known to activate migration and proliferation mechanisms in a range 
of many cell types, including HUVECs (Png et al., 2012). Interestingly 200ng/ml 
IGFBP-2 failed to cause a difference in wound closure compared to the basal control, 
even though we demonstrated 200ng/ml IGFBP-2 was sufficient enough to 
phosphorylate Akt. IGFBP-2s established effect of enhancing cell migration and 
proliferation in an array of cell types with angiogenic potential was mimicked in 
HUVECs using 500ng/ml IGFBP-2 to stimulate mechanisms. However, to confirm 
this enhancement in HUVEC wound closure is due to IGFBP-2, a knockdown of 
IGFBP-2 specifically would eliminate the observation. Using the data obtained from 
Chapter 5 regarding signalling changes, we can hypothesis that IGFBP-2 stimulated 
migration and proliferation in this assay may be stimulated by MAPK activation, rather 
than activation of the Akt pathway.  
Many publications have looked at the effect of IGFBP-2 on proliferation and migration 
separately as we cannot speculate how much of an effect IGFBP-2 has on 
proliferation compared to migration from the combined assay. Previous literature 
suggests IGFBP-2 stimulated proliferation and migration in some cells may function 
through activation of different signalling pathways (Chen et al., 2013; Foulstone et 
al., 2013). 
Mitomycin C, a potent anti-proliferative agent slowed down the rates of HUVEC 
wound closure as a significant difference between the basal and positive control was 
observed at 16 hours rather than 12. This confirms this assay functions through 
migration and proliferation activity.  
Stimulation with IGFBP-2 (500ng/ml) significantly enhanced HUVEC wound closure 
via migration alone to a similar extent as the combined proliferation and migration 
assay. Thus, suggesting IGFBP-2 may predominantly enhance migration of cells, 
rather than proliferation. This supports the speculation that the observed effect is 
functioning through MAPK activation. Most current studies regarding IGFBP-2s 
activation of cell migration has been shown to function via activation of JNK and ERK 
mediated MAPK signalling (Han et al., 2014; Mendes et al., 2010). However, this 
theory could be only confirmed by exploring the effect of IGFBP-2 in a HUVEC 
proliferation assay independent of migration. 
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6.5.3 Exogenous addition of IGFBP-2 enhances HUVEC tube formation 
Mesh formation signifies network formation, whereas if no mesh formation is present, 
and tubes are present, the endothelial cells have been unable stimulate angiogenic 
signalling to establish or maintain a strong network-like structure (DeCicco-Skinner 
et al., 2014). 
Similarly, to IGFBP-2-stimulated HUVEC wound closure, there was no change in 
mesh formation following stimulation with 200ng/ml IGFBP-2 compared to the basal 
control. However, a significant change in HUVEC mesh formation was observed 
following stimulation with 500ng/ml IGFBP-2. Again, paired with the results from the 
signalling data, this suggests HUVEC tube and mesh formation is not initially driven 
by activation of the Akt pathway.  
The tubes formed by endothelial cells are formed within the Matrigel complex. 
Therefore, we assumed the cells would have easier access to IGFBP-2 that is within 
the Matrigel and as a result enhance the effect of IGFBP-2 stimulated network 
formation even further. Unfortunately, adding IGFBP-2 in the Matrigel displayed no 
additional enhancement in mesh formation compared to the condition without any 
IGFBP-2 in the media. A possible explanation to the lack of enhancement may be as 
the matrix solidifies and becomes fibrous, IGFBP-2 may not be able to circulate and 
therefore is not available to the cells (Frantz et al., 2010). 
Over-expression of IGFBP-2 is a common model used to in vitro and in vivo to 
investigate the effects of IGFBP-2 on angiogenic-like mechanisms. We added an 
extra condition using 1000ng/ml IGFBP-2 alongside the optimised 500ng/ml. 
However, the increase availability of IGFBP-2 did cause further enhancement in 
mesh formation. A possible explanation to this may be that IGFBP-2 has a regulatory 
feedback system, as shown with other IGFBPs. IGFBPs have the ability to promote 
and inhibit activity, however very little has been published regarding IGFBP-2s role 
of inhibiting IGF stimulated activity. If IGFBP-2 is able to control its activity regardless 
of how high IGFBP-2 concentrations may be, this mechanism could be a 
breakthrough for therapeutic angiogenesis to control rate and phenotype of vessels. 
This matches the plateau effect we observed with IGFBP-2 stimulated Akt 
phosphorylation in Chapter 5, as increasing concentrations above the optimum 
concentration (200ng/ml) maintained Akt at the same level and did not enhance it 
further. This finding could suggest IGFBP-2 relies on the bioavailability of other 
molecules such as IGF-I, integrins and RPTPβ to determine its function (Zhou et al., 
2013).  
 
P a g e  | 131 
 
 
6.5.4 Study limitations 
It is difficult to replicate cell adhesion that may occur in in vivo angiogenesis, as in 
vivo one endothelial cell senses a VEGF signal to initiate the process. The cells used 
in the assay were not stimulated by angiogenic responses before and therefore this 
assay is not a true representation of angiogenesis. The scratch wound assay has 
been widely used to test in vitro cell migration and proliferation. Although we used 
mitomycin C to separate both mechanisms, it is difficult to establish if IGFBP-2 is a 
more potent regulator of either proliferation or migration. With both the cell adhesion 
and scratch wound assay we cannot be sure the RGD domains within fibronectin and 
gelatin are not affecting IGFBP-2-stimulated cell adhesion, proliferation and 
migration. Even though we used growth factor reduced Matrigel, there are still growth 
factors present. Therefore, we can’t confirm IGFBP-2 is solely responsible for the 
enhancement in tube formation we observe. 
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6.6 Concluding remarks 
Findings from this chapter demonstrate for the first time IGFBP-2 enhances HUVEC 
adhesion to fibronectin, HUVEC wound closure via migration and proliferation and 
migration alone and HUVEC mesh formation. However, the minimum conditions of 
200ng/ml IGFBP-2 which stimulated HUVEC adhesion failed to activate HUVEC 
wound closure or tube formation. This finding suggests that the initial process that 
drives HUVEC migration and proliferation is not activated by the Akt signalling 
pathway but instead relies on MAPK signalling. However, these assays take place 
over hours and therefore we cannot assume the Akt signalling pathway does not play 
a part in regulating these mechanisms at a later stage.  
To identify which signalling pathways do drive this IGFBP-2 stimulated effect in the 
cell adhesion, scratch wound assay and tube formation assay, we would need to use 
signalling inhibitors. In further exploration of which IGFBP-2 domain is responsible 
for this activity, mutant variants of IGFBP-2 with non-functional domains have been 
described in later Chapters. These in vitro angiogenic assays will be repeated in 
Chapter 8, in order to identify which IGFBP-2 domain is critical for adhesion, 
migration and proliferation properties. This will help us identify the mechanism we 
need to exploit to drive healthy vessel growth to rescue ischemic limbs following PAD. 
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Chapter 7 - Expression and 
purification of recombinant IGFBP-
2 
 
7.1 Background 
Previous chapters have all confirmed IGFBP-2 plays a role in activating angiogenic 
signalling pathways and pro-angiogenic functions in HUVECs in vitro, as well as 
displaying angiogenic potential in vivo. The next following chapters describe the 
generation of an in-house recombinant IGFBP-2 and mutations of this generated 
protein in order to determine which IGFBP-2 domain is critical for the enhancement 
in angiogenic mechanisms we see in vitro. 
In Chapter 5, we struggled to validate IGF binding potential of a commercially 
available recombinant hIGFBP-2, which claimed to be validated via an IGF functional 
assay. This led to questioning the functionality of other domains in recombinant 
IGFBP-2. Using an expression system to generate IGFBP-2, we can validate the 
functionality and sequence of the protein through every step of the process, 
confirming it retains its complete activity. 
Expressions systems are commonly used in research to generate large volumes of 
recombinant protein in a short period of time. There are a number of advantages that 
support its use over commercially sourced proteins which will be discussed in the 
following subchapters. 
This is a technical chapter which covers the optimisation and validation steps which 
have led to the generation of the wild-type recombinant IGFBP-2 and its mutant 
variants. 
 
7.1.1 Expression system 
Expression systems essentially involve an expression vector in which the DNA 
coding sequence of a target protein has been inserted into, a multiple cloning site 
(MCS) and a promoter to drive expression of the target gene. The target gene is 
introduced to the host cell via the expression vector. The hosts have protein synthesis 
mechanisms in place to rapidly generate large volumes of the protein. The 
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recombinant protein is then isolated from the host cell and purified, ready for research 
use (Figure 7.1) (Rosano & Ceccarelli, 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are several advantages to using an expression system to generate an in-house 
recombinant protein. The main advantage is producing a large volume of protein in a 
short amount of time. Expression systems are also more cost efficient compared to 
commercially sourcing the same volume of recombinant protein. (Terpe, 2006). You 
can select a specific expression system depending on the protein you want to 
generate; for example, a mammalian protein may be difficult to synthesise using a 
eukaryotic expression system, as it is inefficient for retaining the regular protein 
folding, which in turn can cause overall protein dysfunction (Khow & Suntrarachun, 
2012). Commercial recombinant proteins are often produced using the most low-cost 
method and are only validated using one specific assay, however irregular folding 
could cause other problems that are not tested for. This is providing an explanation 
for the non-IGF binding properties of IGFBP-2 sourced from Abcam in Chapter 4, as 
it was produced using Insect cells. 
Figure 7.1 Mammalian expression system 
A flow diagram showing the process of transformation of the ligated plasmid and expression 
vector being transformed into E. coli. This results in colonies positive for plasmid/expression 
vector. Plasmid/expression vector is then isolated and transfected into mammalian cells in 
DNA form. The cells then express this plasmid/expression vector as a protein into the media 
which is collected and purified. Adapted from Sigma-Aldrich (2018). 
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There are 4 commonly used expression systems; bacterial, yeast, insect and 
mammalian, however each expression system has its own advantages and 
disadvantages depending on the type of protein to be generated and therefore should 
be carefully selected. In regards to the generation of human IGFBP-2, we used a 
mammalian expression system. This expression system is well-known for retaining 
normal protein folding and its biological activity, as well as no non-specific post-
translation modifications being carried out by the host cell (Khan, 2013). Although the 
disadvantage with the mammalian expression system is that it is the most expensive 
expression system to run as the cells require a lot of maintenance and it can take up 
to a few weeks to obtain protein (Yin et al., 2007). Each expression system has its 
specialised vector that can ensure generation of the desired protein. 
 
7.1.2 pM-secSUMOstar vector 
It is important to use an expression vector that corresponds with your chosen 
expression system to yield the best yield of protein, hence our choosing of a 
mammalian expression vector that functions in human Expi293 cells, pM-secretory 
small ubiquitin-like modifier (SUMO)star vector, generated by Lifesensors. This pM-
SUMOstar expression plasmid was chosen over other mammalian vectors, purely 
because many publications have highlighted its enhanced protein production in 
comparison to traditional vectors (Panavas et al., 2009; Peroutka III et al., 2011). 
SUMO technology enhances protein production via regulating post-translational 
modifications of proteins and cell processes, such as protein stabilisation and nuclear 
transport (Malakhov et al., 2004). The SUMOprotease as part of the SUMOstar kit 
has never shown cleavage activity within the sequence of the target protein, 
highlighting the specificity of the protease. SUMOprotease recognises the cleavage 
site produced by the restriction enzyme BsmBI overhang. This overhand is initially 
used to ligate the amplified protein with the vector. As a result, the sequence of the 
target protein is not affected and retains its full N terminus. (Lau et al., 2018).  
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The pM-SUMOstar plasmid drives protein expression via cytomegalovirus (CMV) 
promoter. Bovine growth hormone (BGH) mediates the inhibition of the promoter 
activity. All expression vectors possess signal peptides at the end of their N terminus. 
Signal peptides sometimes affect levels of secretion depending on the protein as they 
are responsible for signalling proteins for translocation. The SUMOstar plasmid 
secretes protein via the mouse IgG kappa secretory signal which has been reported 
to modulate stabilisation of the mammalian protein by ensuring phosphorylation sites 
and protein folding are not affected through translation (Haryadi et al., 2015; Ho et 
al., 2013) 
After the signalling peptide, a his6 tag is present which is used to enhance purification 
of the target recombinant protein. Hispur columns have a great affinity for these tags 
which consist of 6 histidine amino acids and therefore can be used to remove 
contaminants from the protein before and after cleavage with SUMOprotease 
(Spriestersbach et al., 2015). Additionally, ampicillin is the bacterial resistance 
marker used by pM-SUMOstar, ensuring the formation of colonies that only possess 
Figure 7.2 Representative image of the pM-secSUMOstar vector 
This visualisation highlights the location of the protein and all the other site in the circular 
pM-secSUMOstar plasmid, such as the multiple cloning site, which consists of sites which 
are recognised by many restriction enzymes, making it easy to use this vector with a variety 
of proteins. The histidine tag is also located on the side of the SUMOstar furthest from the 
protein, so when SUMOprotease cuts between SUMOstar and the target protein, the his-
tag will not intervene with following purification steps. Adapted from Lifesensors (2013). 
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the vector. The presence of all these tags on the pM-SUMOstar vector will aid the 
successful cloning and expression of IGFBP-2 with its protein folding and 
phosphorylation sites intact. IGFBP-2 has been reported to have a phosphorylation 
site present at Ser106, however no further publications have confirmed this (Graham 
et al., 2007). 
 
7.1.3 IGFBP-2 mutants 
In chapter 5 and 6, we discovered IGFBP-2 functions differently to activate Akt and 
ERK/MAPK signalling pathways and between cell adhesion and migration and 
proliferation. We hypothesis this difference may be a result of different IGFBP-2 
domains affecting the induction of different mechanisms. Most published literature 
has exposed IGFBP-2 to function through integrin interactions to induce migration of 
cells via the MAPK signalling pathway (Mendes et al., 2010). The Akt pathway has 
been referenced to activate critical angiogenic mechanisms including survival (Chen 
et al., 2013). Therefore, by creating IGFBP-2 mutant variants with a non-functional 
RGD domain, IGF, heparin binding or NLS sites, we can identify which IGFBP-2 
domain is critical to induce the in vitro responses we see. 
All of the domains in IGFBP-2 have been mutated in previous literature (Demambro 
et al., 2012; Jones et al., 1993; Xi et al., 2013). We will be using the published 
mutation sequences to optimise our mutations of IGFBP-2. The published mutation 
for the HBD1 crosses over the HBD site and NLS signal and therefore presents itself 
as a combined mutation (Figure 7.3) (Azar et al., 2014). All of these mutations will be 
inserted in the generated WTIGFBP-2/pM-SUMOstar plasmid via site-directed 
mutagenesis to achieve mammalian expression of the mutant proteins. 
 
 
 
 
 
 
 
Figure 7.3 Overlap of HBD1 and NLS in IGFBP-2 
Sequence highlighting at which section of the sequence the HBD1 and NLS overlap. Adapted 
from Azar et al., (2014) and Demambro et al., (2012). 
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The RGD mutant has been used to confirm the importance of IGFBP-2s interaction 
with integrin subunit α5 to promote cell migration and motility responses (Brandt et 
al., 2015). This mutation has been specifically shown to affect migration responses 
in cancer lines via suppression of JNK phosphorylation, possibly due to a reduction 
in lamellipodia at the cell surface resulting in a lack of integrin induced signalling via 
the actin cytoskeleton and ECM (Mendes et al., 2010; Wang et al., 2006). 
Interestingly, the IGF and HBD1 mutations highlighted a possible crosstalk 
mechanism occurring between both domains. Both domains had to retain functional 
activity in order to promote osteoclast differentiation (Demambro et al., 2012). 
Mutation of the HBD1/NLS site prevented nuclear translocation and suppression to 
VEGF signalling (Azar et al., 2014). Non-functional HBD2 significantly enhanced 
differentiation of pre-adipocytes, suggesting it may have importance in regulating 
IGFBP-2s protective role against obesity (Wheatcroft et al., 2007; Xi et al., 2013). 
Published literature regarding IGFBP-2 mutants with non-functional domains will be 
discussed in more detail in the next chapter, Chapter 8. 
 
7.1.4 Summary 
Using a mammalian expression system, the pM-SUMOstar expression vector and 
SUMO technology, we should obtain a high yield of recombinant WTIGFBP-2 protein 
with intact protein folding, glycosylation sites and no post-translational modifications 
carried out by the host cell. Published mutation sequences will be inserted into the 
WTIGFBP-2/pM-SUMOstar plasmid via site directed mutagenesis. This chapter 
includes the optimisation and validation steps to confirm the sequence and 
functionality of IGFBP-2 and its mutants following the expression, secretion and 
purification steps.  
The generated IGFBP-2 variants will be used to interrogate the key domains which 
promote angiogenic potential in in vitro experiments, which are discussed in Chapter 
8. 
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7.2 Experimental Objectives 
This technical chapter outlines each stage of the generation of recombinant 
WTIGFBP-2 and its mutants. There are many variables that need to be optimised to 
ensure the host cell’s machinery does not cause any post-translational modification 
and maintains regular protein folding and function. Purification steps also need to be 
optimised for each IGFBP-2 variant to maximise the final yield and purification. 
The main objectives of this chapter are: 
• Generate WTIGFBP-2 and validate its sequence and functionality  
• Generate individual mutations of the RGD, IGF, HBD1/NLS and HBD2 sites 
• Validate insertion of the mutation using sequencing and their functionality 
  
P a g e  | 140 
 
 
7.3 Method 
7.3.1 Generation of pM-SUMOstar Wild-Type IGFBP-2 
IGFBP-2 cDNA was commercially sourced (BioScience) using the full published 
IGFBP-2 sequence from NCBI: Homo sapiens insulin-like growth factor binding 
protein 2, 36kDa, mRNA (cDNA clone MGC: 88661 IMAGE: 6650239), complete cds 
(GenBank: AAH71967.1). This cDNA provided the foundation plasmid for the 
production of a WTIGFBP-2 which could be used in in vitro assays.  
 
7.3.1.1 Phusion PCR 
PCR was used to exponentially amplify the IGFBP-2 plasmid using primers 
containing restriction enzyme sites, recognised by the pM-SUMOstar vector 
(LifeSensors, 7121). Phusion High Fidelity DNA Polymerase PCR protocol provided 
by New England Biolabs was used, with the addition of Dimethyl sulfoxide (DMSO) 
to all samples. 
WebCutter 2.0 was used to identify restriction enzyme sites which are not present in 
the complete IGFBP-2 sequence but are also recognised by the pM-SUMOstar 
vector. BsmBI and XbaI restriction sites were inserted into the IGFBP-2 sequence 
using the primers in Table 7.1. 
 
Primer Name Primer Sequence 
(5’ to 3’) 
Length of 
Primer (bp) 
Restriction 
Enzyme 
Site 
Restriction 
enzyme 
sequence 
(5’ to 3’) 
Forward 
Primer 
CGGCGCGTCTCGAG
GTGAGGTGCTGTTCC
GCTG 
 
33 BsmBI CGTCTC 
Reverse 
Primer 
GCTGGCTCTAGACTA
CTACTGCATCCGCTG
GGTGTG 
36 XbaI TCTAGA 
Table 7.1 pM-SUMOstar Wild-type IGFBP-2 Primer and Restriction Site  
The forward and reverse primer with the restriction site sequence highlighted in yellow on the 
full primer sequence. These restriction sites represent the restriction sites recognised by the 
pM-secSUMOstar vector to insert the IGFBP-2 DNA into the vector. 
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The PCR cycle, with varying annealing temperatures used is shown in table 7.2. All 
annealing temperatures (63-67°C) provided the correct PCR product. 
 
PCR Stage Number of 
Cycles 
Time Temperature 
Initial Denaturation 1 30 sec 98°C 
Denaturation 35x 10 sec 98°C 
Annealing 30 sec Gradient temperature: 
Lane 1 & 2 = 63°C 
Lane 3 & 4 = 65°C 
Lane 5 & 6 = 67°C 
Extension 30sec 72°C 
Final Extension 1 10 min 72°C 
End 1 ∞ 4°C 
Table 7.2 Phusion PCR cycle 
The Phusion PCR cycle, reporting the different annealing temperatures, 63, 65 or 67ºC that 
were trialled to insert the restriction enzyme sites into the IGFBP-2 sequence.  
 
PCR products were validated using DNA loading buffer (Thermo Scientific R0611), 
agarose gels, stained with Ethidium Bromide (Sigma, E1510). 
 
7.3.1.2 Restriction Enzyme Digest 
PCR products were purified using the QIAquick PCR purification kit prior to and after 
the digestion. Information provided by New England Biosciences determined the 
optimum temperatures and the NEBuffer required for 100% activity of the enzymes 
(Table 7.3). All restriction enzymes were activated for 1 hour and deactivated for 
20mins. The IGFBP-2 sequence was cut at both sites, XbaI and BsmBI. pM-
SUMOstar vector only possesses the BsmBI restriction site, therefore the vector was 
not digested by the XbaI enzyme. When BsmBI cuts at this point, it creates the 
overhang which represents the XbaI site. 
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7.3.1.3 Ligation 
Mixture of the pM-SUMOstar vector and the IGFBP-2 insert containing the specific 
restriction sites recognised by the vector, was incubated with ligase buffer (NEB, 
B0202S) and T4 ligase (NEB, M0202S) overnight at 4ºC. 
 
7.3.1.4 Transformation 
Bacterial growth was carried out in autoclaved lysongeny broth (LB) (Thermo Fisher, 
BP9723-500). Ampicillin (Sigma, A5354), 100µg/ml, was added to the LB-agar 
(Thermo Fisher. BP9724-2) to prepare culture plates. 25ml of the LB-agar and 
ampicillin mixture was added to each bacterial culture plate and was left to set at 
room temperature for 30 minutes. Invitrogen transformation protocol was carried out 
using sourced E. coli competent cells (Invitrogen, 18265017). Agar/ampicillin plates 
coated with the culture were incubated overnight, in an inverted position at 37ºC. All 
plates were stored at 4ºC following the overnight incubation for long-term storage. 
 
7.3.1.4.1 Transformation PCR for pM-SUMOstar vector colonies 
Colonies were picked and suspended in milliQ H2O. PCR (Table 7.4) was carried out 
using the colony water, PCR mastermix (Biorad, 1665009EDU), T7 promoter (T7F) 
primer, Bovine Growth Hormone Terminator (BGH) primer (Table 7.5) and DMSO. 
 
 
 
 
 
Restriction Enzyme Activation 
Temperature (°C) 
Deactivation 
Temperature (°C) 
Optimum 
Buffer 
WTIGFBP-2/pM-SUMOstar Vector 
XbaI 37 65 Buffer 4 
BsmBI 55 80 
Table 7.3 Restriction enzyme ligation conditions 
The optimum restriction enzyme activation and deactivation temperatures provided by New 
England Biosciences, including the most optimum buffer to use for the ligation reaction. As 
the activation temperatures were different, the lowest activation temperature was initiated first, 
following the activation for the BsmBI. XbaI was deactivated first, following BsmBI. Buffer 4 
provided by New England Biosciences was used to stabilise the reaction. 
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PCR stage Cycles Temperature (ºC) Time 
Initial Denaturation 1x 95 7 min 
Denaturation 
Annealing 
Extension 
35x 94 
53 
72 
30 sec 
30 sec 
1 min 30 sec 
Final Extension 1x 53 5 min 
End 1x 72 ∞ 
Table 7.4 PCR cycle for pM-SUMOstar Transformation PCR 
Optimised temperatures and time periods for different PCR stages. These conditions are 
standard to identify successful cloning of the pM-SUMOstar vector/IGFBP-2 plasmid. 
 
 
PCR products were run on 1% agarose gel, stained with ethidium bromide at 100V 
for 1 hour. 
 
7.3.1.5 Miniprep 
Colonies from the re-streaked pM-SUMOstar ampicillin plates were picked and added 
to antibiotic treated LB and incubated in a shaker at 300rpm, 37ºC overnight. An 
aliquot of the incubated mixture was stored in 50% glycerol (Sigma, G5516) at -80ºC. 
The protocol used was “Plasmid DNA Purification using the QIAprep Spin Miniprep 
Kit and a Microcentrifuge” from the QIAprep Miniprep Handbook. 
DNA, along with vector primers (Invitrogen) (Table 7.5) were sent to MRC Protein 
Phosphorylation and Ubiquitylation Unit (PPU) to determine the sequence matched 
the original IGFBP-2 sequence, using Chromas Lite (version 2.1.1) and Emboss 
Needle Pairwise Nucleotide Alignment. 
 
pM-SUMOstar Primers Sequence 5’ to 3’ 
T74 TAA TAC GAC TCA CTA TAG GG 
BGH TAG AAG GCA CAG TCG AGG  
Table 7.5 Primers recognising the pM-SUMOstar vector 
These primers were used to validate the cloning of the pM-SUMOstar vector and the IGFBP-
2 DNA by sequencing. These primers specifically recognise the pM-SUMOstar vector. 
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7.3.1.6 Maxiprep 
The glycerol stock was used re-streak LB-agar antibiotic treated plates. Plates were 
incubated, in an inverted position at 37ºC overnight and then placed in the fridge 
following the incubation to prevent over growth.  
The starting culture was prepared by adding a colony to 200ml LB with ampicillin 
(100µg/ml) and was then incubated in a shaker at 300rpm at 37ºC for 7/8 hours. 
Overnight culture was made using an aliquot from the starting culture diluted in LB. 
The culture was left shaking at 300rpm at 37ºC overnight. 
The protocol “Plasmid DNA Purification using QIAGEN Plasmid Maxi Kits” was 
retrieved from QIAGEN Plasmid Purification Handbook.  
 
7.3.1.7 Transfection 
Expi293 expression system kit and protocol (Thermo Fisher Scientific, A14635) was 
used to transfect the pM-SUMOstar WTIGFBP-2 into Expi293 cells.  
It was critical cell density reached a maximum point of 500,000 cells in each 50ml 
cell/media suspension mixture. Cells were grown in antibiotic-free and light sensitive 
media and supplemented with the growth factors by the company. 
Protocol for the transfection of Expi293 cells was provided by Thermo Fisher 
Scientific. Expi293 transfection enhancers were added to transfected cells after 24 
hours, as stated in the protocol. The cells were incubated in the WTIGFBP-2 Expi293 
product on an orbital shaker (37ºC, 8% CO2, 125rpm). Media was collected 7 days 
after transfection. 
 
7.3.1.8 pM-SUMOstar Protein Purification 
Media was collected and spun for 400xg for 10mins at 4ºC. The supernatant was 
transferred into a fresh tube and the pellet was discarded. The supernatant was 
centrifuged at 4600xg for 15mins at 4ºC. Protease and phosphatase inhibitors 
(1:1000) were added to the media before using a bottle top filter to filter sterilise the 
media. Media not purified immediately was stored at -80ºC. 
Two methods were used for the first stage of the purification process:  
1) Ammonium sulphate (VWR, IC808229) was mixed with the media collected 
from the transfection incubated at 4ºC overnight. Tubes were spun at 4600xg 
at 4ºC for 90 mins. Floating pellets were removed and re-dissolved in PBS, 
pH 7.4. 
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2) Media from the transfection was added into a concentrating column (Thermo 
Scientific, 88532) and left to spin for 2 hours at 4600xg and 4ºC. 
Buffer exchange was carried out using Zeba columns (Thermo Scientific, 87773). 
Samples were added to equilibrated Zeba columns and centrifuged at 1000xg for 2 
mins. 
Flowthrough from the Zeba was added to capped equilibrated HisPur columns 
(Thermo Scientific, 89969) and incubated at 4ºC for 30 mins on a tube rotator. The 
column was then centrifuged at 700xg for 2 mins before 3 washes of equilibration 
buffer (pH 7.4) (50mM NaH2PO4.2H2O (Sigma, 71505), 300mM NaCl and 10mM 
Imidazole (Sigma, I5513)). Elution of the sample was carried out with 3 washes with 
elution buffer (pH 7.4) (50mM NaH2PO4.2H2O, 300mM NaCl and 150mM Imidazole). 
 
7.1.3.8.1 Digestion of pM-SUMOstar expression vector 
β-mercaptoethanol were added to the pM-SUMOstar WTIGFBP-2 and was incubated 
at 30ºC for 60, 30 or 0 mins, followed by an overnight incubation at 4ºC with 1 Unit 
or variable units from 2.5 to 10 Units of pM-SUMOstar Protease.  
 
7.1.3.8.2 Collection of pure WTIGFBP-2 
The digestion mixture was mixed with equilibration buffer (50mM NaH2PO4.2H2O, 
300mM NaCl and 10mM Imidazole). The concentration of imidazole was changed to 
20mM and 40mM to optimise obtaining a high yield of pure IGFBP-2. 20mM imidazole 
was the optimum concentration to gain the most available yield of IGFBP-2. The 
mixture was incubated with a Hispur column for 30 mins at 4ºC. The column was 
centrifuged at 700xg for 2 mins and the flow through was collected. The column was 
washed twice with equilibration buffer and centrifuged at 700xg for 2 mins each time. 
The flow through and washes were all collected in separate falcon tubes. The hispur 
column was cleaned using elution buffer three times to remove all his-tagged 
components.  
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7.3.2 Generation of IGFBP-2 mutants 
7.3.2.1 Mutation and primer design 
Human IGFBP-2 cDNA sequence, which was retrieved from NCBI (GenBank: 
AAH71967.1) was used to create primers to introduce the mutations. Primers were 
made using the primer design tool supplied by Agilent. They recommend a maximum 
of 7 nucleotide substitutions per primer and to have a minimum of 10 nucleotides 
identical to the IGFBP-2 sequence before the first mutation and after the last. Primer 
sequences cannot be more than 46 nucleotides in length. 
All primers were produced by Biorad in a solid state form and diluted in DNA/RNA 
free water to a concentration of 100ng/µl. 
  
7.3.2.1.1 RGD mutation 
The integrin binding site in the IGFBP-2 sequence is highlighted below: 
atccagggagcccccaccatccggggggaccccgagtgtcatctcttctacaatgagcag 
 I  Q  G  A  P  T  I  R  G  D  P  E  C  H  L  F  Y  N  E  Q     
 
The mutated sequence will appear as below: 
atccagggagcccccaccatctggggggaccccgagtgtcatctcttctacaatgagcag 
 I  Q  G  A  P  T  I  R  G  D  P  E  C  H  L  F  Y  N  E  Q   
 
The change to WGD requires a change from a cytosine to thymine (Jones et al., 
1993). 
The following primers were used to insert the mutation, as designed by Agilent Primer 
Tool (Table 7.6, Figure 7.4): 
 
Forward Primer 
 
5’ cccccaccatctggggggacccc 3’ 
 
 
Reverse Primer 
 
5’ ggggtccccccagatggtggggg 3’ 
 
Table 7.6 RGD mutant site-directed mutagenesis primers 
Forward and reverse primers to insert the mutation of cytosine to thymine for the RGD mutant. 
This table highlights the location of the change. 
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Figure 7.4 RGD primer output from Aligent primer tool 
Output of the most optimum primers which can include the chosen mutation, including primer 
details such as length (nucleotides) and melting temperature. This output was sourced 
from the Aligent primer tool which is provided online. 
 
 
7.3.2.1.2 IGF Binding Domain Mutation 
The IGF binding site in the IGFBP-2 sequence is highlighted below: 
ccccacccgggctccgagctgcccctgcaggcgctggtcatgggcgagggcacttgtgag 
 P  H  P  G  S  E  L  P  L  Q  A  L  V  M  G  E  G  T  C 
 
The mutated sequence will appear as below (Demambro et al., 2012): 
ccccacccgggctccgaggcggccgcgcaggcggcggccatgggcgagggcacttgtgag 
 P  H  P  G  S  E  L  P  L  Q  A  L  V  M  G  E  G  T  C 
 
There are 8 substitutions present in this mutation. 
The mutation was split up into a two-step process with 2 sets of primers (Table 7.7, 
Figure 7.5). 
Primer 
1 (A) 
Forward 5’ gcctgcaggggcgcctcggagcccgg 3’ 
Reverse 5’ ccgggctccgaggcgcccctgcaggc 3’ 
Primer 
2 (B) 
Forward 5’ cctcgcccatggccgccgcctgcgcggccgcctcggagc 3’ 
Reverse 5’ gctccgaggcggccgcgcaggcggcggccatgggcgagg 3’ 
 
Table 7.7 IGF mutant site-directed mutagenesis primers 
The forward and reverse primers for each of the two steps required for the IGF mutation. The 
first mutation was inserted via primer 1. A second site-directed mutagenesis was carried out 
on the DNA following the first mutation, using the second primer. 
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Figure 7.5 IGF mutant Aligent primer tool output 
The sequence region of IGFBP-2, plus excess was inputted into the Aligent primer tool with 
the desired mutations. Due to the size of this mutation, the mutation was split into 2 steps, 
ensuring there were at least 10 matching nucleotides from the beginning of the first mutation 
and from the last mutation change. The primers were created according to the output of the 
tool.  
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7.3.2.1.3 Heparin Binding Domain 1 and NLS Mutation 
The HBD1/NLS binding site in the IGFBP-2 sequence is highlighted below: 
cagatgggcaagggtggcaagcatcaccttggcctggaggagcccaagaagctgcgaccac
cc 
 Q  M  G  K  G  G  K  H  H  L  G  L  E  E  P  K  K  L  R  P  P   
 
The mutated sequence will appear as below (Demambro et al., 2012): 
cagatgggcaagggtggcgcggctgcccttggcctggaggagcccgcggcgctggcaccac
cc 
 Q  M  G  K  G  G  K  H  H  L  G  L  E  E  P  K  K  L  R  P  P   
 
 
There are 12 substitutions present in this mutation. 
The mutation was split up into a two-step process with two sets of primers (Table 7.8, 
Figure 7.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer 
1 (A) 
F 5’ gcagatgggcaagggtggcgcggctgcccttggcctggaggagcc 3’ 
R 5' ggctcctccaggccaagggcagccgcgccacccttgcccatctgc 3’ 
Primer 
2 (B) 
F 5' ggcctggaggagcccgcggcgctggcaccaccccctgccag 3' 
R 5’ ctggcagggggtggtgccagcgccgcgggctcctccaggcc 3’ 
Table 7.8 HBD1/NLS mutant primers 
Forward (F) and reverse (R) primer sequences for the two-step mutation process of inserting 
the HBD1/NLS. The mutation using Primer 1 was carried out first. The DNA, following insertion 
of mutation from Primer 1, underwent site-directed mutagenesis using Primer 2.  
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Figure 7.6 HBD1 mutant primers using Aligent primer tool 
The sequence section with HBD1/NLS signal was inputted into the Aligent Primer Tool. The 
HBD1 mutant also had to be split into 2 primer sets. This output provided the most optimum 
primers to induce the mutations to create a non-functional HBD/NLS site. 
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7.3.2.1.4 Heparin Binding Domain 2 
The HBD2 binding site in the IGFBP-2 sequence is highlighted below: 
aactgtgacaagcatggcctgtacaacctcaaacagtgcaagatgtctctgaacgggcagcgtgggga
g     
 
The mutated sequence will appear as below (Xi et al., 2013): 
aactgtgacgcggctgccctgtacaacgccgcacagtgcgcgatgtctctgaacgggcaggctgggga
g 
   
The mutation, KHGLYNLKQCKMSLNGQR>AAGLYNAAQCAMSLNGQA was split 
up into a three-step process with two sets of primers (Table 7.9). 
 
Primer 1 
(A) 
F 5’ cacatccccaactgtgacgcggctggcctgtacaacctcaaa 3’ 
R 5' tttgaggttgtacaggccagccgcgtcacagttggggatgtg 3’ 
Primer 2 
(B) 
F 5' gctggcctgtacaacgccgcacagtgcgcgatgtctctgaacgg 3' 
R 5’ ccgttcagagacatcgcgcactgtgcggcgttgtacaggccagc 3’ 
Primer 3 
(C) 
F  5' tctgaacgggcaggctggggagtgctgg 3' 
R 5’ ccagcactccccagcctgcccgttcaga 3’ 
Table 7.9 HBD2 mutant primers 
Primer sequences of forward and reverse reactions in the three-step site-directed 
mutagenesis process to inset the HBD2 mutation into IGFBP-2. The mutation changes have 
been highlighted in red bold font. These primers were optimised according to the sequence 
inputted into Aligent primer tool. 
 
7.3.2.2 Site Directed Mutagenesis 
100ng WTIGFBP-2+SUMO template DNA (obtained from the maxiprep before 
transfection) was added to the PCR reaction supplied by Aligent Quikchange 
Lightening Site-directed Mutagenesis kit (Aligent, 200523). The PCR components 
were added as stated plus one set of the forward and reverse primers (125ng each). 
Chapter 8.3.7 discusses the protocol regarding 2 step mutations. The optimum 
annealing temperature for all mutants was 68ºC. 
 
7.3.2.3 Ethanol Precipitation 
This step further purifies and concentrates the DNA obtained from the site-directed 
mutagenesis PCR in order to obtain a greater yield of successfully mutated colonies. 
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Sodium acetate (pH 5.2) and 99% pure ethanol were added to the PCR product and 
incubated at -80ºC for 1 hour. The mix was centrifuged at 15,000xg for 30 mins at 
4ºC, following resuspension of the pellet in 70% ethanol. The ethanol was removed 
by centrifuging at the same speed for 5 mins and resuspending the pellet in EB buffer, 
containing tris-HCl and EDTA which helps stabilise DNA. The precipitated DNA was 
then used for the transformation stage. 
 
7.3.2.4 Transformation 
The protocol by Quikchange Lightening kit was used for successful transformation 
into E. coli cells provided by Aligent in their site-directed mutagenesis kit. 
Transformed cells were plated on LB-agar plates with added Ampicillin and colonies 
were left to grow at 37ºC overnight (method in Chapter 7.3.1.4). 
Colonies were picked from the centre of the plate and suspended in 50µl DNA/RNA 
free H2O. These colonies were re-streaked onto Ampicillin treated LB-Agar plates 
and incubated overnight at 37ºC. 
 
7.3.2.5 Miniprep 
The miniprep protocol was carried out in the same manner as stated in 7.3.1.5 but 
with the mutated re-streaked colonies. The obtained DNA product was also sent to 
MRC PPU to identify the insertion of the mutation and to check no further mutations 
had occurred to disrupt the activity of IGFBP-2. The primers sent to PPU were T74 
and BGH (Table 7.5).  
Retrieved sequences were checked using Chromas Lite and Emboss Needle 
Pairwise Nucleotide Alignment. 
 
7.3.2.6 Two-step mutation process 
For the mutations that require a 2-step mutation process, once the insertion of the 
correct mutation from one of the primer sequences had been confirmed, 100ng of 
DNA collected from the miniprep of the half-mutated sequence was used to undergo 
site-directed mutagenesis again (Chapter 7.3.2.2), this time using the other primer 
set. Optimum annealing temperatures remained at 68ºC. Ethanol precipitation, 
transformation and miniprep protocols were carried out again and the DNA product 
was sent to MRC PPU with the primers T74 and BGH. 
This time the full mutation was be validated via Chromas Lite and Emboss Nucleotide 
Alignment. 
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7.3.2.7 Maxiprep and transfection 
The same protocols were carried out in an identical manner as stated in chapters 
7.3.1.6 and 7.3.1.7. 
 
7.3.2.8 pM-SUMOstar mutant purification 
Media was harvested and separated from the cells via the centrifugation and 
sterilisation steps as mentioned at the beginning of chapter 7.3.1.8. Media was 
concentrated to a smaller volume using concentrating columns. The remaining 
purification protocol was carried out as stated in chapter 7.3.1.8. 
Digestion of the pM-SUMOstar from the mutant was carried out with only pM-
SUMOstar Protease (1 Unit) at 4ºC, overnight. The digested mixture of RGD and IGF 
domain mutant was mixed with equilibration buffer with 20mM imidazole (50mM 
NaH2PO4.2H2O, 300mM NaCl and 20mM Imidazole pH 7.4) and incubated in a hispur 
column for 30 mins.  The HBD1 mutant was mixed with 10mM imidazole equilibration 
buffer. The flow through plus 2 further washes with the corresponding equilibration 
buffer were collected. Elution buffer (50mM NaH2PO4.2H2O, 300mM NaCl and 
150mM Imidazole, pH 7.4) was used to remove the remaining his-tagged 
contaminants separately. 
 
7.3.2.9 Mutant validation  
Sequence checks, as well as IGF binding blots were used to validate the IGFBP-2 
mutant variants. The protocol for IGF binding blot can be found in the General 
methods Chapter 3.4. 
 
7.3.3 Data analysis 
GeneTools was used to perform densitometry analysis of the bands on each western 
blot. Unpaired t-tests were carried out to test data for statistical significance. All error 
bars represent standard error of the mean (SEM). Some preliminary studies only had 
n=2 due to time and funding constraints and therefore statistical tests were not carried 
out on these samples. 
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7.4 Optimisation and Validation Results 
7.4.1 Optimising phusion PCR of WTIGFBP-2 
Phusion PCR is the process used to insert the primers that contain the restriction 
enzyme sites recognised by the expression vector pM-SUMOstar.  
However, as IGFBP-2 has a high GC content, as well as the primers, PCR has to be 
optimised to ensure we do not obtain any undesirable mutations that may affect 
IGFBP-2s full sequence. The standard Phusion High-Fidelity Buffer in the absence 
of DMSO did not achieve successful PCR product for IGFBP-1 (control) or IGFBP-2. 
With the addition of DMSO, a clear band was observed for IGFBP-1 with an annealing 
temperature of 60ºC. However, no clear bands were obtained for IGFBP-2 Phusion 
PCR. The Phusion GC Buffer was used instead of Phusion High-Fidelity Buffer, as 
this GC buffer specifically stabilises sequences with a high GC content. Successful 
Phusion PCR product was obtained with IGFBP-2 at annealing temperatures in 
between 63-67ºC with Phusion GC Buffer (Figure 7.7). 
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Figure 7.7 Optimising Phusion PCR 
Agarose gel (1%) was stained with Ethidium Bromide. It contained Phusion PCR products 
of IGFBP-1(BP1) and IGFBP-2(BP2) at varying annealing temperatures (63-67ºC). 250ng 
of DNA was used for each reaction. Positive IGFBP-1 bands should have an approximate 
MW of 750bp. Positive IGFBP-2 bands should present a MW of approximately 980bp. (A) 
In the absence of DMSO and Phusion High-Fidelity (HF) buffer, with IGFBP-1 (BP1) as a 
negative control, (B) In the presence of DMSO and Phusion HF buffer, BP1 represents a 
positive control. (C) BP2 using Phusion GC buffer (to stabilise high GC rich sequences) 
in the absence and presence of DMSO. 
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7.4.2 WTIGFBP-2/pM-secSUMOstar bacterial transformation PCR gels 
Transformation involves the uptake of protein/expression vector DNA into E. coli cells 
using heat shock. A proportion of the cells will take up the plasmid DNA and rapidly 
replicate the inserted sequence. Positive colonies that have taken up the plasmid 
DNA will appear as a band with a molecular weight higher than the empty vector. As 
DMSO was required to stabilise the DNA in the Phusion PCR, the transformation 
PCR was successful in the presence of DMSO (Figure 7.8). 
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Figure 7.8 Successful transformation of IGFBP-2+pM-SUMOstar vector using E. coli cells 
confirmed by PCR 
Agarose gels (1%) stained with Ethidium Bromide (A) in the absence of DMSO, un-transformed 
bands appear as an identical band to the empty vector (600bp) and transformed bands appear 
fragmented. (B) In the presence of DMSO, all transformed bands appear as one single band at 
an approximate MW of 1400bp. Empty vectors appear as a lower molecular weighted single 
band. A 10000bp MW marker was used to identify the molecular weight of the desired 
transformation. Successful transformation confirms fusion of the IGFBP-2 plasmid into the 
vector. 
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7.4.3 Confirmation of complete WTIGFBP-2 sequence 
Miniprep was carried out to isolate the DNA consisting of the pM-SUMOstar/IGFBP-
2 sequence from the bacterial cells. The DNA was sent to an external sequencing 
unit, where a nucleotide sequence of the DNA was provided to us in a written format. 
The sequence was validated against the original full IGFBP-2 sequence sourced from 
an NCBI hit of the protein (GenBank: AAH71967.1), confirming no unexpected 
mutations were present (Figure 7.9 A). A Chromas output file highlighted the peaks 
of nucleotides that were reported in the DNA was used to support the sequence we 
had retrieved by the MRC sequencing unit (Figure 7.9 B). 
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Figure 7.9 Confirmation of correct IGFBP-2 sequence in the plasmid product 
Following preparation of vector+IGFBP-2 plasmid DNA using a miniprep kit, the DNA 
was sent for sequencing to the MRC Sequencing Unit. (A) Representative data 
displaying a section of the alignment between the sequence of miniprep product 
(retrieved from MRC Protein Phosphorylation and Ubiquitylation Unit, using the primers 
T7 (Forward) and BGH (Reverse) and the published complete hIGFBP-2 sequence 
(IGFBP2) using EMBOSS needle sequence alignment tool. (B) A representative 
selection of a chromatogram displaying the nucleotide peaks identified during the DNA 
sequencing of the 
WT
IGFBP-2+pM-SUMOstar. 
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7.4.4 Purification of pure IGFBP-2 
Expi293 cells expressed large quantities of the IGFBP-2/pM-SUMOstar following 
transfection with the IGFBP-2/pM-SUMOstar DNA. To retrieve the WTIGFBP-2, the 
protein was precipitated from the cells and purified. The purification process involved 
using SUMO protease to digest the vector at the cleavage site, resulting in separation 
of the expression vector, pM-SUMOstar and IGFBP-2. Aliquots taken from the media 
before cleavage of the pM-secSUMOstar vector.  
Unfortunately, initially we only obtained very small amounts of WTIGFBP-2, which 
were barely visible on a coomassie, but validated on an immunoblot probing for 
IGFBP-2 (Figure 7.10). 
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Figure 7.10 Digestion of WTIGFBP-2+SUMO to produce pure IGFBP-2 using SUMO 
protease 
Purification of transfected Expi293 media, containing the WTIGFBP-2+SUMO was carried 
out using ammonium sulphate purification. (A) Coomassie stain on a 4-12% Bis-Tris gel, 
with lane 1 showing the molecular weight ladder, 1, 5 or 25µl of transfected media containing 
WTIGFBP-2+SUMO (MW=50kDa) (lane 2-4) and 1, 5 or 25µl purified WTIGFBP-2 
(MW=36kDa) loaded onto the gel (lane 5-7). Recombinant IGFBP-2 (MW=36kDa) (10 and 
100ng) was loaded as a positive control (lane 8–9). SUMOstar vector alone has an 
approximate MW of 10kDa. (B) Immunoblot, probed with goat polyclonal anti-IGFBP-2 on a 
4-12% Bis-Tris gel, with lane 1 showing the molecular weight ladder, 1, 5 or 25µl of 
transfected media containing WTIGFBP-2+SUMO (MW=50kDa) (lane 2-4) and 1, 5 or 25µl 
purified WTIGFBP-2 (MW=36kDa) loaded onto the gel (lane 5-7). Recombinant IGFBP-2 
(MW=36kDa) (10 and 100ng) was loaded as a positive control (lane 8–9), highlights 
presence of IGFBP-2. (C) Densitometry analysis compares the two bands in lane 7 from 
immunoblot 7.10B, 25µl purified WTIGFBP-2, of WTIGFBP-2+SUMO (MW=50kDa) and 
purified IGFBP-2 (MW=36kDa) (n=2). 
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7.4.5 Optimising precipitation of WTIGFBP-2 from Expi293 media 
Ammonium sulphate precipitation is a commonly used method of protein purification 
from cultured cells. However, as established previously, due to the high GC rich 
content, the sequence of IGFBP-2 is unstable and we could not confirm if ammonium 
sulphate affected the pure IGFBP-2 yield obtained. Therefore, we used another 
precipitation method, which involved concentrating the media with the cells using 
concentrating columns with a 100kDa MW cut off point. This ensured the protein with 
a total MW of just less than 50kDa was collected and any waste with higher MWs 
was removed. The difference in yield of pure WTIGFBP-2 was confirmed by 
coomassie staining and western blotting probing for IGFBP-2 (Figure 7.11). 
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Figure 7.11 Purification method affects the purity of WTIGFBP-2 
(A) Flow diagram depicting the different purification methods tested and the changes made, 
extending the final incubation stage with the HisPur column so the final constructs 
possessing the His tag are retained. (B) Coomassie stained gel (4-12% Bis-Tris) with 
products from different stages of the purification process using ammonium sulphate 
purification and concentrating, pre- and post-digest. 5µl of sample was loaded onto the gel 
for each condition. Bands for WTIGFBP-2 + SUMO complex (50kDa) and pure IGFBP-2 
(36kDa) can be identified. Recombinant IGFBP-2 (100ng/ml) was used as a positive control. 
(C) Immunoblot probing for goat polyclonal anti-IGFBP-2 with 5µl and 25µl samples of media 
before purification and the end product after each purification (ammonium sulphate and 
concentrating) method. Recombinant IGFBP-2 (100ng/ml) was loaded as the positive control. 
Bands for WTIGFBP-2 + SUMO complex (50kDa) and pure IGFBP-2 (36kDa) can be 
identified. (D) Graph shows calculated densitometry, from immunoblot 7.11C of comparing 
the concentration of pure IGFBP-2 obtained in a 25µl sample following ammonium sulphate 
purification and concentrating of media (n=3). 
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7.4.6 Removal of contaminants in pure WTIGFBP-2 
Once the cleavage site in the expression vector has been cleaved, the IGFBP-2/pM-
SUMOstar complex at approximately 50kDa should not be seen. Only two bands 
should appear representing the pure IGFBP-2 (36kDa) and the SUMOstar vector at 
approximately 10kDa. The IGFBP-2 alone is isolated from this broken mixture using 
hispur columns. The his6 tag on the vector ensures the SUMOstar vector remains 
bound to the column and therefore the non-bound flow through should contain all of 
the IGFBP-2 protein. The final elutions of the column should only contain the 
SUMOstar vector. Coomassie staining of samples taken at different stages of the 
purification process confirmed we were losing the maximum yield of pure WTIGFBP-
2 in the elutions (Figure 7.12). 
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Figure 7.12 Pure non-his tagged IGFBP-2 is eluted in final elution of all his-tagged 
components 
Transfected Expi293 media was purified using the concentration method. Aliquots were 
taken at each stage of the purification process, including pre-, post-digest and elution 
outputs, to identify at which stage, the purification process was not taking place successfully. 
(A) Coomassie stain, on a 4-12% Bis-Tris gel, displays the WTIGFBP-2+SUMO complex 
(50kDa), pure WTIGFBP-2 (36kDa), SUMOstar vector (10kDa) and recombinant IGFBP-2 
(positive control – lane 9 (36kDa)) bands from 25µl aliquots from the media (lane 2), 
concentrated waste (lane 3), pre-digest (lane 4), post-digest (lane 5), pure WTIGFBP-2 (lane 
6), 1st elution (lane 7), 2nd and 3rd elution (lane 8). (B) Graph displays the concentration of 
IGFBP-2 obtained in the pure WTIGFBP-2 wash and following elution 1 and elution 2&3 
containing any remaining residue bound to the column, including WTIGFBP-2 from 
densitometry collected from the Coomassie stain 7.12A (n=3). (C) This graph highlights the 
concentration of pure WTIGFBP-2 and WTIGFBP-2+SUMO complex in the post-digest wash 
and elution washes, which should not contain un-digested WTIGFBP-2+SUMO complex, 
using the densitometry collected from the Coomassie stain, 7.12A (n=3). 
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7.4.7 Increasing WTIGFBP-2 yield by further washes  
Figure 7.10 confirmed pure IGFBP-2 remained adhered to the hispur column in the 
elution, which should only contain his-tagged components (SUMOstar vector). Extra 
washes were carried out using equilibration buffer after the flow through had been 
collected to see if purer IGFBP-2 could be removed off the column. Extra washes 
with equilibration buffer removed more of the pure WTIGFBP-2 from the Hispur mixture 
(Figure 7.13). 
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Figure 7.13 Further washes of the His-Pur column releases purer IGFBP-2 
Transfected Expi293 media was purified using the concentration method. Aliquots were taken 
at each stage of the purification process, including pre-, post-digest, pure WTIGFBP-2, with 
additional washes and elution outputs, to identify at which stage, the purification process was 
not taking place successfully. (A) Coomassie stain, on a 4-12% Bis-Tris gel, displays the 
WTIGFBP-2+SUMO complex (50kDa), pure WTIGFBP-2 (36kDa), SUMOstar vector (10kDa) 
and recombinant IGFBP-2 (positive control – lane 10 (36kDa)) bands from 25µl aliquots from 
the media (lane 2), pre-digest (lane 3), post-digest (lane 4), pure WTIGFBP-2 (lane 5), pure 
WTIGFBP-2 wash 1 (lane 6), pure WTIGFBP-2 wash 2 (lane 7), 1st elution (lane 8) and elution 
2 (lane 9). (B) Densitometry from Coomassie stain 7.13A, showing the IGFBP-2 concentration 
in the pure WTIGFBP-2 flow-through and wash 1 and wash 2 is displayed in the graph (n=3). 
(C) This graph shows the concentration of un-digested WTIGFBP-2+SUMO complex which 
remains in the elution 1 and elution 2&3, post-digest, measured from the densitometry of the 
bands in the Coomassie stain 7.13A (n=2). 
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7.4.8 Optimising imidazole concentrations for WTIGFBP-2 purification 
Imidazole is a molecule that is commonly used for protein elution from histidine 
matrices (Bornhorst & Falke, 2000). It is added to wash buffers (low concentrations) 
and elution buffers (high concentrations) to act competitively with non-histagged 
proteins, preventing non-specific binding. As pure IGFBP-2 remained bound to the 
column, we hypothesised increasing imidazole concentrations in the wash buffer 
would release a larger yield of pure IGFBP-2 into the flow through. As imidazole 
possesses a histidine ring, it will have a higher affinity for the column than IGFBP-2, 
therefore IGFBP-2 is less likely to remain bound. Increasing imidazole concentrations 
to 20mm removed the majority of WTIGFBP-2 from the elution (Figure 7.14). 
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Figure 7.14 Increasing imidazole concentration aids the elution of purer IGFBP-2 
The imidazole concentration in the wash buffer was altered from 10mM to 20mM or 40mM. 
Aliquots were collected from all stages of the purification process. 25µl aliquots were loaded 
onto a 4-12% Bis-Tris gel. (A) Coomassie staining on the gel shows the abundance of pure 
WTIGFBP-2 present in the initial flow-through (lane 2-4), wash 1 (lane 5-7), wash 2 (lane 8-
10), after changing the imidazole concentration in the wash buffers used throughout the 
purification process. (B) Coomassie staining on the gel shows the abundance of pure 
WTIGFBP-2 present in the 1st elution (lane 2-4) and 2nd elution (lane 5-7), after changing 
the imidazole concentration in the wash buffers used throughout the purification process. 
(C) Densitometry of the bands representing WTIGFBP-2 (36kDa) in the flow through, from 
gel 7.14A, show the change in IGFBP-2 concentration obtained in the initial purification, in 
response to increasing imidazole concentration from 10mM to 20mM or 40mM (n=2). (D) 
Densitometry of the bands representing WTIGFBP-2 (36kDa) in the elution 1, from gel 7.14B, 
show the change in IGFBP-2 concentration obtained in the final elution, which should 
contain all the waste residue, in response to increasing imidazole concentration from 10mM 
to 20mM or 40mM throughout all purification steps (n=2). (E) Densitometry of the bands 
representing WTIGFBP-2+SUMO complex (50kDa) in the flow through, 1st wash and 2nd 
wash with 20mM imidazole, from the gel 7.14A, show the change in WTIGFBP-2+SUMO 
complex contamination in the samples which should only contain pure WTIGFBP-2 (n=2). 
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7.4.9 Double digest of WTIGFBP-2/pM-SUMOstar complex 
As we have shown in previous figures, a large abundance of IGFBP-2/pM-SUMOstar 
complex remained undigested by the SUMOprotease, therefore resulting in a lower 
yield of pure WTIGFBP-2. To tackle this, we attempted to digest elutions collected from 
previous purification attempts, which contained the IGFBP-2/pM-SUMOstar complex 
for the second time. Increasing the concentration of SUMOprotease enhanced the 
digestion at the cleavage site (Figure 7.15 A and B).  
β-Mercaptoethanol is a common substance added to the mixture prior to incubation 
with SUMOprotease. It compromises the disulphide bonds in the cleavage site 
beforehand, making it easier for SUMOprotease to function (Bondos & Bicknell, 
2003). However, we have previously observed these substances may also be 
affecting the IGFBP-2 sequence, which could alternatively be inhibiting maximum 
digestion. Reduced incubation times with β-mercaptoethanol failed to increase the 
yield of pure WTIGFBP-2 (Figure 7.15 C and D). 
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Figure 7.15 Double digest using increasing concentrations of SUMOprotease 
increases digestion activity 
Due to problems with the digestion of the complex, different concentrations of 
SUMOprotease (2.5, 5, 7.5 or 10 units) were used for a double digest of the un-digested 
WTIGFBP-2+SUMO complex. (A) 25µl aliquots were taken from different stages of the 
digest step and loaded on a 4-12% Bis Tris gel and stained with Coomassie blue. Media 
(lane 2), elution following 1st digest (lane 3), elution following 2nd digest with 2.5 units 
(lane 4), 5 units (lane 5), 7.5 units (lane 6) and 10 units (lane 7). Recombinant IGFBP-
2 (100ng/ml) (36kDa) was loaded (lane 8) as a positive control. WTIGFBP-2+SUMO 
complex has a MW of 50kDa and WTIGFBP-2 has a MW of 36kDa. (B) This graph 
highlights the reduction in un-digested WTIGFBP-2+SUMO complex following the 2nd 
digest, in response to incubation with increasing units of SUMOprotease (n=2). (C) The 
elution following the 1st digest was incubated with β-mercaptoethanol for the normal 
time, 60min or 30min or in absence, following a 2nd digest with 5 or 10 units of 
SUMOprotease. 25µl aliquots were loaded onto the gel and stained with Coomassie 
blue. WTIGFBP-2+SUMO complex has a MW of 50kDa and WTIGFBP-2 has a MW of 
36kDa. (D) This graph shows densitometry measuring change in pure IGFBP-2 
concentrations, following different incubation periods (30 or 60min) with or without β-
mercaptoethanol, followed by a 2nd digest with 5 or 10 units SUMOprotease (n=2). 
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7.4.10 Validation of functional WTIGFBP-2 
There are many components in the purification process, which may alter the 
functionality of the WTIGFBP-2. Using IGF-I ligand blotting, we confirmed WTIGFBP-2 
retained functional IGF-I domains (Figure 7.16).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.16 WTIGFBP-2 retains its IGF binding ability through all stages of the 
purification process 
Samples, non-denatured were run using immunoblotting. Membranes were incubated with 
biotinylated IGF and imaged using streptavidin. Non-IGF binding commercial IGFBP-2 was 
used as a negative control. 25µl aliquots were taken following the digestion and loaded 
onto a 4-12% Bis-Tris gel. (A) Non-IGF binding IGFBP-2 (50ng/ml (lane 1) and 100ng/ml 
(lane 2)) was used as the negative control. Digested WTIGFBP-2+SUMO complex (lane 3), 
pure WTIGFBP-2 (lane 4 and 5) and elution following the 1st digest was incubated with the 
biotinylated IGF-I and visualising the bound IGF-I with streptavidin to confirm IGF-binding 
functionality in the WTIGFBP-2+SUMO complex (50kDa) and pure WTIGFBP-2 (36kDa). (B) 
This blot 7.16A was stripped, checked for residue and probed with goat polyclonal anti-
IGFBP-2 (36kDa) showing the presence of IGFBP-2 within the WTIGFBP-2+SUMO complex 
(50kDa) and pure WTIGFBP-2 (36kDa). (C) The undigested WTIGFBP-2+SUMO complex 
underwent a 2nd digest. The product of the 2nd digest and the pure WTIGFBP-2 obtained 
was tested for functional IGF binding domains in the IGFBP-2 containing bands, by 
incubating the blot with biotinylated IGF-I and streptavidin. (D) Blot 7.16D was stripped, 
checked for residue and probed with goat polyclonal anti-IGFBP-2 (36kDa), showing the 
presence of IGFBP-2 in the complex (50kDa) following 2nd digest and pure IGFBP-2 
(36kDa). 
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7.4.11 Confirmation of RGD mutant and successful purification 
Mutation of the RGD site inhibits all activity mediated via integrin interactions, 
however IGF and HBD sites will still remain functional. The RGD mutation, C to T 
was inserted via site-directed mutagenesis. Following transformation, the miniprep 
DNA product was sent to MRC sequencing unit to confirm the insertion of the correct 
mutation. Purification was carried out using the optimised steps from Section 7.4.4-
7.4.10. Samples taken from different stages of the purification process were run on 
a Coomassie stained gel to confirm the presence of pure RGD mutant (Figure 7.17).  
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Figure 7.17 Confirmation of RGD mutant 
DNA collected from the Miniprep following insertion of the RGD mutation were sent for 
DNA sequencing. (A) Mutant sequence retrieved from MRC PPU was compared with the 
full IGFBP-2 sequence using Emboss Sequence Alignment Tool highlights the successful 
change of Cysteine to Thymine. (B) End products from each stage of the purification 
process were visualised using Coomassie staining. 25µl of aliquots taken from each stage 
were loaded onto a 4-12% Bis-Tris gel, confirming successful digestion and purification of 
the RGD mutant (outlined, 36kDa) from the RGDIGFBP-2+SUMO complex (50kDa). Elutions 
contain the waste and the un-digested RGDIGFBP-2+SUMO complex (50kDa). 
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7.4.12 Confirmation of IGF binding mutant and successful purification 
The IGF mutation was carried out using a two-step process of site-directed 
mutagenesis. The first mutation inserted via site-directed mutagenesis was 
confirmed after retrieving sequencing analysis from MRC sequencing unit (Figure 
7.18 A). The mutated DNA was used to undergo another round of site-directed 
mutagenesis, inserting the remaining mutation. Sequence was clarified after 
transformation and miniprep (Figure 7.18 B). Purification steps of the IGF mutant 
following transfection into Expi293 cells were examined using coomassie staining to 
confirm the retrieval of pure IGF mutant. (Figure 7.18 C). 
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Figure 7.18 Confirmation of IGF mutant 
(A) DNA from the Miniprep, following site-directed mutagenesis to insert the IGF 
binding domain mutation in, was sent to MRC sequencing unit. IGF mutant sequence 
compared to the full sequence of IGFBP-2 published on NCBI confirms insertion of 
mutation from primer 1 using EMBOSS Nucleotide Alignment. (B)  Compared against 
the full IGFBP-2 sequence, confirmation of the insertion of the remaining nucleotide 
mutations present using primer 2. (C) 25µl samples were loaded onto a 4-12% Bis-
Tris gel. Coomassie stain of products from the different purification stages after 
transfection, post digestion with SUMOprotease (displaying 2 bands, complex 
(50kDa) and pure IGF mutant (36kDa) and pure IGF mutant (36kDa) was confirmed. 
Undigested IGFIGFBP-2+SUMO complex (50kDa) remains in post-digest and in the 
final elution aliquots. 
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7.4.13 IGF and RGD mutant binding to IGF-I 
IGF-I ligand blots were carried out to validate the functionality of the proteins. 
Samples from different stages of the purification process were examined for IGF 
binding potential. The mutant proteins were not denatured before being loaded on to 
immunoblot gels. Blots were probed with biotinylated IGF-I that bound to recognised 
IGF-I binding sites and visualised using streptavidin (Figure 7.19). Stripped blots 
were probed with IGFBP-2 antibody to confirm the mutants were still recognised as 
IGFBP-2. 
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Figure 7.19 IGF mutant fails to bind IGF but RGD retains IGF binding ability 
25µl sample loaded onto a 4-12% Bis-Tris gel and the blot was incubated with biotinylated 
IGF-I and streptavidin. (A) IGF binding blot displays the IGF mutant at different stages of 
the purification process, in the media, post-digest, pure IGF mutant and IGF mutant elution. 
The RGD mutant was used as a positive control, as it retained full IGF binding ability to 
biotinylated IGF in the media, post-digest, pure RGD mutant and RGD mutant elution. (B) 
Blots were stripped and then probed with goat polyclonal anti-IGFBP-2. Immunoblotting 
confirms the presence of the IGF mutants and RGD mutants on the blot by probing for total 
IGFBP-2 levels. Successful stripping with 2% glycine was confirmed by imaging the blot 
before probing with IGFBP-2. (C) Graphical representation of the densitometry measuring 
the abundance of biotinylated IGF-I bound to 25µl of the IGF mutant and RGD mutant 
(*=p<0.01, n=3). Error bars represent SEM. 
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7.4.14 HBD binding mutants  
The HBD1/NLS mutant was carried out in two steps, inserting half of the total 
mutation at a time. After each site-directed mutagenesis step, transformation and 
miniprep, the DNA was sent for sequencing. The retrieved sequences were 
compared against the complete IGFBP-2 sequence to validate insertion of the 
mutation. IGF ligand binding blots were used to validate the IGF binding functionality 
of the HBD1 mutant at different stages of the purification process. The blot was then 
stripped and probed for IGFBP-2 to observe the IGFBP-2 antibody still recognised 
the mutant as IGFBP-2 (Figure 7.20). 
 
Unfortunately, site-directed mutagenesis of the HBD2 mutation into WTIGFBP-2 was 
not successful. Positive colonies were not formed following transformation. Further 
attempts to mutate this site were halted due to time limitations. 
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Figure 7.20 Confirmation of the HBD1 mutant 
DNA was collected following the Miniprep after site-directed mutagenesis and sent for 
DNA sequencing. EMBOSS Nucleotide Alignment compares the mutated sequence to 
complete IGFBP-2 sequence published and confirms successful insertion of the mutation 
using primer 1 (A) and the complete mutation with the addition of primer 2 (B), without 
affecting the remaining IGFBP-2 sequence. (C) 25µl of samples were loaded onto a 4-
12% Bis-Tris gel and probed for IGF-binding functionality in the aliquots collected during 
the purification process of the HBD1 mutant, from the media, post-digest, pure HBD1 
mutant and elution. (D) The IGF-I binding blot was stripped and probed with goat 
polyclonal anti-IGFBP-2, confirming the presence of IGFBP-2 in the different steps of the 
purification process to purify the HBD1 mutant variant. Stripping before probing for 
IGFBP-2 was carried out using 2% glycine and successful stripping was confirmed by 
imaging the blot again. 
 
P a g e  | 181 
 
 
7.4.15 Purification of contaminated HBD1 mutant 
Protein purification was carried out using the optimised steps in Chapter 7. However, 
these steps needed optimising for the HBD mutant as excess HBD1 IGFBP-2/pM-
SUMOstar complex was leaking into pure mutant flow through (Figure 7.21). 
Imidazole concentrations were lowered during the final purification process to 
optimise the yield of pure HBD1 mutant. Samples from different stages of the 
purification process were analysed to observe the effect of changing imidazole 
concentrations (Figure 7.22). 
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Figure 7.21 Pure HBD1 is contaminated when using the same purification 
conditions as the IGF and RGD mutant 
25µl of sample was loaded onto a 4-12% Bis-Tris gel from different stages of the 
purification process. (A) Coomassie stain visualises the products from different stages 
of the purification process of the HBD1 mutant. The red arrow depicts contamination of 
the undigested SUMO/HBD1 mutant complex within the pure HBD1. (B&C) Coomassie 
stains of from the purification of the RGD and IGF mutant depict no contamination from 
the undigested complex in the pure IGFBP-2 mutant samples. (D) Graphical 
representation of the densitometry of the bands from 7.21A, B and C, measured using 
Genetools, of the coomassie stained gels highlight the contamination of the 
SUMO/HBD1 mutant complex in comparison to absence of contamination in the pure 
RGD and IGF mutant products (*=p<0.01, n=3). Error bars show SEM. 
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Figure 7.22 Reducing imidazole concentration achieves non-contaminated HBD1 
mutant 
25µl of sample was loaded onto a 4-12% Bis-Tris gel from each stage of the protein 
purification process. (A) Purification end products, from media, containing the complex 
(50kDa) (lane 2), pure HBD2 mutant, using 20mM imidazole wash buffer (lane 3), pure HBD1 
mutant flow through (lane 4), 1st and 2nd wash (lane 5 and 6), using 10mM imidazole wash 
buffer, elution (lane 7) and recombinant IGFBP-2 (36kDa) as a positive control. The gel was 
stained with Coomassie blue. The arrow highlights the contaminant present when using 
20mM imidazole for final washes. When reduced to 10mM imidazole, the contaminant is 
absent in the final flowthrough and all further washes. Undigested complex still appears in 
the elution. (B) Densitometry measured using Genetools, highlights the change in the 
abundance of undigested SUMO/HBD1 mutant contaminating the sample using 20mM 
imidazole wash buffer and 10mM wash buffer (n=2). 
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7.5 Discussion 
7.5.1 WTIGFBP-2, RGD, IGF and HBD1/NLS molecular size and mutant 
sequences verified against published hIGFBP-2 sequence data 
The expected MW of the IGFBP-2 was checked throughout the cloning and 
expression process, ensuring it was correct before moving forward. The MW was 
confirmed after Phusion PCR, providing an expected molecular size of 898bp. Once 
transfected and purified, the WTIGFBP-2/pM-secSUMOstar plasmid was presented at 
a 50kDa and purified IGFBP-2 appeared at approximately 36kDa, matching IGFBP-
2s published MW. As all the mutations were missense in the three mutants, the MW 
of the plasmid or pure protein did not differ from WTIGFBP-2. We can confirm post-
translational modifications that may have occurred have not affected the MW or the 
nucleotide sequence compared to the complete published IGFBP-2 information. 
However, we would have to carry out further examination into post-translational 
modifications that may have occurred which could alter the affinity of binding and the 
full activity of IGFBP-2. Immunoprecipitation and western blotting could be used to 
identify post-translational modifications which may have occurred during production 
of these mutants. 
The sequences retrieved from MRC Sequencing Unit confirmed that WTIGFBP-2 
displayed complete alignment with the published NCBI sequence of hIGFBP-2 
(GenBank: AAH71967.1). Any misread mutations that appeared were verified as 
mistakes using the chromatogram. This may occur due to two peaks being read very 
close to each other, which can often misalign the remaining sequence. However, 
misreading usually takes place at the beginning or end of the sequence. The 
sequences were also read forwards and in reverse, via the T7 forward primer or the 
BGH reverse primer (resulting in the sequence being reverse complemented). The 
forward and reverse sequences were compared for mistakes as a true non-specific 
mutation would be present in both sequences.  
The insertion of the mutations was also verified using pairwise nucleotide alignment. 
Except for the mutated area, the remaining sequence completely aligned with the 
published IGFBP-2 sequence.  
 
7.5.2 WTIGFBP-2, RGD, HBD retained full IGF binding potential except the 
IGF mutant 
The functionality of the proteins produced was tested via IGF ligand blots, which has 
become a common method of testing IGFBPs (Rosenzweig, 2004). We confirmed all 
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IGFBP-2 variants except the IGF mutant bound to biotinylated IGF-I throughout the 
purification stages. This was supported by the confirmation of the full IGF binding 
sequence being present in the earlier sequences. The mutation at the N terminal IGF 
binding site eliminated all binding to the biotinylated IGF-I, confirming that both IGF 
binding sites are involved in the sequestering of IGF molecules.  
 
7.5.3 Ammonium sulphate precipitation reduced the yield of protein 
obtained 
As mentioned previously, ammonium sulphate precipitation is a common salt 
precipitation process used due to its rapid precipitation of a large yield of protein, 
condensing it into a small workable volume (Wingfield, 1998). We cannot confirm the 
salting out process does have negative effects on the IGFBP-2 protein. However, we 
believe WTIGFBP-2 was lost when collecting the floating pellets which contained the 
protein at the end of the technique.  
The use of the concentrating columns to reduce the media to a workable volume 
enhanced the yield of WTIGFBP-2 slightly compared to the yield obtained with 
ammonium sulphate precipitation. Concentrating columns would not result in the 
same purity of the protein as obtained by ammonium sulphate, however the 100kDa 
cut off point ensures larger molecules present in the media are removed. The 
remaining components in the protein mixture would be eliminated via the use of the 
hispur column in a later stage of the purification process which would only bind the 
WTIGFBP-2/pM-secSUMOstar complex.  
 
7.5.4 Altering imidazole concentration in equilibration buffer enhances 
the obtained yield 
Imidazole in the purification buffers contributes to the purification of the protein in the 
end product. Imidazole has a histidine ring, which can bind to the free spaces on the 
hispur column. However, it is important to note it doesn’t compete with the pM-
secSUMOstar at low concentrations as the his6 tag has an increased affinity in 
comparison to imidazole. Initially, the use of 10mM imidazole resulted in WTIGFBP-2, 
RGD and IGF mutant protein sticking to the column. This suggests there were still 
free areas on the hispur column causing non-specific binding. With an increased 
concentration of 20mM imidazole, we obtained an increased yield of IGFBP-2 with a 
significantly smaller amount of pure IGFBP-2 remaining in the final elution of 
everything in the column.  
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Further washes with the equilibration buffer also increased overall yield of the pure 
IGFBP-2 obtained as more IGFBP-2 was isolated following every wash. This 
suggests IGFBP-2 is able to non-specifically bind to the hispur column quite strongly. 
Increasing the concentration of imidazole to 40mM resulted in the IGFBP-2/pM-
secSUMOstar contaminating the pure fraction. It is difficult to identify why all of 
IGFBP-2 is not eluted in the first flow through. We would need to assess the structure 
of IGFBP-2 and understand how IGFBP-2 is interacting with the column to optimise 
this step.  
Interestingly, the HBD mutant was the only mutant not to yield pure IGFBP-2 with 
20mM imidazole. Some of the undigested HBD/pM-secSUMOstar complex also 
came through in the initial flow through that should only contain pure HBD mutant. 
This highlighted the concentration of 20mM imidazole was acting competitively 
against the binding of the his6 tag of the vector to the column. When reduced to 
10mM imidazole, a pure HBD mutant sample was obtained. This may suggest a 
possible post-translational modification which could have affected the protein folding, 
however this could only be confirmed via further proteomic studies. 
 
7.5.5 SUMOprotease failed to cleave 100% of the WTIGFBP-2/SUMO 
protein 
Publications have reported the use of SUMOprotease to promote cleavage is an easy 
and efficient mechanism to obtain clear separation of the vector and pure protein (Lee 
et al., 2008). As observed throughout the purification process, a large amount of the 
complex remains undigested by SUMOprotease. We attempted to carry out a double 
digest by incubating the initial elution with the undigested complex with 
SUMOprotease again, however the concentration of SUMOprotease was increased 
above the recommended units.  
Interestingly, the double digest did reduce the concentration of the complex, however 
the abundance of IGFBP-2 or SUMO vector alone did not increase as much. Also the 
addition of increased concentrations of the SUMOprotease did not enhance the 
digestion of the complex. Although the sequence of the end of the vector and the N-
terminal of IGFBP-2 were correct, post-translational modifications may have taken 
place at this region, affecting the cleavage. This can only be confirmed via structural 
analysis using techniques such as X-ray crystallography or nuclear magnetic 
resonance (NMR) (Andrec et al., 2007). 
β-mercaptoethanol is a compound used to reduce the disulphide bonds between the 
protein and vector, priming the complex for successful cleavage. However, as 
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mentioned in the introduction, IGFBP-2 retains 12 conserved cysteine molecules 
which all form disulphide bonds (Baxter, 2000). The β-mercaptoethanol may also 
affect these bonds as they are closely located to the cleavage site and as a result 
affecting the overall cleavage. In the absence of incubation with β-mercaptoethanol, 
the yield of pure WTIGFBP-2 slightly increased. Therefore, this incubation step was 
removed for following generation of the WTIGFBP-2 and its mutants. 
 
7.5.6 Study limitations 
Size exclusion chromatography was attempted to purify the proteins further as a few 
non-specific bands were noted on coomassie stains. However, we were unable to 
achieve successful separation of the markers or the protein according to molecular 
size. Due to time constraints, this could not be optimised further. 
Ideally, the mutants would have been validated in more detail than sequencing and 
IGF ligand blots. The individual mutations of the domains should be clarified to 
support the sequence data. We also cannot be sure that post-translational 
modifications have not taken place affecting a part of the protein that has not been 
verified. Heparin binding assays should have been used to confirm the loss of heparin 
binding function in the middle domain. Integrin binding potential could be clarified 
through functional assays. 
Structure of the protein should have been assessed to ensure the secondary 
structure of IGFBP-2 was maintained. Circular dichroism spectra or crystallisation 
techniques such as X-ray crystallography could have used to determine any changes 
in protein folding or secondary structure that may have occurred (Greenfield, 2006).  
Unfortunately, due to funding and time constraints, we were unable to validate this. 
The inability to achieve complete cleavage of the WTIGFBP-2/pM-secSUMOstar 
suggests a post-translational modification, which may have altered the cleavage site. 
We cannot be certain of this unless the secondary structure has been analysed. 
However, this problem has resulted in a lower yield of the protein than expected. 
Unfortunately, we were unable to obtain successful transformation of the HBD2 
mutant on multiple attempts. Due to time restraints, we were unable to optimise the 
generation of this mutant further. 
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7.6 Concluding remarks 
This chapter describes experiments carried out to generate, purify and test the 
function of mutant variants of IGFBP-2, in order to ensure they have maintained their 
expected functionality. 
Except for the inserted mutation, the sequences of WTIGFBP-2 and its mutant variants 
completely aligned the published complete sequence of hIGFBP-2 (GenBank: 
AAH71967.1). The WTIGFBP-2, RGD and HBD variants all retained full IGF binding 
potential as confirmed by IGF ligand blotting. The IGF mutant, as expected fail to 
display IGF binding capabilities.  
Obtaining a pure yield of IGFBP-2 was optimised for each individual IGFBP-2 variant 
by altering concentrations of imidazole in the buffer. The HBD mutant was the only 
mutant which resulted in a weaker interaction with the column, and therefore required 
a lower concentration of imidazole for elution. 
Unsuccessful cleavage of the SUMO vector from the pure protein remains a problem 
unsolved. Double digesting did reduce the amount, however other methods of 
exploring the structure of the cleavage region should be interrogated further. 
Although the recombinant protein and the mutants were verified through sequence 
checks and IGF binding potential, more validation is required to confirm the RGD and 
HBD mutations are functional. Due to the issues during the purification of the protein, 
it is essential we use structural analysis techniques such as X-ray crystallography to 
confirm no post-translational modifications have altered the structure. The biological 
functionality of these variants will be tested in the series of experiments described in 
the next chapter, to observe if they mimic the responses of commercially sourced 
recombinant IGFBP-2 in in vitro angiogenic signalling and the assays (Chapter 5 and 
6).  
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Chapter 8 - Influence of mutant 
IGFBP-2 variants on in vitro 
angiogenic signalling and 
properties in endothelial cells 
 
 
8.1 Background 
In the previous Chapters, 4, 5 and 6, we have shown through in vivo and in vitro 
means that IGFBP-2 does display potential in angiogenesis and promotes angiogenic 
mechanisms in endothelial cells. However, many publications have highlighted 
certain IGFBP-2 domains (e.g. RGD site and HBDs) determine IGFBP-2s activity 
(Mendes et al., 2010; Ross & Gericke, 2009). Some publications have created 
peptides of the domains to enhance angiogenic responses driven by those domains 
in particular (Xi et al., 2014). Therefore, identification of the key interaction involved 
will enable to exploit this interaction alone therapeutically, providing a more specific 
modulation of the therapeutic angiogenesis treatment to PAD. 
In Chapter 7, we validated the insertion of the mutations of the RGD, HBD/NLS and 
IGF domains into IGFBP-2 and confirmed, as expected, all except the IGF mutant 
retained complete IGF binding potential. In this chapter, these validated mutant 
variants will be used to determine which domains are responsible for the effect of 
IGFBP-2 in signalling (Chapter 5) and fundamental assays (Chapter 6) (Figure 8.1). 
As an additional experiment, we have also observed the effect IGFBP-2 and its 
mutants may have on vascular permeability compared to the endothelial cell 
hyperpermeable responses exerted by VEGF (Kumar et al., 2009). The importance 
of maintaining vascular permeability will be discussed below in Section 8.1.4. 
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8.1.1 RGD mutant 
The majority of publications discussing IGFBP-2 induced cell migration have reported 
integrin interactions, specifically with α5 and β1 are responsible for JNK and ERK 
mediated activation of the MAPK pathway (Han et al., 2014; Wang et al., 2017c). This 
proposed mechanism has been verified using IGFBP-2 consisting of a non-functional 
RGD site. Although, we substituted the arginine (R) site to tryptophan (W) to mutate 
the integrin site, another common RGD mutation incorporates substitution of aspartic 
acid (D) with glutamic acid (E).  
Over-expression of the RGE mutant in neuroblastoma cells increased integrin-ECM 
interaction, potently enhancing cell migration, proliferation and invasion (Russo et al., 
2005). The RGE mutant also presented the same survival activity in hematopoietic 
stem cells as the WTIGFBP-2 (Huynh et al., 2011). Therefore, this suggests the RGD 
domain may not be responsible for IGFBP-2-stimulated promotion of these 
mechanisms. Contrastingly, GK Wang et al., (2006), highlighted the RGE mutant 
failed to induce glioma cell motility due to a reduced abundance of lamellipodia 
presented by cells. This was validated by the non-functional RGD disrupting the 
activation of the ERK/MAPK, and Akt/PI3K signalling pathways (Holmes et al., 2012).  
Figure 8.1 Location of IGFBP-2 mutations 
Representative visualisation of IGFBP-2 structure with the location of the mutations for each 
mutant variant mutated in a white colour. IGFBP-2’s RGD mutation is at the C terminal end of 
the protein. The IGF mutant is located on the N-terminus. The HBD1/NLS mutation is located 
within the flexible mid-region. Adapted from (Yau et al., 2015b). 
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The effect of the RGD mutant could vary between different cell types and therefore 
may display a different phenotype in vascular endothelial cells.  
 
8.1.2 IGF binding mutant 
Creating a non-functional IGF binding domain within IGFBP-2 has proven to be the 
most interesting mutant. All IGFBP’s were first established to primarily function 
through IGFs, however IGFBP-2 has multiple IGF-independent domains which may 
have more influence over enhancing angiogenic mechanisms. The majority of 
publications discussing IGFBP-2s potential in angiogenesis refer more to IGF-
independent mechanisms rather than IGF-dependent mechanisms, suggesting IGF 
driven activity is not as prominent via this binding protein. 
IGF binding activity of IGFBP-2 plays an essential role in differentiation of 
osteoclasts. IGF-independent domains are unable to compensate for the lack of 
differentiation displayed by the non-IGF binding domain, to the level of differentiation 
induced by fully functional IGFBP-2. Interestingly, the IGF mutant supresses PTEN 
activity, similarly to WTIGFBP-2, suggesting IGF-independent domains modulate 
PTEN activation. It has been highlighted there may be interplay between the IGF 
binding domain and the other domains. A functional IGF domain requires a functional 
HBD in addition to elevate osteoclast differentiation, to a level induced by WTIGFBP-
2, via activation of the PI3K/Akt pathway (Demambro et al., 2012). 
This finding was supported by further published research. The non-IGF binding 
IGFBP-2 reduced the phosphorylation activity of RPTPβ, however a variant with the 
HBD1 site mutated with a functional IGF binding site had no effect on the 
phosphatase capabilities of RPTPβ. WTIGFBP-2 enhances RPTPβ phosphorylation 
and therefore highlighting both a functional IGF and HBD are required to replicate the 
WTIGFBP-2 induced effect (Shen et al., 2012). 
 
8.1.3 HBD1/NLS mutant 
Shen et al., (2012), confirmed the HBD1 IGFBP-2 mutant can interact via RPTPβ, 
whereas the HBD2 present on the C terminal cannot, highlighting both HBDs have 
significantly different roles.  Non-functional HBD1’s failure to activate RPTPβ has 
been established to also contribute to downstream PTEN levels. HBD1’s suppression 
of PTEN is an essential modulator of osteoclast formation and differentiation, through 
regulation of Akt phosphorylation (Demambro et al., 2012). 
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Although less potent than HBD2, this central HBD1 and NLS domain has been shown 
to also suppress preadipocyte differentiation and proliferation by generating mutants 
of both of these regions (Xi et al., 2013).   
Mutation of the HBD and NLS in the variable region also failed to induce migration 
and invasion of WT-SHEP cells, whereas WTIGFBP-2 enhanced these activities (Azar 
et al., 2014).  
Mutation of the NLS sequence prevents nuclear translocation of IGFBP-2 via importin 
α (Azar et al., 2014; Chelsky et al., 1989). Therefore, as hypothesised, if IGFBP-2 
activates VEGF via its NLS, and IGFBP-2 stimulated angiogenesis functions through 
VEGF activation, the NLS mutant would abolish all IGFBP-2s angiogenic potential. 
From current published literature, it is clear this central region encapsulating the 
HBD1 and NLS interactions is vital for differentiation and motility of essential cell 
types.  
 
8.1.4 VE-cadherin in vascular permeability 
Permeability is a crucial component of successful angiogenesis as weak blood 
vessels will be unable to withstand the pressure and cause leakages within the 
circulatory system. As observed in many in vitro studies and clinical phase trials using 
VEGF as an angiogenic stimulus results in an excessive leakiness due to the 
induction of a hyperpermeable state (Ved et al., 2017). Vascular permeability is 
determined by adheren junctions. These junctions mediate cell-cell adhesion through 
transmembrane proteins called cadherins. VE-cadherin is the most prominent 
cadherin that regulates adhesion between endothelial cells and therefore is key 
during angiogenesis. VEGF creates a hyperpermeable state by disrupting the 
function of VE-cadherin, resulting in poor adhesion between endothelial cells (Gavard 
& Gutkind, 2006).  
As IGFBP-2 has been reported to promote angiogenesis by increasing expression of 
VEGF, it is crucial we are able to show that IGFBP-2 does not cause 
hyperpermeability as a potential therapeutic (Das et al., 2013). However, it is 
important IGFBP-2 can maintain permeability at a regular level. IGFBP-2 has recently 
been shown to enhance adhesion between endothelial progenitor cells to HUVECs 
via its RGD domain, displaying the opposite effect to VEGF (Feng et al., 2015). 
However, we need to investigate the effect IGFBP-2 and its mutants may have on 
VE-cadherin. 
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8.1.5 Summary 
The individual domains we have mutated within IGFBP-2 have been reported to effect 
cell differentiation, migration, proliferation and permeability, possibly in combination 
with each other via integrin activation, PI3K/Akt, MAPK, nuclear transport or RPTPβ 
activation. The mutants will help us identify which domain is critical to promoting in 
vitro endothelial cell adhesion, migration, proliferation and vascular permeability. 
Identification of the predominant mechanism IGFBP-2 functions through to enhance 
angiogenic properties will enable the creation of a more specific and targeting 
therapeutic angiogenesis treatment to direct the angiogenic responses to treat 
ischemia. 
 
 
8.2 Aim and Hypothesis 
In this chapter, we have two main aims. Firstly, to determine the effect the IGFBP-2 
mutants (RGD, IGF and HBD1/NLS) may have on pro-angiogenic signalling and pro-
angiogenic in vitro angiogenic assays investigated in HUVECs in Chapter 5 and 6. 
Inhibitors were also used to identify the pathways responsible for IGFBP-2s 
enhancement in por-angiogenic functional assays. Secondly, to determine the effect 
IGFBP-2 may have on vascular permeability using in vitro methods to assess 
changes in endothelial cell barrier function and cell-cell junctions.  
The chapter objectives we aim to target are: 
• Investigate the effect of IGFBP-2 variants on angiogenic signalling pathways 
in HUVECs. 
• Determine the angiogenic potential of IGFBP-2 and its mutant variants using 
in vitro angiogenic assays in HUVECs. 
• Confirm the signalling pathways responsible for the enhancement in 
angiogenic mechanisms we see, using signalling inhibitors 
• Investigate the effect of IGFBP-2 and its mutant variants on vascular 
permeability. 
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8.3 Method 
8.3.1 Angiogenic Signalling and Assays 
The HUVEC culture and immunoblotting methods used for signalling have been 
stated in the General Methods (Chapter 3.1-3.3). Cell adhesion, scratch wound and 
tube formation protocols were used from Chapter 6.  
HUVECs were serum-starved for 2 hours before stimulation for signalling pathways 
only (Chapter 5.3.3). They were stimulated with 500ng/ml WTIGFBP-2 of 500ng/ml 
IGFBP-2 mutant (H = HBD1/NLS, I = IGF, R =RGD) for all signalling and angiogenic 
assays.  
 
In the tube forming assay, fluorescein-5-isotheiocyanate (fitC) (EMD Milipore, 
1.24546) was diluted into a sodium chloride solution (0.145M in 100ml). 2.5µg/ml was 
added to the media prior to the incubation to stain cells. 
 
8.3.2 Use of Akt and MAPK inhibitors 
Inhibitors were used in functional tube forming assays to confirm which pathway was 
responsible. 
8.3.2.1 Signalling 
Confluent HUVECs were incubated with 10µM Akt inhibitor (Calbiochem, MK-2206) 
for 30 mins. 500ng/ml WTIGFBP-2 or mutants were added to cells for 10 mins. Cells 
were cultured, lysed and collected for immunoblotting using the protocol in Chapter 
3.1, 3.2 and 3.3) 
8.3.2.2 Assays 
Akt (10µM) or (10µM) p38MAPK (Calbiochem, SB 203580) competitive inhibitors 
were added to conditioned media at the beginning of scratch wound and tube 
formation assays with 500ng/ml WTIGFBP-2 or mutants.  
 
8.3.3 Cytodex bead assay 
Adapted from Nakatsu et al., (2007). HUVECs were grown in EGM-2 (Lonza, CC-26-
6) (+ ECGM-2 BulletKit (Lonza, CC-3162). HUVECs were incubated with cytodex-3 
beads (Amersham, 17-0485-01) in a 37ºC/5% CO2 incubator and agitated every 20 
mins for 4 hours. Cells were left to adhere to the beads overnight. 
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Beads were washed with EGM-2 media twice to remove any non-adhered cells. The 
adhered cells and beads were resuspended in filter sterilised 2mg/ml fibrinogen 
(Sigma-Aldrich, F8630) (diluted in PBS, pH 7.4), 0.15 Units/ml aprotinin (Sigma, 
Aldrich, A-1153), 5ng/ml VEGF and 5ng/ml FGF solution. The mixture (300µl in total 
volume) was pipetted into wells of an 8-well glass bottom treated IBIDI plate and store 
in a cell culture incubator. Beads were incubated in conditioned media with the basal 
control being 2% serum media, 500ng/ml WTIGFBP-2 and 500ng/ml RGD mutant.  
After 24 hours, cells were imaged at a 10x magnification using an optical microscope. 
 
8.3.4 Cytodex bead assay immunofluorescent staining 
Cells were fixed using 4% paraformaldehyde (PFA) (Sigma-Aldrich, 30525-89-4) for 
20 mins at room temperature and then washed 3 times with PBS, pH 7.4, for 1 min 
each time. 1ml 0.5% triton X-100 (v/v) (Sigma-Aldrich, T9284) was added to the well 
for 10 mins at room temperature to permeabilise the cell membranes. The cells were 
washed with 3x PBS pH 7.4, followed by a final incubation with fresh PBS, pH 7.4, 
for 30 mins. Cells were blocked with 1% BSA/PBS solution for 30 min. After washing 
the blocking solution with 3 washes of PBS, pH 7.4, cells were incubated with 1% 
rhodamine phallodin (Thermo Fisher, R415) (diluted in PBS (1:100)) for 1 hour at 
room temperature. Cells were washed 3 times again and kept in PBS, pH 7.4, ready 
for imaging. Images were taken using a Zeiss LSM700 confocal microscope. Z stack 
images were captured at a 20x magnification using the red laser. 
 
8.3.5 Cell Barrier Quality 
This experiment was carried out the University of Nottingham in Professor David 
Bates laboratory, under the supervision of Dr Andrew Benest. 
Electric Cell-substrate Impedance Sensing (ECIS) was used to quantify the barrier 
formed by endothelial cell monolayer. HUVECs were seeded onto electrode array 
plates (8W10E PET, Applied Biophysics) until 100% confluence was reached in 10% 
fetal calf serum (FCS) supplemented media (C-22220, Promocell) with the addition 
of endothelial cell growth media supplement pack (C-39220, Promocell). IGFBP-2 
(500ng/ml), the mutants (500ng/ml) or VEGF (30ng/ml) were added to condition the 
basal media (5% serum). Arrays were placed on array holder and ECIS software was 
used to collect readings. Readings were taken every 60 seconds at 4000Hz. 
Resistance data against the endothelial cell barrier was collected by the ECIS 
software. 
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8.3.6 Vascular permeability Immunofluorescent staining  
This experiment was carried out the University of Nottingham in Professor David 
Bates laboratory, under the supervision of Dr Andrew Benest. 
HUVECs were plated onto IBIDI treated 8 well glass bottom plates in 10% FCS 
supplemented media plus endothelial cell growth factor supplement and incubated 
until a 100% confluent state had been obtained. Cell media was changed and 
supplemented with IGFBP-2 (500ng/ml), the mutants (500ng/ml) or VEGF 
(Promocell, C-64423) (30ng/ml) for 48 hours. The cell monolayer was washed with 
PBS, pH 7.4, following fixation of cells using 2% PFA for 30 mins. Surface was 
washed again with PBS, pH 7.4, followed by a wash with 0.5% PBLEC (PBS (pH 6.8) 
with the addition of 1M MgCl2, 1M CaCl2, 1M MnCl2, 10% Triton X-100). 1% BSA 
(A7906, Sigma Aldrich)/PBLEC was used as a blocking agent for 1 hour at room 
temperature. The primary antibody VE-Cadherin (ab7047, Abcam) (1:200 dilution in 
1% BSA/PBLEC) was incubated in the plates overnight at 4ºC. Following 3 washes 
with 0.5% PBLEC, incubation with the Alexa Fluor 488 donkey anti-mouse IgG 
(A21202, Thermo Fisher) (1:500 dilution in 1% BSA/PBLEC) was carried out at room 
temperature for 2 hours. Phalloidin 680 (21839, Thermo Fisher) (1:500 dilution) and 
DAPI (62248, Thermo Fisher) (1:1000 dilution) was also added at the same conjugate 
incubation stage. Cells were washed with 0.5% PBLEC and imaged using confocal 
microscopy (Zeiss, LSM 880). Green, blue and red filters were used to capture single 
images at a 10x and 20x magnification. 
 
8.3.7 Data analysis 
GeneTools was used to perform densitometry analysis of the bands on each western 
blot. ImageJ Cell Counter tool was used to count the number of cells in each image 
for the cell adhesion assay. ImageJ Area tool was used to measure the area between 
scratch wounds using the gridded plate. Incucyte Zoom Wound Closure Review Tool 
was used to measure images taken using the Incucyte for the scratch wound assay. 
Image J Cell Counter tool was used to count the number of meshes in a pre-
determined area. Image J Cell counter was used to count sprouts in the angiogenic 
bead assay. Unpaired t-tests were used to test for significance. Error bars represent 
SEM. 
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8.4 Results 
8.4.1 Mutant stimulated Akt and p44/42 MAPK phosphorylation 
We have shown in Chapter 5, complete functional IGFBP-2 significantly enhanced 
Akt and MAPK phosphorylation. WTIGFBP-2 and the HBD and IGF mutants 
significantly enhanced Akt phosphorylation compared to the basal control. However, 
the RGD mutant prevented phosphorylation of Akt, back to the basal level of (Figure 
8.2 A). 
WTIGFBP-2 significantly elevated p44/42 MAPK phosphorylation compared to the 
serum free control, replicating the effect of commercially sourced IGFBP-2 in Chapter 
5. However, the HBD, IGF and RGD mutant failed to display a significant 
enhancement in p44/42 MAPK phosphorylation compared to the vehicle control 
(Figure 8.2 B). 
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Figure 8.2 RGD mutant failed to phosphorylate Akt or MAPK 
20µg of protein in HUVECs was loaded onto a 4-12% Bis-Tris gel and the blots were 
probed for the relevant genes. HUVECs were stimulated with WTIGFBP-2, HBD, IGF or 
RGD mutants (500ng/ml; 20min). Densitometry of the blots was measured using 
Genetools. (A) The blots were probed with rabbit polyclonal anti-phospho Akt 
(MW=60kDa) and the loading control, murine monoclonal Hsp90 (MW=90kDa) to 
observe the change in Akt phosphorylation, in response to stimulation with WTIGFBP-
2, HBD, IGF or RGD mutants in HUVECs (*=p<0.01 vs serum-free (SF) control, n=3). 
(B) The blots were probed with rabbit polyclonal anti-phospho p44/42 MAPK 
(MW=42/44kDa) and the loading control, murine monoclonal Hsp90 (MW=90kDa) to 
observe the change in MAPK phosphorylation, in response to stimulation with 
WTIGFBP-2, HBD, IGF or RGD mutants in HUVECs (*=p<0.05 vs serum-free (SF) 
control, n=3). Error bars represent SEM. 
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8.4.2 Effect of the RGD mutant on Akt and p44/42 MAPK activation 
Following the results from Figure 8.10, the RGD mutant failed to phosphorylate Akt 
and MAPK. To confirm this was a true finding we replicated the Akt phosphorylation, 
normalising against total Akt levels (Figure 8.3 A). Dose-dependent response 
stimulation of the RGD mutant did not replicate the commercial IGFBP-2 dose-
dependent enhancement of Akt phosphorylation shown in Chapter 5 (Figure 8.3 B).  
The RGD mutant failed to up-regulate the phosphorylation of MAPK compared to the 
enhancement displayed following stimulation with WTIGFBP-2 and commercial 
recombinant IGFBP-2 (Figure 8.3 C). 
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Figure 8.3 RGD domain is critical for Akt and p44/42 MAPK phosphorylation 
20µg of protein from HUVEC cell lysates was loaded for each condition onto the gel and 
probed for the gene of interest. Western blots were stripped following probing for phospho 
variations of the gene with 2% glycine before being probed for total levels. Successful 
stripping was confirmed by imaging the blot after stripping to ensure no residue remained 
on the blot. Densitometry was carried out using Genetools. (A) HUVECs were stimulated 
with WTIGFBP-2 and RGD mutant (500ng/ml; 20min). The blots were probed for rabbit 
polyclonal anti-phospho Akt (MW=60kDa), murine polyclonal anti-Akt (MW=60kDa) the 
loading control, murine monoclonal Hsp90 (MW=90kDa) (*p<0.001, n=3). (B) Change in 
Akt phosphorylation, compared to total levels and normalised to murine monoclonal anti-
β-Actin (43kDa) was observed in response to a dose dependent stimulation of the RGD 
mutant (100-500ng/ml; 20min) on HUVECs (n=3). (C) Serum-starved HUVECs were 
stimulated with WTIGFBP-2 (500ng/ml; 20min), commercially sourced recombinant IGFBP-
2 (RE BP2) (500ng/ml; 20min), the RGD mutant (500ng/ml; 20min) or VEGF (30ng/ml; 
15min). Blots were probed for MAPK phosphorylation changes, rabbit polyclonal anti-
phospho-MAPK (MW=44/42kDa), murine polyclonal anti- MAPK (MW=44/42kDa) and the 
loading control, murine monoclonal Hsp90 (MW=90kDa) (*=p<0.01 vs serum-free (SF) 
control, n=3). Error bars represent SEM. 
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8.4.3 Effect of mutants on eNOS and FAK phosphorylation 
As mentioned in Chapter 5, published literature has highlighted IGFBP-2 may 
phosphorylate eNOS via stimulation of the Akt pathway in HUVECs (LI et al., 2018). 
IGFBP-2 has also been shown to stimulate FAK phosphorylation via integrin 
interactions (Patil et al., 2016). However, we failed to replicate elevated eNOS and 
FAK phosphorylation stimulated by completely functional IGFBP-2 in HUVECs.  
HUVECs stimulated with WTIGFBP-2, the HBD-, IGF- and RGD-mutants did not cause 
any further phosphorylation of eNOS or FAK (Figure 8.4). 
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Figure 8.4 WTIGFBP-2 nor the mutants phosphorylated eNOS or FAK 
Serum-starved HUVECs were stimulated with WTIGFBP-2 (500ng/ml; 15min) or its mutant 
variants, HBD, IGF and RGD (500ng/ml; 15min) or VEGF (30ng/ml; 15min). 20µg protein was 
loaded onto a 4-12% Bis-Tris gel. Blots were cut according to the molecular weight of the gene 
of interest. Blots probed for phospho levels were stripped with 2% glycine, confirmed by 
imaging for residue and then probed for total levels. (A) Blots were probed for rabbit polyclonal 
anti-phospho eNOS (MW=140kDa) and rabbit polyclonal anti-eNOS (MW=140kDa) and the 
loading control, murine monoclonal Hsp90 (MW=90kD). Change in eNOS phosphorylation vs 
total levels, normalised to Hsp90, was measured, in response to stimulation with WTIGFBP-2, 
the mutant variants and VEGF (n=3). (B) Immunoblot was probed for rabbit polyclonal anti-
phospho-FAK (MW=125kDa), rabbit polyclonal anti-FAK (MW=125kDa) and the loading 
control, murine monoclonal anti-β-Actin (43kDa). Change in FAK phosphorylation vs total 
levels, normalised to β-Actin was measured, in response to stimulation with WTIGFBP-2, the 
mutant variants and VEGF (*=p<0.001, n=3). Error bars represent SEM. 
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8.4.4 Mutant stimulated HUVEC adhesion to fibronectin 
We previously showed in Chapter 6, IGFBP-2 enhanced HUVEC adhesion to 
fibronectin, which also supports published literature that IGFBP-2 is able to promote 
adhesion via integrins (Feng et al., 2015). Most adhesion responses are stimulated 
through integrin interactions. However, HBD1 is also known to interact with the ECM 
via activation of RPTPβ. Therefore, to determine the domain in IGFBP-2 responsible 
for this effect the HUVEC cell adhesion assay was replicated using the mutants. The 
RGD mutant was the only IGFBP-2 mutant which failed to enhance HUVEC adhesion 
to fibronectin (Figure 8.5). 
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Figure 8.5 RGD mutant affected HUVEC cell adhesion to fibronectin 
50,000 HUVECs were plated onto a fibronectin coated plate and incubated to adhere for 30 
minutes in a 37ºC/5% CO2 incubator. After 30 minutes, non-adhered cells were washed off 
using PBS. Remaining cells were imaged at 5 different points in the well od of the cell. (A) 
Representative Images taken at a 40x magnification using an optical microscope of cells that 
adhered to fibronectin after 30min in conditioned media with WTIGFBP-2, IGF, HBD or RGD 
mutants (500ng/ml) or a positive control of 20% serum + ECGS. (B) The cells counted at 5 
different points were averaged per well. Graph representation shows the change in HUVECs 
adhered to the fibronectin matrix in response to stimuli with WTIGFBP-2 (500ng/ml), IGF 
mutant (500ng/ml), HBD mutant (500ng/ml), RGD mutant (500ng/ml) or positive control (20% 
serum + ECGS) (*=p<0.01 vs basal control, n=5). Error bars represent SEM. 
P a g e  | 205 
 
 
8.4.5 Mutant stimulated HUVEC wound closure 
IGFBP-2 enhances migration and proliferation, as shown in many published articles 
and by the findings in Chapter 6, however a clear mechanism responsible for 
promoting this activity has not yet been established. Integrin, VEGF, RPTPβ and IGF-
I interactions have all been reported to be responsible for driving migration and 
proliferation. However, using these mutants, we will be able to establish which 
domain, and therefore, identifying the interaction that is critical for this activity. After 
13 hours, the RGD mutant failed to enhance HUVEC wound closure to the level 
achieved by WTIGFBP-2 and the IGF and HBD mutants (Figure 8.6). 
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Figure 8.6 RGD mutant fails to enhance HUVEC wound closure 
Cells were left to reach confluency in a 96 well plate in triplicate. Conditioned media 
containing WTIGFBP-2 (500ng/ml), IGF mutant (500ng/ml), HBD mutant (500ng/ml), RGD 
mutant (500ng/ml) or positive control (10% serum) were added to the cells prior to serum-
starving. The images, before and after a 13-hour incubation, were taken using an optical 
microscope at a 40x magnification. ImageJ polygon tool was used to measure the change 
in wound area from the before and after images. (A) Representative Images taken using 
the Incucyte at a 10x magnification of when a scratch was first made and the closure after 
13 hours in conditioned media with control (2% serum), WTIGFBP-2, IGF, HBD or RGD 
mutant (500ng/ml) and the positive control (5% serum). (B) Graphical presentation 
highlighting the change in wound closure in response to stimulation with WTIGFBP-2 
(500ng/ml), IGF mutant (500ng/ml), HBD mutant (500ng/ml), RGD mutant (500ng/ml) or 
positive control (10% serum) (*=p<0.05 vs basal control, n=3). Error bars show SEM. 
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8.4.6 Mutant stimulated HUVEC tube formation 
Tube formation assays are used commonly as an in vitro representation of 
endothelial cell movement in angiogenesis. We previously supported Das et al., 
(2013) findings that IGFBP-2 promotes endothelial tube formation. Similarly, to 
wound closure, tube formation uses a combination of adhesion, migration and 
proliferation.  
The RGD mutant failed in to enhance HUVEC mesh formation to match the level of 
enhancement achieved following stimulation with WTIGFBP-2 and the HBD and IGF 
mutants (Figure 8.7). Observations at regular intervals over the tube formation period 
displayed RGD struggled to form a clear mesh-like type structure (Figure 8.8).  
In order to identify a clear mechanism of how IGFBP-2 could promote angiogenic-
like properties, it is essential we determine which signalling pathways the 
enhancement in tube formation is due to. Therefore, Akt and p38 MAPK inhibitors 
were used inhibit tube formation stimulated by either of these pathways. The Akt 
pathway is a requirement for IGFBP-2 induced tube formation (Figure 8.9), however 
inhibiting p38 MAPK did not diminish IGFBP-2 stimulated mesh tube formation 
(Figure 8.10). 
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Figure 8.7 RGD mutant did not enhance HUVEC mesh formation 
100,000 HUVECs were plated onto set Matrigel in conditioned media (stimulated with 
IGFBP-2, mutants, or VEGF, in duplicate and incubated for 8 hours in a 37ºC/5% CO2 
incubator. Images were taken using an optical microscope at a 40x magnification after 
the incubation period. (A) Representative Images of HUVECs in a tube formation assay 
taken after 8 hours of incubation with conditioned media containing basal control (1% 
serum) WTIGFBP-2 (500ng/ml), IGF mutant (500ng/ml), HBD mutant (500ng/ml) or RGD 
mutant (500ng/ml) and positive control (10% serum). (B) ImageJ Cell Counter Tool was 
used to count the number of meshes measured in 5 different points of the well. The 
measurements were averaged according to each well. Graphical representation of the 
meshes counted in 5 different areas of the well for each non-stimulated and stimulated 
well, showing the effect of WTIGFBP-2 (500ng/ml), IGF mutant (500ng/ml), HBD mutant 
(500ng/ml) or RGD mutant (500ng/ml) and positive control (10% serum) compared to 
basal levels (1% serum) (*=p<0.05 vs basal control, n=4). Error bars show SEM. 
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Figure 8.8 Mesh tube formation over time decreases 
100,000 HUVECs were plated onto a set Matrigel matrix, in duplicate, in conditioned media. 
Cells were immediately incubated in a 37ºC/5% CO2 incubator, which was connected to the 
Incucyte. Images were taken every 3 hours at a 10x magnification. (A) Representative Images 
taken on the Incucyte, of the basal control wells (1% serum), WTIGFBP-2 (500ng/ml), RGD 
mutant (500ng/ml) and positive control (10% serum), every 3 hours for 12 hours. (B) Change 
in wound closure was measured using the Incucyte Zoom software. Graphical representation 
of tube mesh formation changes over 12 hours in conditioned media with the control, 
WTIGFBP-2 (500ng/ml), IGF, HBD or RGD mutants (500ng/m) and positive control (10% 
serum) (*=p<0.05, n=4). Error bars represent SEM. 
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Figure 8.9 Akt inhibitor suppresses WTIGFBP-2 stimulated mesh formation 
100,000 HUVECs were plated onto set Matrigel, in duplicate, in conditioned media. FitC stain 
was also added to the media. Images of the tube forming were taken using the Incucyte after 
an 8-hour incubation at 37ºC/5% CO2. Inhibitors were added in before the incubation. (A) 
Signalling studies carried out on HUVECs stimulated with Akt inhibitor (MK-2206) probing for 
rabbit polyclonal anti-phospho Akt (MW=60kDa) and murine polyclonal anti-Akt (MW=60kDa), 
normalised to murine monoclonal anti-Hsp90 (MW=90kDa). Blots were stripped and checked 
for remaining residue before probing for phospho and total levels of Akt. (B & C) Akt inhibitor 
was added to conditioned media with basal control (1% serum), 500ng/ml WTIGFBP-2 and 
positive control (10% serum) at the beginning of 8-hour incubation. (B) Representative images 
taken on the Incucyte using fitC staining at a 10x magnification of mesh formation in 
conditioned media with control, WTIGFBP-2 and positive control, in the presence and absence 
of the Akt inhibitor. (C) Graphical representation highlighting the change in tube mesh 
formation, in response to stimulation with IGFBP-2 (500ng/ml) and positive control (10% 
serum) in the absence and presence of the Akt inhibitor (MK-2206) (*=p<0.01, n=4). Error bars 
show SEM. 
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Figure 8.10 p38 MAPK inhibitor lowered WTIGFBP-2 stimulated mesh tube 
formation 
100,000 HUVECs were plated onto set Matrigel, in duplicate, in conditioned media 
stimulated with IGFBP-2 (500ng/ml) or positive control (10% serum), in the absence or 
presence of the inhibitor p38 MAPK. Images were taken at 5 different points in a well 
after an 8-hour incubation at 37ºC/5% CO2. (A) Representative images were taken at a 
40x magnification using the optical microscope after an 8-hour incubation in the 
absence and presence of p38 MAPK inhibitor in conditioned media (with IGFBP-2 
(500ng/ml) or positive control (10% serum)) with basal control (1% serum). (B) The 
number of meshes were counted using ImageJ and averaged per well. Graphical 
representation highlights differences in tube mesh formation in the absence and 
presence of p38 MAPK inhibitor, following stimulation with WTIGFBP-2 (500ng/ml) or the 
positive control (10% serum) and the basal control (1% serum) (*=p<0.05, n=3). Error 
bars represent SEM. 
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8.4.7 IGFBP-2 mutant effects on angiogenic bead sprouting assay 
This assay represents the sprouting that occurs in the initial process of angiogenesis. 
It involves coating of a polystyrene ball with endothelial cells in a fibrinogen matrix 
(Nakatsu et al., 2007). These endothelial cells use a combination of adhesion, 
migration and proliferation to form a network around the bead. Once the network 
around the bead is formed, endothelial cells begin sprouting off the network as they 
migrate into the environment. Sprouting is a different angiogenic process compared 
to tube formation as sprouting is the initial stage, whereas tube formation takes place 
during the migration of endothelial cells, and therefore may rely on the activation of 
different signalling pathways. WTIGFBP-2 and the RGD mutant both significantly 
increased the number of sprouts formed in comparison to the basal control (Figure 
8.11).  
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Figure 8.11 WTIGFBP-2 and RGD mutant enhances HUVEC sprouting 
HUVECs were incubated in a mix of beads and left to adhere in a 37ºC/5% CO2 incubator (in 
duplicate). Following coating of the bead, conditioned media containing IGFBP-2 (500ng/ml) and 
other growth factors, FGF (5ng/ml) and VEGF (5ng/ml) were added into the well. The coated 
beads were incubated for 24 hours. Confocal images were carried out after fixing of the beads 
following the 24-hour incubation. (A) Representative 3D Images taken of HUVEC angiogenic 
bead sprouting in conditioned media containing basal control (2% serum), WTIGFBP-2 
(500ng/ml) and RGD mutant (500ng/ml), using confocal microscopy after being fixed following 
24-hour incubation for sprouting. The stain, rhodamine phalloidin was used to label the actin 
fibres. The confocal images were taken at a 20x magnification. (B) Representative 2D images 
taken at a 10x magnification using an optical microscope of HUVEC sprouting after 24-hour 
incubation. (C) Graphical representation of the number of sprouts counted from images taken 
using the optical microscope, highlighting the HUVEC sprouting induced following stimulation 
with WTIGFBP-2 (500ng/ml) and the RGD mutant (500ng/ml) (*=p<0.05, WTIGFBP-2 vs RGD 
=p=0.09, n=3). 
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8.4.8 Effect of IGFBP-2 and its mutants on cell permeability 
As mentioned, the introduction (Chapter 1.4), cell permeability is essential for 
achieving healthy angiogenesis. It is well known that VEGF causes hyperpermeability 
and during angiogenesis induces the formation of leaky blood vessels. Although we 
have shown in Chapter 4 evidence that IGFBP-2 may not upregulate VEGF to 
promote angiogenesis, we needed to prove IGFBP-2 does not cause the same 
hyperpermeable response that VEGF does. These findings would support the use of 
IGFBP-2 as a viable therapeutic agent in clinical use. Permeability was tested using 
a system called Electric Cell-substrate Impedance (ECIS), which relies on measuring 
the resistance required for electrical currents to get through a confluent monolayer of 
cells. WTIGFBP-2 did not increase permeability in comparison to VEGF. IGF mutant 
increased permeability compared to the RGD and HBD mutant and WTIGFBP-2 
(Figure 8.12). 
VEGF causes its hyperpermeable response by disrupting VE-Cadherin and 
compromising vascular integrity (Ourradi et al., 2017). This endothelial cadherin is a 
molecule that controls cell to cell adhesion via modulating cellular junctions. Under 
confocal microscopy, normal permeability depicts VE-cadherin outlining the surface 
of cells. Contrastingly, VEGF causes VE-cadherin to change confirmation, thus 
causing the opening of gaps. VE-cadherin normal morphology was retained with 
WTIGFBP-2 but was disrupted upon stimulation with VEGF-A (Figure 8.13). 
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Figure 8.12 WTIGFBP-2 does not cause hyperpermeability 
The ECIS system was used to measure change in resistance required to pass through a 
confluent HUVEC monolayer. Once a confluent monolayer had been obtained in Ibidi plates, in 
duplicate, the conditioned media was added, stimulating the HUVECs with WTIGFBP-2 
(500ng/ml), the mutant variants (500ng/ml) of VEGF-A (30ng/ml) . The plate was placed into the 
ECIS machine which transmitted electrical currents to measure the resistance of the monolayer. 
The measurements were provided by the ECIS software and compared using Excel. (A) 
Comparison between the fold change in resistance in cells conditioned in basal media (5% 
serum), either non-stimulated (basal control) or stimulation with the addition of WTIGFBP-2 
(500ng/ml; 25h) or VEGF-A (30ng/ml;’25h) (n=4). (B) Graphical representation of the fold 
change in resistance compared between the mutants, IGF, HBD and RGD and WTIGFBP-2 
(500ng/ml; 25h) and the non-stimulated basal control (n=3).  
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Figure 8.13 WTIGFBP-2 does not disrupt VE-cadherin 
HUVEC confluent monolayers were maintained in conditioned basal media (5% serum), with WTIGFBP-
2 (500ng/ml; 48h) or VEGF-A (30ng/ml; 48h) after running through the ECIS reader. The ECIS did not 
adversely affect the monolayer (data not shown). Cells were fixed and probed with phalloidin and/or 
VE-cadherin antibody and their corresponding fluorophores, following with DAPI. White arrows depict 
changes to VE-cadherin. DAPI highlights the nucleus of the cells in blue, VE-cadherin staining is 
highlighted in green and Phalloidin staining is highlighted in red. (A) Images were captured at a 10x 
magnification using confocal microscopy. (B) Images were captured at a 20x magnification using a 
confocal microscope, closely showing the jagged appearance of VE-Cadherin, in response to 
stimulation with VEGF-A. 
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8.5 Discussion 
8.5.1 RGD mutant fails to activate p44/42 MAPK and Akt phosphorylation 
in HUVECs 
We previously found in Chapter 5, IGFBP-2 (500ng/ml; 20mins) does stimulate Akt 
and p44/42 MAPK phosphorylation in HUVECs. WTIGFBP2, as well as the HBD1 and 
IGF mutants significantly enhanced Akt activation. This finding with the mutants 
contradicts current findings in other cell types highlighting functional HBD or IGF or 
both in a combination is critical to phosphorylate Akt. 
The interaction between IGFBP-2s HBD1 and RPTPβ was critical to the signalling of 
PTEN and downstream activation of Akt. Stimulation with the HBD peptide alone 
stimulated Akt phosphorylation in osteoblasts (Kawai et al., 2011). In osteoclasts, the 
HBD and IGF mutants independently failed to phosphorylate Akt. However, to rescue 
Akt phosphorylation, both domains were required to be functional (Demambro et al., 
2012). It was suggested the mechanism modulating this activity was the 
enhancement in phosphatase activity due to HBD not mediated RPTPβ, coordinated 
with inaction of IGF-I and as a result Akt in VSMCs. In HUVECS, we have determined 
the HBD or IGF mutant relies on other mechanisms to compensate for the loss of 
activity and still is able to enhance Akt activation to the same level as fully functional 
IGFBP-2. 
Our findings suggest that HUVEC Akt phosphorylation is mediated through integrin 
interactions. In glioma cells, IGFBP-2 actions of promoting cell migration and 
proliferation are mediated by integrins recruitment of integrin-linked kinase (ILK) 
(Holmes et al., 2012). The ILK pathway leads to the activation of downstream targets 
PI3K and Akt (Kimura et al., 2010). Increased levels of IGFBP-2 correlate with 
phosphorylated FAK levels; however, the upregulation in FAK does not cause an 
enhancement in Akt phosphorylation (Lu et al., 2013). Thus, suggesting IGFBP-2s 
integrin recruitment of ILK is likely to be a more favourable mechanism contributing 
to IGFBP-2 stimulated Akt phosphorylation via its RGD domain. 
Stimulation with WTIGFBP-2 with the same conditions as optimised in Chapter 5 
caused approximately a 1.3 significant fold increase in p44/42 MAPK activation 
compared to the basal serum-free control. WTIGFBP-2 also significantly enhanced Akt 
phosphorylation compared to the basal control. These findings mimic the effects on 
signalling observed with commercially sourced recombinant IGFBP-2 and display the 
same biological functionality.  
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Interestingly, the HBD, IGF and RGD mutants fail to enhance p44/42 MAPK 
phosphorylation to the same level as WTIGFBP-2. There has been an indirect 
association with low IGFBP-2 levels enhance IGF-stimulated ERK/MAPK signalling 
via inhibiting the suppressive activity of p53 in prostate cancer cells (Grimberg, 2000). 
This contradicts our initial finding of high IGFBP-2 levels enhances MAPK signalling 
in HUVECs. No further publications have shown that the HBD1 and IGF domains 
directly activate MAPK via JNK or ERK. The HBD1 and IGF failure to activate MAPK 
may be specific to vascular endothelial cells in particular but should be examined 
further in an array of cell types.  
Interactions with α5 and β1 are critical to enhancing JNK and ERK mediated MAPK 
pathways (Han et al., 2014; Mendes et al., 2010). We support this finding by the 
suppressive effect the RGD mutant has on p44/42 MAPK signalling compared to 
WTIGFBP-2 and the HBD mutant, highlighting the RGD mutant is a requirement for 
MAPK activation. However, since there is no significant decrease between the IGF 
and RGD mutant stimulated phosphorylation of MAPK, there may be crosstalk 
between both of these domains to regulate the activity exerted by IGFBP-2/integrin 
binding. 
 
 
8.5.2 WRIGFBP-2 and the mutants fail to phosphorylate eNOS and FAK 
Recent literature has highlighted a link between IGFBP-2 stimulated Akt leading to 
the phosphorylation of eNOS (LI et al., 2018). WTIGFBP-2 and the mutants failed to 
enhance eNOS phosphorylation, confirming the finding from Chapter 5 that IGFBP-2 
in HUVECs does not function through the Akt/eNOS pathway. An alternative Akt-
stimulated pathway may be responsible for the changes we observe in the angiogenic 
functional assays. 
An association in pancreatic cancer has been established between IGFBP-2 levels 
and upregulation of phosphorylated FAK (Liu et al., 2017). However, we 
hypothesised earlier using our current and published findings, IGFBP-2 in HUVECs 
may function via integrin interactions recruiting ILK instead of FAK. This correlates 
with our findings that commercially available IGFBP-2 or our in-house generated 
WTIGFBP-2 does not up-regulate FAK phosphorylation. 
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8.5.3 RGD domain of WTIGFBP-2 is required for enhancement of adhesion 
Previously, in Chapter 6 we showed IGFBP-2 enhanced HUVEC adhesion to 
fibronectin. WTIGFBP-2, displayed the same functionality as the commercially sourced 
recombinant IGFBP-2.  The HBD and IGF (but to a lesser extent) significantly 
enhanced HUVEC adhesion to fibronectin compared to the basal control. This was 
an expected result since they only promote interactions from the surface of the ECM 
with RPTPβ and IGF-1R, without modulating the cell-ECM adhesion (Lin et al., 2015; 
Liu et al., 2017).  
The RGD mutant fails to enhance HUVEC to adhesion to fibronectin. This contradicts 
the mechanism stipulated in publications highlighting IGFBP-2s role in promoting de-
adhesion (Beattie et al., 2015; Holmes et al., 2012). Their mechanism states 
activation of IGFBP-2s RGD domain binds cell surface integrins and therefore, 
prevents the cell surface integrins from attaching to the ECM in cancer cell lines. 
However, we have observed the opposite effect that a fully functional RGD domain 
enhances HUVEC adhesion to fibronectin. Supporting our findings, a functional RGD 
domain with IGFBP-1 was shown to enhance human coronary arterial endothelial cell 
and HUVEC adhesion to fibronectin, specifically via αVβ3 and α5β1 (Aziz et al., 
2018). The mechanism suggested to explain this increase, was that endothelial cells 
stimulated with IGFBP-1 increased the cellular expression of integrins and as a result, 
enhances the number of integrin-ECM interactions that can take place causing further 
cell adhesion. IGFBP-2, as the only other IGFBP to possess an RGD may act in 
exactly the same way. Cell surface integrins could be visualised in future experiments 
to interrogate the hypothesis that IGFBP-2 enhances cell adhesion specifically 
through the RGD domain via a similar mechanism to IGFBP-1.  
 
 
8.5.4 WTIGFBP-2 stimulated wound closure and mesh formation is 
mediated by the RGD domain 
As stated previously in Chapter 6, IGFBP-2 stimulated wound closure and tube 
formation both target proliferation and migration angiogenic mechanisms. WTIGFBP-
2 mimicked the enhanced effect induced by the commercially sourced IGFBP-2 in 
the scratch wound assay and the tube formation assay, thus confirming it is retained 
all IGFBP-2 expected functionality. IGF-I is well known to directly influence cell 
proliferation and migration via activation of the ERK/MAPK or Akt signalling cascade 
(Choi et al., 2008; Nieto-Estévez et al., 2016). The HBD also has the ability to 
indirectly influence Akt-mediated migration and proliferation via its interaction with 
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RPTPβ (Demambro et al., 2012). However, research on the action of these two 
domains in IGFBP-2 stimulated proliferation and migration is extremely limited. This 
may be due to reason that both HBD and IGF mutant functioned in the similar manner 
to the WTIGFBP-2, significantly enhancing HUVEC wound closure and HUVEC mesh 
formation. 
RGD mutant failed to enhance wound closure and mesh formation to the level of 
WTIGFBP-2, highlighting it is the most critical domain to induce cellular migration and 
proliferation responses. This supports the majority of IGFBP-2 research highlighting 
Akt and MAPK promotes cell proliferation and migration (Myers et al., 2015). IGFBP-
2s interactions with integrin subunits α5 and β1 are critical to mediating MAPK-
stimulated cell migration, however IGFBP-2/integrin interactions have not been 
identified to cause upregulation of Akt phosphorylation (Han et al., 2014; Mendes et 
al., 2010). Our findings confirm IGFBP-2s interaction with integrins via its RGD 
domain is essential for cell migration and proliferation in HUVECs. 
 
8.5.5 Akt and p38 MAPK inhibitor suppresses WTIGFBP-2 induced tube 
formation 
WTIGFBP-2 failed to display its enhancement in HUVEC mesh/tube formation in the 
presence of an Akt inhibitor, thus confirming IGFBP-2 relies on activation of Akt to 
drive this elevated effect. This contrasts slightly to our hypothesis as in Chapter 5, 
200ng/ml IGFBP-2 was sufficient to activate the maximum response in Akt 
phosphorylation as this plateaued with increasing IGFBP-2 concentrations. In 
Chapter 6, 200ng/ml commercially-sourced recombinant IGFBP-2 was not sufficient 
to induce an enhancement in tube formation, but 500ng/ml IGFBP-2 was. Therefore, 
we assumed that the pathway would be driven by the MAPK pathway as p44/42 
MAPK phosphorylation also did not occur at 200ng/ml. However, our results 
highlighted that IGFBP-2 stimulated Akt also plays a significant role in enhancing 
IGFBP-2 induced tube formation. 
IGFBP-2 has been established to activate JNK, leading to the activation of p38 MAPK 
in glioma cells and mesenchymal stem cells (Mendes et al., 2010; Wang et al., 
2017c). However, due to time constraints, we focused on establishing activation of 
p44/42 MAPK as it was reported JNK mediated MAPK activation was responsible for 
specific cell migration activity (Han et al., 2014). As we have established that Akt 
plays a significant role, we used a JNK inhibitor to observe if inhibiting p38 MAPK 
mediated migration activity would also inhibit tube formation. However, although to a 
lesser extent compared to the effect in the absence of the inhibitor, IGFBP-2 in the 
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presence of p38 MAPK inhibitor significantly enhanced tube formation in comparison 
to its basal control. Thus, suggesting that JNK/p38 MAPK may play a moderate role 
and not a significant role in the enhancement of IGFBP-2 induced HUVEC mesh 
formation in the tube formation assay.   
 
8.5.6 WTIGFBP-2 stimulation of HUVEC sprouting is not dependent on a 
functional RGD domain 
In the Introduction (Chapter 1) we discussed how the sprouting by endothelial cells 
from the pre-existing vessel is the initial process of angiogenesis. This angiogenic 
bead assay results in endothelial cells forming a mesh-like network around a bead. 
Once the network is stable, endothelial cells are able to begin migrating to the ECM. 
As expected, following published data regarding IGFBP-2s upregulation of cell 
migration and proliferation responses, as well the data from this thesis thus far 
regarding IGFBP-2s enhancement in cell adhesion, WTIGFBP-2 significantly 
increased the number of sprouts grown compared to the basal control. This supports 
IGFBP-2 is able to maintain a network to stabilise and enhance the migrating of 
endothelial cells via angiogenic mechanisms in vitro. 
Unexpectedly, although the RGD mutant has failed to enhance cell adhesion, 
migration and proliferation in this chapter, there were significantly more sprouts 
formed when stimulated with the RGD mutant compared to the basal control. This 
suggests the RGD domain and integrin interactions with IGFBP-2 may not be 
required and is compensated by the HBD and IGF binding domain at the initial stage 
of angiogenesis. This opens up the need for further investigation into IGFBP-2s levels 
and roles at different stages of angiogenesis such as tip cell formation, endothelial 
sprouting, lumen formation and maturation (Francavilla et al., 2009). It is well-
established that other cytokine and growth levels fluctuate during the angiogenesis. 
Studies have shown IGFBP-2 can interact with HIF-1α to promote angiogenesis, as 
well as VEGF (Azar et al., 2011; Lin et al., 2015). However, from our findings we can 
confirm that the RGD domain does not significantly play a role in the sprouting of 
endothelial cells. 
 
 
8.5.7 WTIGFBP-2 does not increase permeability like VEGF165a 
Vascular permeability is essential to prevent formation of unstable blood vessels 
which may lead to vessel leakage, but IGFBP-2 has not been investigated in the 
context of permeability and its possibly interactions with VE-cadherin. As previously 
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discussed in the background of this chapter, VEGF causes a hyperpermeable state 
by disrupting VE-cadherin between cell-cell interactions which has led to leaky 
vessels being formed through therapeutic angiogenesis (Ourradi et al., 2017). Using 
the ECIS system, we confirmed findings of published literature that VEGF-A causes 
a hyperpermeable response in a HUVEC monolayer. Contrastingly, our in-house 
generated WTIGFBP-2 failed to replicate this effect and maintained the permeability 
of the endothelial monolayer at a near to basal level. This suggests that IGFBP-2 
may not exert its angiogenic effects through activation of VEGF, as reported by Azar 
et al., (2011) and Das et al., (2013).  
Further investigation into which domain may be responsible for maintaining 
endothelial cell permeability highlighted slight differences between the WT and its 
mutant variants. WTIGFBP-2, HBD and RBD all maintained permeability at a similar 
level, with WTIGFBP-2 showing a slight reduction in permeability. Surprisingly, 
stimulation with, the IGF mutant caused immediate increase permeability but 
maintained it at this lower level for 30 hours. Therefore, it did display a gradual 
decrease as VEGF does. IGF-I has been shown in enhance the resistance required 
for currents to pass through an epithelial cell monolayer, therefore reducing the 
permeability of the monolayer (Lorenzo-Zúñiga et al., 2006). This suggests IGF-I 
binding is a requirement for maintaining a strong endothelial monolayer too, hence 
the mutant that could not bind to IGF-I was the only mutant to display an increase in 
permeability. 
Immunofluorescent staining and confocal microscopy on an endothelial monolayer 
left for 30 hours, alongside the ECIS experiment confirmed IGFBP-2 did not disrupt 
VE-cadherin as opposed to the “jagged” type effect caused by stimulation with VEGF-
A. For the first time we have shown WTIGFBP-2 maintains VE-cadherin, supporting 
the data obtained from the ECIS experiment that IGFBP-2 does not increase 
permeability. Unfortunately, we were not able to carry confocal microscopy with the 
mutants. It would be interesting to observe the effect of the IGF mutant and compare 
it to the complete functional IGFBP-2, as this has not previously been investigated. 
The findings from this set of experiments suggest IGFBP-2 will not cause the same 
problem of leakage as VEGF does and therefore is a more viable therapeutic 
angiogenic treatment option. 
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8.5.8 Study limitations 
Unfortunately, due to time constraints, we were unable to use the Akt and p38 MAPK 
inhibitors on all functional assays. We also planned to observe the effects of the 
mutants on p38 MAPK and JNK mediated signalling because IGFBP-2s interactions 
with integrins α5 or β1 specifically, are known activate these pathways. 
Again, due to a limit of time, we were unable to interrogate the effect of the mutants 
on other permeability assays and in vivo. It is extremely important to determine 
IGFBP-2 in its non-mutated and mutated state does not mimic the effect of VEGF on 
hyperpermeability. 
It is important to note that cells from different passages function differently in relation 
to angiogenesis. Cells function most efficiently at a low passage and HUVECs 
beyond passage 6 should not be used for angiogenic assays. We only used HUVECs 
between passage 2 and 5; however, there was variability in wound closure, mesh 
formation and the permeability ECIS experiment due to the differences in the HUVEC 
passage number. For cost-effective reasons, it is not efficient to only use cells at 
passage 2. 
 
8.6 Concluding remarks 
Supporting the previous chapters, WTIGFBP-2 displays the same biological function 
as the commercial recombinant IGFBP-2 by enhancing Akt phosphorylation, p44/42 
MAPK phosphorylation as well as cell adhesion, scratch wound and tube formation 
assays. 
All mutants except the RGD domain significantly enhanced Akt phosphorylation. 
However, all the mutants failed to activate p44/42 MAPK phosphorylation. The RGD 
domain is required for both Akt and MAPK activation.  
The HBD and IGF mutant significantly enhanced HUVEC adhesion to fibronectin 
wound closure and mesh formation to a similar level of that induced by WTIGFBP-2. 
The RGD mutant failed to promote cell migration and proliferation, as well as 
adhesion in all angiogenic functional assays, suggesting these mechanisms function 
through IGFBP-2s interactions with integrins. WTIGFBP-2 and the RGD mutant 
significantly enhanced sprouting and migration of endothelial cells in the angiogenic 
sprouting bead assay, suggesting integrin interactions may not be involved in the 
initial sprouting stage of angiogenesis. 
Akt inhibitor eliminated the enhanced mesh formation response induced by WTIGFBP-
2. Inhibition of p38 MAPK lowered the elevation of WTIGFBP-2 induced mesh 
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formation, compared to the condition without the MAPK inhibitor but was still 
significant compared to its basal control. 
For the first time, we have identified IGFBP-2 does not cause the same negative 
effects on permeability as VEGF does, causing leaky blood vessels. WTIGFBP-2 
maintained permeability of a HUVEC monolayer at the basal level. However, IGF 
binding may play a significant role in determining permeability. IGFBP-2 maintained 
VE-cadherin morphology, whereas VEGF disrupted VE-cadherin, contributing to the 
hyperpermeability. 
 
In conclusion, the RGD domain is critical to IGFBP-2 stimulated angiogenic 
mechanisms and IGFBP-2/integrin interactions could be exploited further as a 
therapeutic. The RGD domain may not be responsible for driving angiogenic 
mechanisms through all stages of angiogenesis. IGFBP-2 retains vascular integrity 
in the in vitro studies, suggesting that it will not cause formation of leaky blood vessels 
if used as an angiogenic therapeutic agent. 
 
  
P a g e  | 225 
 
 
Chapter 9 – General discussion 
and conclusion 
9.1 Background 
IGFBP-2 was presented by our laboratory as a putative angiogenic treatment for 
ischaemic diseases due to reports of angiogenic-like mechanisms evoked by IGFBP-
2 in a variety of cell-types in published literature. Although upregulation of IGFBP-2 
has been correlated with tumour growth in cancers, IGFBP-2 has not previously been 
definitively shown to directly stimulate angiogenesis. Potential molecular 
mechanisms have been proposed by which IGFBP-2 interacts with cells via its 
structural domains which could be pertinent to angiogenesis. 
IGFBP-2 has domains which can interact with IGF molecules, integrins, RPTPβ, 
glycosaminoglycans (e.g. heparin), as well as facilitate entry into the nucleus. These 
interactions have all been investigated to enhance a range of functional effects in a 
variety of cell types. These include migration of glioma cells through MAPK pathway 
stimulated by IGFBP-2 interaction with integrins; survival in breast cancer cells or 
osteoblast differentiation, mediated by the Akt pathway following interaction of 
IGFBP-2 with the cell surface receptor RPTPβ (Han et al., 2014; Xi et al., 2014). 
Although IGFBP-2s interactions with cell surface receptors share certain 
characteristics, the mechanisms by which IGFBP-2 modulates cellular events and 
activity is likely to vary from cell to cell type. Therefore, it is important to investigate 
how IGFBP-2 may alter the function of endothelial cells. As the hypothesis 
interrogated by this thesis relates to the potential exploitation of IGFBP-2 in a clinical 
setting, we need to understand how it acts in response to ischemia in an in vivo 
system and determine if it causes any of the adverse effects associated with other 
pro-angiogenic factors, for example VEGF, in therapeutic angiogenesis.  This thesis 
describes a programme of cellular, molecular and in vivo experiments by which we 
have identified a protective role for IGFBP-2 in ischemia-recovery in vivo and 
determined clear mechanisms critical to IGFBP-2s angiogenic actions, while 
providing reassurance that IGFBP-2 does not adversely affect vascular endothelial 
permeability. 
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9.2 hIGFBP-2 enhances early recovery to ischemia in vivo 
IGFBP-2 has never previously been investigated in vivo in relation to recovery from 
ischemia, specifically in the setting of PAD. For the first time in vivo, we have shown 
that local IGFBP-2 expression in ischaemic hind limb is elevated after 24 hours 
following the induction of ischemia to the lower limbs. In the well-established 
angiogenesis mechanism, HIF-1α activated by an inflammatory response caused by 
the lack of oxygen is usually responsible for the upregulation of cytokines that are 
required for vessel formation. However, in vitro studies highlighted knockdown of HIF-
1α in a breast cancer cell line did not supress basal IGFBP-2 or IGF-stimulated 
IGFBP-2 expression (Martin & Baxter, 2007). To confirm this, we would have to 
examine HIF-1α levels in the muscles 24 hours after induced ischemia and 
demonstrate they do not a show a trend with the upregulation trend of IGFBP-2 we 
observe in response to ischemia.  
The overall recovery response suggests hypoxia was not induced to drive 
angiogenesis as an increase in perfusion to the limb in WT littermates is observed 
within 7 days, relieving the hypoxic environment. Over the 28-day recovery period, 
vessel growth continues to restore perfusion to a maximal level resulting in a plateau 
in perfusion being achieved by day 21. The clear differences between triggers of 
angiogenesis and arteriogenesis, suggest this recovery may be due to fluid shear 
stress influencing the expansion of a pre-existing collateral network rather than the 
formation of new blood vessels (Heil et al., 2006). However, the particular method of 
hindlimb ischemia surgery used is by cutting a segment of the artery out. Hence, 
recovery is more likely to be through a mix of angiogenesis and arteriogenesis, rather 
than just collateral recruitment. To confirm this, we would have to carry out further 
analysis on the legs at regular points during recovery, using techniques and tools 
such as immunohistochemistry and angiography (Cao et al., 2003). 
Both the global and endothelial-specific over-expressing hIGFBP-2 mice 
demonstrated a significant enhancement in recovery at early stages of recovery 
following ischemia surgery. A study by (Rakue et al., 1998) demonstrated VEGF- and 
FGF- stimulated hind limb ischemia recovery was as a result of angiogenesis rather 
than arteriogenesis as the number of vessels formed increased but vessel diameter 
area remained unchanged. 
HGF demonstrated a more potent recovery to HLI by significantly increasing end-
point perfusion rates at day 28 compared to its WT littermates (Yamamoto et al., 
2009). Therefore, the increase in perfusion on day 7 (in global expressers) and day 
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14 (in endothelial-specific), may replicate VEGF and FGF’s activity to stimulate 
growth of new collaterals as well as expansion of the pre-existing collaterals. As 
mentioned previously an angiography would have to confirm collateral vessel 
changes. The vascularity of the vessels would also need to be verified via histology, 
as even in clinical trials, VEGF administration caused leaky vessels, resulting in fluid 
swelling (Isner et al., 1996). 
Feedback from clinical trials suggests the method of administration of the growth 
factor is crucial. Protein delivery failed significantly as a therapeutic therapy in 
coronary artery disease and therefore gene therapy is commonly trialled (Simons et 
al., 2002). Gene therapy has its own disadvantages and may result in failure of growth 
factor delivery. However, PCR data from ischemic muscles has shown hIGFBP-2 in 
the global over-expresser, as well as mIGFBP-2 is directed to the ischemic soleus 
and tibialis. These muscles have been reported to be most affected by necrosis 
during restoration of perfusion (Shireman & Quinones, 2005). 
Recently, since VEGF and FGF trials have failed in patients suffering from critical 
limb ischemia, more research is being driven into the role of these growth factors in 
diseased mice. Diabetic mice are specifically of interest, due to diabetes significantly 
increasing the risk of CVD development. Gene therapy of VEGF significantly 
enhanced perfusion compared to the impaired function in type 2 diabetic mice alone 
(Li et al., 2007). Most of IGFBP-2s in vitro functions have been observed in 
compromised diseased states, such as cancer and obesity. Therefore, it may be 
possible we may see a further enhancement in recovery from a mouse which has 
impaired vascularisation. Clinically, we would be using IGFBP-2 as a therapeutic at 
a late stage of PAD or CLI, when amputation is the only option, IGFBP-2 would be 
administered to rescue the dying limb. 
It is evident, HLI surgery is not sufficient enough to make any clear assumptions on 
IGFBP-2s potential role in angiogenesis or arteriogenesis. However, we have 
observed an initial enhancement that suggests IGFBP-2 has a significant role in 
recovery in vivo and this should be investigated further. 
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9.3 IGFBP-2 phosphorylates Akt and p44/42 MAPK in HUVEC 
in vitro 
Administration of IGFBP-2 to HUVEC significantly enhanced Akt phosphorylation, but 
higher concentrations were required to induce ERK-mediated MAPK 
phosphorylation. 
Previous studies have reported that IGFBP-2 enhances Akt-, ERK- and JNK-
mediated MAPK and FAK signalling cascades via interactions with cell surface 
tyrosine kinase receptors and its nuclear interactions in a range of cancer, muscle, 
fat and bone cell lines (Demambro et al., 2012; Holmes et al., 2012; LI et al., 2018; 
Mendes et al., 2010; Xi et al., 2016).  However, we were unable to confirm activation 
FAK phosphorylation by IGFBP-2 in HUVECs, which was supported by IGFBP-2 
having no effect on GSK3β phosphorylation. Although, FAK phosphorylation is 
induced in lung cancer cells and adipocytes, it has also been shown to be down-
regulated in breast cancer cells (Lu et al., 2013; Schütt et al., 2004; Yau et al., 2015c). 
Therefore, IGFBP-2s RGD domain may function differently in HUVECs and could 
possibly induce the recruitment of ILK in order to activate the Akt pathway. 
Phosphorylation of the downstream target of Akt, eNOS also was not affected by 
IGFBP-2. Similarly, the critical regulator of Akt signalling, PTEN, was not 
phosphorylated by IGFBP-2 in HUVECs.  
The activation of Akt and MAPK pathways (in addition to other pathways which we 
have not looked at) are significantly involved in in vitro and in vivo angiogenesis. Most 
growth factors, specifically VEGF and FGF are known to mediate their angiogenic 
effects through Akt and MAPK phosphorylation (Dellinger & Brekken, 2011; Johnson-
Farley et al., 2007). FGF has specifically been shown to activate these pathways via 
IGF-I signalling in neuronal cells. Thus, suggesting IGFBP-2 has the ability to induce 
the same angiogenic effects exerted by VEGF and FGF in vivo and possibly clinically 
showing promising effects to CLI patients.  
Contrasting to VEGF and FGF, IGFBP-2 is able to suppress IGF-I stimulated Akt and 
ERK even when IGFBP-2 levels are upregulated (Kiepe et al., 2002). Therefore, 
clinically IGFBP-2 presents more of a regulatory role over angiogenic mechanisms 
which may promote healthy vessel growth by balancing its angiogneic activity in the 
ischemic site.  
Interestingly, the idea that IGFBP-2 may exert more pronounced angiogenic effects 
in diseased mice (mentioned in Section 9.2) was supported by IGFBP-2 activating 
Akt and MAPK phosphorylation more potently when endothelial cells had lost their 
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morphology and their health had become compromised. IGFBP-2 may be designated 
to play a recovery role in compromised or diseased states in vitro and in vivo. This 
finding was displayed by Aziz et al., (2018) who highlighted cells put into an 
inflammation state by TNFα or cells stimulated with IGFBP-1 alone failed to present 
an enhanced effect on cell adhesion. However, when IGFBP-1 was administered to 
the cells in an inflamed state by TNFα, the cell adhesion response was enhanced. 
IGFBP-2s role to act as a protector has also been observed in vivo in high-fat fed 
hIGFBP-2 overexpressing mice, preventing pre-adipocyte differentiation and 
proliferation to protect the onset of obesity (Wheatcroft et al., 2007).  
IGFBP-2s role in compromised states clearly needs to be interrogated further to 
identify which chemokines may regulate the bioactivity and –availability of IGFBP-2 
in circulation. However, IGFBP-2 ability to regulate activation of angiogenic 
mechanisms by the sequestering of IGF-I suggests that it can control activity 
depending on external stimulants. Therefore, this can be manipulated to enhance 
and suppress angiogenic activity as required to modulate the formation of a healthy 
blood vessel network. 
 
9.4 IGFBP-2 enhances angiogenic mechanisms in HUVECs in 
vitro 
For the first time, we have demonstrated that IGFBP-2 enhanced HUVEC adhesion 
to fibronectin. HUVEC wound closure was also enhanced by IGFBP-2. In the 
presence of an anti-proliferative agent, Mitomycin C, IGFBP-2 enhanced wound 
closure in a migration-dependent only assay. IGFBP-2 was also responsible for 
increased mesh formation in a tube formation assay. All these assays are driven by 
angiogenic-like characteristics which IGFBP-2 has been shown to modulate in a 
variety of cell types. Previous studies have shown IGFBP-2 has the ability to regulate 
adhesive properties via integrins in glioma cells, osteoclasts and other cell types, 
however IGFBP-2 has been mostly associated with de-adhesive effects (Han et al., 
2014; Kawai et al., 2011). Migration and proliferation has been driven through Akt 
and MAPK signalling, as well as integrin interactions (Brandt et al., 2015; Liu et al., 
2017; Wang et al., 2017c).  
Angiogenesis relies on the activation of migration and proliferation. Reports have also 
highlighted endothelial adhesion is essential to initiate the sprouting process as an 
endothelial tip cell forms. VEGF and FGF, as proangiogenic factors have previously 
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been identified to enhance these mechanisms via angiogenic signalling pathways 
such as Akt and MAPK (Oommen et al., 2011; Sahni et al., 2004). Interestingly, in 
both referenced studies, VEGF and FGF both enhance endothelial cell adhesion to 
the ECM, promoting outside-in and inside-out signalling cascades. This may explain 
IGFBP-2s ability to enhance HUVEC adhesion to the ECM.  
To further determine the signalling mechanisms which promote each mechanism, we 
need to repeat all functional assays using inhibitors. We have already demonstrated 
inhibition of the Akt pathway eliminated most mesh formation in the tube formation 
assay, whereas p38 MAPK inhibition only caused a slight decrease in total mesh 
formation. This is important in our understanding of target specific IGFBP-2 
interactions and exploiting these, depending on the activity we would aim to promote.  
 
9.5 RGD is critical for promoting angiogenic signalling and 
angiogenic functional properties 
As mentioned in the previous chapter, we wanted to determine which interactions 
and angiogenic signalling pathways promote in vitro enhancement of IGFBP-2 
stimulated HUVEC adhesion, migration and proliferation. This will enable us to offer 
a more direct and specific approach to exploiting IGFBP-2s angiogenic potential. We 
mutated the N terminal IGF binding site, the central heparin binding domain and 
nuclear localisation signal and the RGD domain in three individual mutant variants.  
Mutation of the RGD domain to prevent integrin binding prevented the ability of 
IGFBP-2 to enhance Akt phosphorylation, whereas all three mutants prevented 
phosphorylation of ERK/MAPK. The RGD significantly suppressed HUVEC adhesion 
to fibronectin, wound closure and tube formation. Therefore, the majority of IGFBP-
2s angiogenic potential is driven through its interaction with integrins. Published 
literature highlights IGFBP-2/integrin interactions are critical for the recruitment of ILK 
to stimulate Akt phosphorylation and JNK or ERK mediated MAPK activation which 
in turn activate cell migration and proliferation (Han et al., 2014; Hoeflich & Russo, 
2015; Holmes et al., 2012). IGFBP-1, the only other IGFBP to possess an RGD 
domain, has demonstrated enhancement in glucose clearance and insulin sensitivity 
via IGFBP-1/integrin interactions (Haywood et al., 2017). Therefore, exploiting 
IGFBP-2s RGD domain may prove beneficial to promoting IGFBP-2 stimulated 
angiogenesis.  
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9.6 IGFBP-2 does not affect vascular permeability 
Vascular permeability is extremely important in regard to angiogenesis. This is 
because VEGF failed as a possible therapeutic option due to its negative effect on 
the endothelium, causing high permeability and in turn resulting in leaky blood 
vessels (Alfranca, 2009). The leaky vessels resulted in fluid swelling in the lower 
limbs which was successfully treated in a clinical study with VEGF by Isner et al., 
(1996), however possible damage caused by the fluid was never interrogated and 
the limb had was amputated later for gangrene reasons.  
There have been reports suggesting IGFBP-2 functions via its NLS to promote VEGF 
activation by aiding its transport via nuclear importins to its VEGF2R, in order to exert 
angiogenic-like responses (Azar et al., 2011; Das et al., 2013). Although we 
previously showed upregulated levels of hIGFBP-2 or mIGFBP-2 following ischemia 
showed no association with mVEGF levels, it was important we confirmed IGFBP-2 
does not cause the same effect to permeability as VEGF. 
IGFBP-2 did not affect the endothelial monolayer and retained regular morphology of 
VE-cadherin, whereas VEGF-A caused a hyperpermeable response and disrupted 
VE-cadherin junctions. We also discovered IGF binding may be a key regulator of 
determining IGFBP-2s effect on permeability as the mutant IGF caused increased 
permeability, whereas WTIGFBP-2, HBD and RGD mutants sustained a normal 
permeability level. This supported published evidence demonstrating the role of IGF-
I mediating intestinal barrier function (Lorenzo-Zúñiga et al., 2006). 
From our findings also plausible to assume IGFBP-2 does not cause upregulated 
expression of VEGF in HUVECs as we can confirm IGFBP-2 does not mediate the 
same adverse effects on permeability as VEGF. Therefore, IGFBP-2 presents a safer 
option to stimulate healthy blood vessel growth via the promotion of angiogenic 
activity we have seen in the previous chapters and supports its use clinically in cases 
of CLI or PAD. 
 
9.7 Clinical significance 
Upregulation of IGFBP-2 significantly enhances early stages of recovery from 
ischemia. IGFBP-2s RGD domain is critical to IGFBP-2 stimulated enhancement of 
phosphorylation of the angiogneic signalling pathways, Akt and MAPK, as well as 
angiogenic functionality, HUVEC adhesion, wound closure and tube formation. 
Therefore, IGFBP-2 displays translational angiogenic potential in vascular 
P a g e  | 232 
 
 
endothelial cells, suggesting it may play a significant role in the endothelial 
remodelling that occurs in arteriogenesis or endothelial migration in angiogenesis. 
We have also shown it possesses distinct differences between VEGF and FGF’s 
angiogenic effects, specifically VEGF’s hyperpermeability response; therefore, 
functions in an alternative method which may prove to be more beneficial. 
IGFBP-2 as a new potential therapeutic agent shows promising potential to produce 
positive outcomes on preventing amputation, death in CLI and also the onset of other 
CVD, via its angiogenic effects on vascular endothelial cells. If successful, this could 
the greatest advance in CVD as it will increase PAD-associated survival rates 
significantly. 
 
9.8 Future directions 
IGFBP-2s specific role in collateral vessel formation needs to be extensively 
investigated. Its actions via the RGD domain also play a crucial role in mediating 
IGFBP-2 stimulated angiogenic effects in vitro. The mutant RGD domain could also 
be tested in vivo via in vivo expression vectors, delivering liver-specific expression of 
the mutant form of IGFBP-2. It is clear by the outcomes of PAD clinical trials may be 
dependent on delivery mode, and therefore trialling different therapeutic angiogenic 
delivery therapies of IGFBP-2 in in vivo models may prove beneficial. The safety of 
using IGFBP-2 via exploitation of its RGD domain would have to be extensively 
verified via use of in vivo models. New directions from this project may include 
identifying IGFBP-2s angiogenic ability in diseased models. 
 
9.9 Conclusion 
Throughout this project, we have demonstrated increasing IGFBP-2 can speed up 
recovery following ischemia in vivo, as IGFBP-2 levels are upregulated following 
ischemia and IGFBP-2 over-expression cause an enhancement in early recovery 
stages following HLI. IGFBP-2 mediates angiogenic-like mechanisms in HUVECs 
such as adhesion, proliferation and migration, which may possibly be mediated 
through IGFBP-2 induced phosphorylation of Akt or p44/42 MAPK.  The RGD domain 
is critical for all angiogenic-like mechanisms, including the phosphorylation of Akt and 
MAPK. HBD and IGF are also important to IGFBP-2 stimulated MAPK activation. The 
RGD domain is not involved in the sprouting of endothelial cells, suggesting different 
P a g e  | 233 
 
 
domains may have different levels of activity at different stages of angiogenesis. 
Finally, IGFBP-2 maintains vascular permeability and does not cause a 
hyperpermeable response as does VEGF.  
Therefore, IGFBP-2 has promising potential as an acute angiogenic therapeutic 
treatment, possibly via its RGD domain and IGF domain to drive angiogenic 
processes and maintain vascular permeability in cases of PAD or critical limb 
ischemia, in order to restore blood flow to rescue lower limbs from amputation. 
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